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Abstract 
The G protein-coupled receptor kinases (GRKs) are best known for their role in 
phosphorylating G protein-coupled receptors (GPCRs). In addition to their canonical 
role, the GRKs have a number of non-receptor substrates and binding partners. GRK5 
contains functional nuclear localisation and export sequences and many newly 
discovered binding partners of the kinase are, indeed, nuclear.  
 
My thesis outlines the discovery of novel nuclear GRK5 binding partners, class I 
histone deacetylases (HDACs), HDACs 1, 3 and 8, as well as the repressor protein, 
Swi-independent 3 (Sin3) A, and reports a role for GRK5 in regulating B cell lymphoma 
protein 2 (Bcl-2) gene transcription in conjunction with this repressor complex. 
Attempts to map the HDAC1 and Sin3A binding sites on GRK5 were carried out using 
GRK5 peptide arrays. Suspected GRK5 residues involved in binding were identified 
and mutated, but no viable binding deficient mutants were identified. Using HDAC and 
Sin3A inhibitors, I show GRK5 to negatively regulate Bcl-2 transcription in a class I 
HDAC and, most likely, a Sin3A dependent manner. Bcl-2, an anti-apoptotic protein, is 
upregulated in the early stages of many colorectal cancers (CRCs) and is, at least in 
part, responsible for the apoptotic resistance of metastatic CRCs. Notably, GRK5 
expression levels are low in the colon cancer cell line, HT-29, in comparison to other 
tumour-derived cancer cell lines and overexpressing the kinase in HT-29 cells by cDNA 
transfection increases the susceptibility of these cells to chemotherapeutically induced 
apoptosis. Furthermore, overexpression of an inhibitor of miR-135a, a micro RNA 
(miRNA) that is upregulated in CRC, increases endogenous GRK5 expression as well 
as apoptosis in HT-29 cells, highlighting the potential use of a miR-135a inhibitor as a 
novel therapeutic strategy to treat CRC patients. 
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Chapter 1. Introduction 
1.1 G protein-coupled receptor kinase (GRK) structure 
The GRK family of serine/threonine kinases were discovered in the 1990s and 
classified into three subfamilies based on sequence homology [1]. Figure 1.1 
illustrates the GRKs grouped according to subfamily. The GRK1 subfamily includes 
GRK1 and GRK7, which are expressed in the retina. GRK1 is additionally 
expressed in the pineal gland [2]. The GRK2 and GRK4 subfamilies, comprising 
GRK2 and GRK3, and GRK4, 5 and 6 respectively, are ubiquitously expressed, 
with the exception of GRK4 that is exclusively expressed in the testes, kidney and 
cerebellum [3-6].  
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Figure 1.1 GRK subfamily organisation   
The schematic shows the multi-domain structure of the GRKs along with key regulatory and 
interaction sites that have been mapped. The lipid modifications depicted in the carboxy-termini 
are farnesylation (GRK1), geranylgeranylation (GRK7) and palmitoylation (GRKs 4 and 6). RH, 
regulator of G protein signalling homology domain; CaM, calcium/calmodulin; NLS, nuclear 
localisation sequence; NES, nuclear export sequence; PL, phospholipid, PH, pleckstrin 
homology; auto (±), stimulatory or inhibitory autophosphorylation sites. Adapted from [7]. 
 
The GRKs have a common, multi-domain, structure with similar amino (N) and 
catalytic domains, as shown in Figure 1.1. An N-terminal region of approximately 
183–188 residues precedes the catalytic domain and includes a region 
homologous to regulator of G protein signalling (RGS) proteins, known as the RGS 
homology (RH) domain. While RGS domains increase the inherent guanosine 
triphosphate (GTP) hydrolytic activity of Gα subunits of heterotrimeric G proteins, 
the RH domains do not posses this function [7]. The RH domains span 
approximately 120 residues and while they are a common N-terminal feature of the 
GRKs, these domains only share approximately 27% sequence identity. The RH 
domains of GRK2 and GRK3 bind activated members of the Gα protein family, 
specifically Gαq, Gα11 and Gα14 and act to sequester Gα proteins from effector 
proteins. Additionally, the RH domain of GRK2 binds adenomatous polyposis coli 
(APC) [8] and interactions of this RH domain with the kinase domain and carboxyl 
(C)-terminal pleckstrin homology (PH) domain may work to regulate kinase activity. 
The RH domains of GRK5 and GRK6 have not been reported to interact with Gα 
proteins and their binding partners, like the RH binding partners of the other GRKs, 
have not been identified [6]. In addition to the RH domain, the N-termini of the 
GRK4 subfamily also contain a phosphatidylinositol (4,5) biphosphate 2 (PIP2) 
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binding site, which flanks the RH domain. This region serves to localise the kinase 
to the membrane and enhances receptor-mediated phosphorylation. The N-
terminal PIP2 binding site overlaps with a calcium/calmodulin (Ca2+/CaM) binding 
site, such that these binding events are thought to be mutually exclusive [7]. 
 
The central serine/threonine kinase domain consists of around 320 residues and 
has approximately 42% sequence identity across the GRKs [9]. GRK5, as well as 
GRK4 and GRK6, contain a functional nuclear localisation sequence (NLS) and 
nuclear export sequence (NES) within their catalytic domain, as shown in Figure 
1.1 [10, 11]. Mutation of the basic residues in the GRK5 NLS, Arg388–Glu395 
(RKEKVKRE to AAEAVAAE) to generate a GRK5ΔNLS mutant, results in the 
nuclear exclusion of the kinase without affecting its catalytic activity [10, 12]. The 
GRK1 subfamily contain putative NLS and NESs located towards the N-terminus of 
the kinase domain [11, 13]. GRK5 and GRK6 share a conserved NLS located at 
the C-terminus of the catalytic domain, whereas the NLS of GRK4 is homologous 
to that of the GRK1 subfamily kinases. 
 
The GRK C-termini show very little sequence homology, but each subfamily 
contains similar domains that mediate membrane binding. The GRK1 subfamily 
kinases contain short CAAX sequences that mediate prenylation to facilitate 
plasma membrane binding [14]. The GRK2 subfamily have PH domains, the C-
terminus of which binds PIP2 and the N-terminal portion binds Gβγ. Both proteins 
bind cooperatively to the PH domain and coordinately trigger the re-localisation of 
these soluble kinases to the cell membrane following agonist stimulation. Agonist 
occupation of G protein-coupled receptors (GPCRs) leads to the dissociation of 
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Gβγ from heterotrimeric G proteins, which are then free to bind the PH domains of 
GRK2 and GRK3. PIP2 and Gβγ contribute synergistically to the membrane 
localisation of GRK2, which leads to enhanced GRK-mediated receptor 
phosphorylation following the allosteric activation of the GRKs by agonist occupied 
GPCRs [15-17]. In contrast to the GRK2 subfamily, GRK4 and GRK6 are 
palmitoylated, a post-translational modification that promotes membrane 
association [15]. GRK5 contains positively charged residues in its C-terminus to 
mediate phospholipid binding, which in turn stimulates autophoshorylation and 
activation of the kinase. GRK5 is autophosphorylated at Ser484 and Thr485. While 
autophosphorylation does not enhance the catalytic ability of GRK5 towards 
soluble peptides, it is necessary for GRK5-mediated phosphorylation of receptor 
substrates and is considered a mechanism of GRK5 membrane localisation [18]. 
GRK5 also contains a C-terminal Ca2+/CaM binding site. The binding of Ca2+/CaM 
to either the N- or C-terminal sites regulates the subcellular localisation of GRK5. 
This is discussed in more detail in section 1.3.3. 
1.1.1 Crystal structures of the GRKs 
The Tesmer group has solved the crystal structures of GRK1, GRK2 and GRK6. 
The GRK2 crystal structure has been solved alone, in complex with Gβγ and in 
complex with Gβγ and Gαq [19-23]. Similarities between the GRK crystal structures 
highlights the conserved nature of the RH-kinase domain interface, which may 
function to correctly orientate membrane binding elements of the GRKs, or stabilise 
the inactive conformation of the kinase. Interestingly, in all of the GRK crystal 
structures, the kinase domain adopts an open, inactive conformation, similar to 
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protein kinase A (PKA). It is suggested that GPCR activation of the GRKs may 
induce kinase domain closure.  
 
GRK6 is the most ubiquitous member of the GRK4 subfamily and shares 70.1% 
sequence identity with GRK5 [24], which is the main kinase that I focus on in my 
thesis. I will therefore use the crystal structure of GRK6 to make reasonable 
inferences regarding the tertiary structure of GRK5. In contrast to GRK2, GRK6 
crystallises as a dimer, via a surface of its RH domain that is shared among the 
GRK4 and GRK1 subfamily members [19]. The Tesmer group assume that GRK6 
dimerisation is an artefact of crystallisation, resulting from high GRK6 protein 
concentrations in the crystals. The group explain that results from size exclusion 
chromatography and sedimentation equilibrium analysis suggests that soluble, 
palmitoylation-deficient GRK6 is monomeric. Furthermore, dimerisation is not 
required for receptor phosphorylation; three GRK6 constructs, each with a key 
residue involved in dimerisation mutated to alanine, were expressed in COS-1 cells 
and were all capable of phosphorylating rhodopsin to the same degree as wildtype 
GRK6 and the overexpression of double mutants only slightly impinged receptor 
phosphorylation [19]. Contrary to the opinion of the Tesmer group, Lan Ma’s group 
propose GRK5 to dimerise in a cellular setting and suggest a role for the self-
association of the kinase in promoting F-actin bundling at the cell membrane. In 
HEK293 cells, the Ma group showed Flag-GRK5 to co-immunoprecipitate with 
green fluorescent protein (GFP) tagged GRK5, whereas Flag-GRK2 did not. These 
data suggest that GRK5 may not just dimerise but could also form oligomers. The 
group propose that a GRK5 dimer works to crosslink F-actin into bundles via its C-
terminal F-actin binding domain [25].  
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Based on these data, I would predict that while dimerisation may not be involved in 
receptor phosphorylation, GRK5 could act as a dimer to promote other cellular 
functions. GRK5 has a plethora of substrates and binding partners, extending the 
role of the kinase far beyond that of GPCR phosphorylation, the best-known 
function of the GRKs. As will be discussed in section 1.3.1.4, the kinase activity of 
GRK5 is not required for its role in F-actin bundling, implying that GRK5 
dimerisation may be important for kinase-independent GRK5 functions. GRK5 
contains a functional NLS that, in conjunction with an N-terminal polybasic domain 
(NTPB), is required for DNA binding [11]. The crystal structure of GRK6A orients 
the NLS and NTPB at opposing ends of the dimer structure with the NLS located at 
the extremities while the NTPB domains are located at the dimer interface. Dimers 
of GRK5 may therefore wrap around the DNA helix with the NLS and NTPB 
domains forming direct DNA contacts [11, 19]. So while GRK5 dimerisation may 
not be required for the phosphorylation of GPCRs, or even of non-receptor 
substrates, I propose that there may well be a functional role for the GRK5 dimer, 
potentially to catalyse F-actin bundling and DNA binding.   
1.2 GRK function: modulating G protein signaling 
GRKs were discovered for their role in negatively regulating G protein mediated 
signalling via GPCRs. Agonist binding to GPCRs triggers a conformational change 
in the receptor, such that it serves as a guanidine nucleotide exchange factor for its 
associated heterotrimeric G protein, catalysing the exchange of guanosine 
diphosphate for GTP on the G protein Gα subunit, thereby initiating G protein 
signalling. Following agonist binding, GRKs phosphorylate the receptor, enabling β-
arrestin protein binding and the initiation of multiple intracellular signalling pathways, 
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one of which negatively regulates G protein signalling [15]. The role of GRKs as 
coordinators of GPCR signalling is perhaps under appreciated, with the main focus 
generally being on the β-arrestin adapter proteins, whose binding sterically inhibits 
G protein coupling to the receptors and triggers GPCR internalisation [26].  
 
An analogy can be drawn between the signalling pathways initiated by GRKs 
downstream of GPCR activation and those initiated by Janus kinases (Jaks) 
downstream of haematopoietin cytokine receptors. [27]; Jaks provide the key link 
between extracellular ligand binding to cytokine receptors and intracellular protein 
phosphorylation, much like the GPCR/GRK relationship [28]. Jak and GRK 
mediated phosphorylation ensues following agonist occupation of receptors. Much 
like GRK5, whose phospholipid-stimulated autophosphorylation is necessary for its 
receptor-directed kinase activity, Jaks must first be transactivated via tyrosine 
phosphorylation. Following their phosphorylation and activation, GRKs and Jaks in 
turn phosphorylate their respective receptor targets. GRKs phosphorylate GPCRs 
at serine and threonine residues usually located in the third intracellular loop or the 
C-terminal tail, which are exposed following agonist binding [15]. Phosphorylated 
residues of GPCRs and cytokine receptors then act as binding sites for adapter 
proteins, β-arrestin and Signal transducers and activators of transcription (Stats), 
respectively. Docking of β-arrestins or Stat recruitment, plays a key role in negative 
feedback. β-Arrestin binding to GPCRs results in receptor desensitisation, as the 
coupling of heterotrimeric G proteins to the receptor is prevented, as is subsequent 
G protein-mediated signalling. Furthermore, the β-arrestin-mediated recruitment of 
proteins including the clathrin adapter, AP2, triggers receptor internalisation [29]. 
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My thesis focuses on GRK5 and its role in the nucleus as opposed to at the plasma 
membrane. I will, therefore, proceed to discuss additional functions of GRK5 
distinct from GPCR phosphorylation, but I will compare and contrast with other 
GRK family members where relevant. 
1.3 Functions of GRK5 
In recent years, the role of GRKs has extended beyond the initiation of GPCR 
desensitisation. GRK5 is now widely recognised as an independent signalling 
coordinator, regulating a multitude of signalling pathways at the membrane, as well 
as in the nucleus. As more GRK-specific substrates and binding partners are 
discovered, distinct and specific roles for the kinases are being identified. Figure 
1.2 depicts the multiple substrates and binding partners of GRK5 identified to date, 
detailing some of the physiological and pathophysiological processes that are 
regulated by the kinase. 
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Figure 1.2 Substrates and binding partners of GRK5 
GRK5 has a range of substrates and binding partners in addition to GPCRs, which are located 
not only at the cell surface but also in the cytoplasm and nucleus. Starting with membrane 
substrates and binding partners and working from left to right: GRK5 promotes F-actin bundling 
at the cell membrane, leading to the formation of filopodia and dendritic branches in neurons, 
thus implicating GRK5 in the control of cytoskeletal dynamics. GRK5 phosphorylates !-
synuclein and tubulin, promoting the dissociation of !-synuclein from tau and the formation of 
microtubules respectively. Serine and threonine phosphorylation is shown in bright yellow. !-
Synuclein accumulates in Lewy bodies during Parkinson’s disease. Accumulation of 
phosphorylated tau is common to Alzheimer’s disease and relocalisation of GRK5 from the cell 
membrane is also thought to contribute to disease pathology. The best-known substrate of 
GRK5 are GPCRs, whose phosphorylation stimulates "-arrestin protein binding that in turn 
triggers receptor endocytosis and desensitisation by preventing G protein coupling to receptors. 
Two distinct mechanisms of ERK regulation operate downstream of activated GPCRs, either via 
"-arrestin or Gq. Gq-activation may also trigger the GRK5 cellular relocalisation, potentially to 
the nucleus (Bold arrows). GRK5 phosphorylates platelet derived growth factor receptor " 
(PDGFR"), which promotes tyrosine phosphorylation (shown as pale yellow phosphate groups), 
to which SH2-domain-containing protein tyrosine phosphatase-2 (Shp2) binds to activate 
Sarcoma virus homologue (Src). The Wnt signalling receptor, low density lipoprotein receptor-
related protein (LRP) 6, is phosphorylated by GRK5, which inhibits the action of glycogen 
synthase kinase-3" (GSK3"), thus resulting in the accumulation of "-catenin and the 
upregulation of Wnt target genes. Cytoplasmic GRK5 substrates and binding partners include 
inhibitor of kappa B! (I#B!), whose phosphorylation activates nuclear factor kappa enhancer of 
activated B cells (NF#B). GRK5 is also known to inhibit NF#B signalling by preventing the 
phosphorylation of I#B isoform, p105. GRK5 is implicated in cell cycle control by localising at 
centrosomes and by directly and indirectly promoting the phosphorylation of nucleophosmin 1 
(NPM1). Nuclear GRK5 substrates include histone deacetylase 5 (HDAC5), whose 
phosphorylation leads to the upregulation of pro-hypertrophic genes, such as atrial natriuretic 
factor (ANF), and p53, whose phosphorylation and degradation inhibits apoptosis and whose 
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activation promotes hypertrophy. GRK5 also negatively regulates B-cell lymphoma 2 (Bcl-2) 
gene transcription, which may be a functioning mechanism in Parkinson’s disease.  
1.3.1 Functions of GRK5 at the plasma membrane 
1.3.1.1 Regulation of extracellular signal-regulated kinase (ERK) signalling 
via !-arrestins 
The !-arrestin proteins are appreciated as independent signalling mediators, 
playing a signalling role distinct from GPCR desensitisation and internalisation. The 
canonical means of !-arrestin activation is reliant upon GRK-mediated 
phosphorylation of agonist occupied receptors. Moreover, the signalling pathway 
mediated by !-arrestin proteins can be further determined by the specific GRK that 
catalyses GPCR phosphorylation.  
 
ERK is a downstream effector kinase of the angiotensin type 1A receptor (AT1AR), 
activated in response to receptor stimulation. ERK1/2 activation occurs by two 
distinct and parallel pathways, via Gq or !-arrestin 2, which GRK2 and GRK3, and 
GRK5 and GRK6 regulate respectively. Gq-mediated signalling requires protein 
kinase C (PKC)-mediated ERK1/2 activation. Stimulation of the AT1AR with 
angiotensin II (AngII) in HEK293 cells, however, results in significant ERK1/2 
activation that is only approximately 60% diminished by treatment with the PKC 
inhibitor, Ro-31-8425, thus implying an additional G protein-independent means of 
regulating this pathway. Indeed, the remaining ERK1/2 activation was abolished 
following knockdown of !-arrestin 2 or GRK5 [30]. !-Arrestin 2 acts as a scaffold 
for the mitogen activated protein kinase (MAPK) cascade, enabling the 
phosphorylation and activation of ERK1/2 by directly binding to the MAPK, Raf1, as 
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well as to ERK1/2, which mediates an indirect interaction of MAPK/ERK kinase 1 
(MEK1) with !-arrestin 2 [31].  Phosphorylation of the AT1AR by either GRK2 or 3, 
or GRK5 or 6, stimulates a different arm of the signalling pathway. Phosphorylation 
by GRK2 or 3 promotes receptor internalisation and thereby reduces ERK1/2 
activation by preventing G protein coupling, whereas phosphorylation by GRK5 or 6 
stimulates !-arrestin 2-mediated ERK1/2 activation. Knockdown of GRK2 or GRK3, 
or the overexpression of GRK5 or GRK6 enhanced !-arrestin 2-mediated ERK1/2 
activation in HEK293 cells [32]. The contrasting effects mediated by GRK2/3 and 
GRK5/6 therefore suggest that the GRK2 and GRK4 subfamily kinases recognise 
specific receptor conformations and phosphorylate different serine and threonine 
residues of the AT1AR. GRK5 subfamily-dependent stabilisation of specific receptor 
conformations is presumably reflected in different conformations of receptor bound 
!-arrestin 2 and thus differential recruitment of binding partners. This suggests a 
function for GRK5 that extends beyond the canonical role of GRKs in controlling 
receptor internalisation and suggests that GRK5 can in fact function as a positive 
regulator of ERK1/2 signalling. This function for GRK5 is not specific to the AT1AR 
but is also operative at the !-adrenergic receptor and vasopressin V2 receptor [33, 
34].  
 
As discussed above, the parallel signalling pathways evoked from the AT1AR 
suggests discrete active conformations of the receptor. Biased agonists, which 
selectively activate specific signalling pathways downstream of receptors, pave the 
way for therapeutic advances. !-Arrestin-dependent signalling downstream of the 
!1 adrenergic receptor (!1AR) is cardioprotective, whereas classical G protein 
signalling is injurious, with the different cardiovascular phenotypes attributed to the 
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activation of distinct ERK signalling events [35]. G protein-mediated signalling 
promotes rapid and transient ERK activation leading to its nuclear relocalisation, 
which activates transcription of the early growth response 1 gene. In contrast, !-
arrestin-mediated signalling results in slower activation of ERK [35]. ERK signalling 
is initiated following the transactivation of epidermal growth factor receptors 
(EGFRs), which occurs following the GRK5/6-mediated phosphorylation of !1AR 
and results in cardioprotection. Transgenic mice overexpressing a mutant receptor 
lacking the GRK phosphorylation sites develop left ventricular dilation and myocyte 
apoptosis following chronic stimulation with the !-adrenergic receptor agonist, 
isoproterenol. Additionally, wildtype mice stressed with isoproterenol and treated 
with the EGFR inhibitor, erlotinib, have impaired cardiac function [36]. Chronic 
stimulation of !-adrenergic receptors and AT1ARs are involved in heart disease 
pathogenesis, such that most treatments function to block signalling from these 
receptors, inhibiting both G protein and !-arrestin signalling pathways. The 
development of biased ligands that preferentially inhibit the G protein arm and/or 
stimulate the !-arrestin signalling arm may have a more beneficial effect. The 
synthetic AT1AR ligand, [Sar1, Ile4, Ile8]-Ang and the !-blocker, carvedilol, both 
work to this effect, with cardioprotective effects demonstrated in vivo and in human 
patients respectively [35].  
 
Interestingly, and in contrast to the previously described example, GRK5 negatively 
regulates Sarcoma virus homologue (Src)/ERK signalling downstream of the 
serotonin receptor, 5-HT4, in both HEK293 cells and in neurons. Overexpression of 
GRK5 and the 5-HT4 receptor in HEK293 cells attenuates ERK and Src 
phosphorylation. Overexpression of a transactivator of transcription (TAT) cell-
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permeable peptide fused to the GRK5 binding site on the receptor, which therefore 
prevents the GRK5/5-HT4 interaction, increased ERK activation in both HEK293 
cells and in neurons. It was subsequently demonstrated that the GRK5-mediated 
inhibition of the ERK signalling pathway downstream of 5-HT4 activation required 
GRK5-mediated phosphorylation of both the receptor and !-arrestin 1 [37]. GRK5 
thereby differentially regulates ERK signalling, possibly in a manner that is 
dependent on the upstream receptor as well as the !-arrestin isoform recruited to 
the phosphorylated, activated receptor. 
1.3.1.2 Platelet derived growth factor receptor-beta (PDGFR!) regulation 
GRK2 is the dominant GRK phosphorylating the tyrosine kinase receptor, PDGFR! 
following acute stimulation in endothelial cells. Prolonged receptor activation in 
mouse aortic smooth muscle cells (SMCs), however, results in down-regulation of 
GRK5, while GRK2 expression levels are unaffected [38]. The two kinases regulate 
PDGFR! function via distinct mechanisms, phosphorylating different receptor 
serine residues. GRK5-mediated seryl phosphorylation results in subsequent 
phosphorylation of PDGFR! at Tyr1009, to which the phosphatase SH2-domain-
containing protein tyrosine phosphatase-2 (Shp2) binds (Figure 1.2). 
Autophosphorylation of PDGFR! at Tyr1021 is reduced, which is the binding site 
for phospholipase C (PLC)-"1, such that this signalling pathway is inhibited. GRK5 
thereby desensitises inositol phosphate signalling via PLC-"1, but promotes Src 
signalling, as Shp2 dephosphorylates Src at its autoinhibitory residue, Tyr527. 
Overexpression of GRK5 in SMCs thus leads to greater Src activation but 
interestingly not ERK1/2. In a pathological setting where PDGFR! is upregulated, 
so are GRK5 expression levels; atherosclerotic arteries of mice contain 
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substantially more GRK5 and PDGFR! per unit of "-SMC actin compared to 
wildtype mice, as assessed by immunofluorescence. Like PDGFR!, GRK5 may 
therefore also have a role in atherosclerosis and based on these data I would 
predict the kinase to promote disease pathogenesis [38]. 
1.3.1.3 Regulation of Wnt signalling 
Wnt ligands bind 7-transmembrane, Frizzled receptors, which heterodimerise with 
the single transmembrane, low density lipoprotein receptor-related proteins (LRP) 5 
and 6 to activate the canonical Wnt signalling pathway that regulates 
organogenesis and tissue regeneration [39]. Activation of Wnt signalling receptors 
leads to the inhibition of the cytosolic protein, glycogen synthase kinase-3! 
(GSK3!), which is part of a destruction complex that includes casein kinase I, the 
scaffolding protein, axin, and the tumor suppressor gene product, APC, and 
functions to degrade !-catenin. Wnt signalling, therefore, subsequently stabilises !-
catenin, such that it translocates to the nucleus and acts as a transcriptional co-
activator, leading to the upregulation of target genes including c-Myc and cyclin D1, 
which promote cell proliferation [40]. GRK5 and GRK6 stimulate Wnt signalling by 
phosphorylating serine and threonine residues within the five PPPSP motifs in 
LRP6 (Figure 1.2). Knockdown of GRK5 in zebrafish causes a simultaneous 
reduction in Wnt signalling, noted by a reduction in !-catenin protein levels, as well 
as reduced mRNA levels of Wnt target genes [41].  
 
A role for !-arrestins in the same signalling pathway has also been identified, 
regulating Wnt signalling in an opposing manner to GRK5 and GRK6; !-arrestin 2 
promotes Wnt5A-stimulated internalisation of the Frizzled 4 receptor [42]. The 
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opposing roles played by GRK5 and !-arrestin 2 in regulating Wnt signalling 
support the notion that GRK5 can function as an independent signalling mediator, 
in a role distinct from its regulation of !-arrestin mediated signalling. Furthermore, 
the role of GRK5 and GRK6 in phosphorylating LRP6 to activate Wnt signalling 
solves a previously unexplained paradox. GSK3! was proposed to translocate to 
the membrane and bind LRP6 via axin, to catalyse receptor phosphorylation at the 
PPPSP motif. Axin binding, however, is dependent on the phosphorylation of the 
motif, which suggests that receptor phosphorylation and axin recruitment must be 
GSK3! independent. The involvement of GRK5 and GRK6 in the Wnt signalling 
pathway suggests these kinases function upstream of GSK3! to activate the 
receptor. The implications of these findings by the Lefkowitz and Chen groups may 
potentially be vast, as Wnt target genes are involved in major developmental 
processes and deregulated Wnt signalling has been implicated in numerous 
cancers, including colorectal, which will be discussed in section 1.4.3.  
1.3.1.4 Cytoskeletal regulation 
GRK5 is associated with cytoskeletal regulation via interactions with and regulation 
of "-synuclein, tubulin and actin. The function of "-synuclein is not entirely clear but 
it is known to bind to the cell membrane via phospholipids and play a role in 
vesicular trafficking. The Benovic group showed GRK5-mediated phosphorylation 
of "-synuclein at Ser129 reduces phospholipid binding, which is thought to be 
responsible for a loss in phospholipase D2 inhibition [43]. Phospholipase D2 
promotes vesicle formation indirectly, firstly by generating phosphatidic acid from 
phosphatidylcholine hydrolysis, which stimulates vesicle assembly and secondly 
via its role in the rearrangement of the cortical actin cytoskeleton. GRK5-mediated 
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!-synuclein phosphorylation may therefore enhance receptor endocytosis. In 
addition to its potential role coordinating vesicular trafficking, !-synuclein also has a 
role in cytoskeletal regulation in neurons, via interactions with the microtubule-
associated protein, tau. !-Synuclein binds soluble tau at its microtubule binding 
domain and this interaction is blocked by tubulin. Furthermore, !-synuclein 
stimulates PKA-catalysed phosphorylation of tau at sites including Ser262 and 
Ser356, which also inhibits the association of tau with microtubules (Figure 1.2) 
[44]. The GRK5 phosphorylation site on !-synuclein overlaps with the tau binding 
site, such that GRK5-mediated phosphorylation of !-synuclein could alter the 
dynamics of microtubule assembly by disrupting its interaction with tau, potentially 
resulting in a higher proportion of microtubule associated tau. Moreover, !-
synuclein and GRK5 both interact with tubulin, which polymerises to form 
microtubules and GRK5-mediated tubulin phosphorylation may promote 
microtubule assembly [45, 46].  
 
GRK5 and GRK2 bind and phosphorylate soluble tubulin heterodimers as well as 
insoluble microtubules and immunofluorescence experiments in COS-1 cells 
showed co-localisation of the kinases with microtubules [46]. GRK5-mediated 
tubulin phosphorylation may play a role in regulating microtubule function, as 
phosphorylation of microtubules enhances their interaction with plasma 
membranes as well as with actin filaments. It is also possible that interactions with 
tubulin may regulate the cellular localisation of GRK5. While neither of these 
possibilities has been investigated, in vitro functional analyses performed by the 
Benovic group suggest that tubulin phosphorylation by GRK5 may promote 
microtubule assembly, as following incubation with GRKs and ["-32P] ATP, 
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approximately 90% of phosphorylated and thus radiolabelled tubulin was 
associated with insoluble microtubule pellets. Overall, therefore, GRK5 may 
positively regulate microtubule growth via !-synuclein and tubulin phosphorylation. 
 
The other main component of the cytoskeleton is actin, which Lan Ma’s group 
identified as a binding partner of GRK5. A kinase-independent role for GRK5 in 
promoting the membrane localisation and bundling of F-actin has been identified, 
as actin negatively regulates the catalytic activity of GRK5. GRK5 acts as a scaffold 
for F-actin bundling, coordinating its association with the membrane via PIP2 
(Figure 1.2). The C-terminal of GRK5 is responsible for actin binding while its N-
terminal PIP2 binding site targets the filaments to the plasma membrane. GRK5 
thereby promotes neuronal morphogenesis by stimulating actin bundling at the 
membrane to form filopodia, which are essential for neurite initiation and dendrite 
branching and are precursors for presynaptic termini and postsynaptic spines [47]. 
Moreover, spine morphology is important for synaptic plasticity, which in turn 
controls long-term memory formation. GRK5 knockout mice, which suffer 
reductions in the number of hippocampal neurites and dendritic spines also have 
impaired long-term memory [25]. 
1.3.2 Functions of GRK5 in the cytosol 
1.3.2.1 Cell cycle control 
The Benovic group discovered GRK5 localises to centrosomes, preferentially the 
mother centriole, inferred by immunofluorescence experiments showing co-
localisation of GRK5 with "-tubulin, which polymerises to form centrosome 
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microtubules. GRK5 promotes de novo microtubule formation, a process known as 
microtubule nucleation. HeLa cells were treated with nocodozole to depolymerise 
microtubules and re-growth was assessed by monitoring the size of asters, which 
hold centrioles at the poles of the cell during mitosis. In comparison to control cells, 
stable GRK5 knockdown in HeLa cells significantly impaired aster size. This work 
directly implicates GRK5 in cell cycle regulation and indeed, GRK5 knockdown in 
HeLa cells results in growth 2 /mitosis (G2/M) cell cycle arrest, as assessed by flow 
cytometry [48]. A possible mechanism whereby GRK5 regulates the cell cycle was 
suggested to involve the activation of aurora A kinase (AUKA), which 
phosphorylates polo-like kinase 1 (PLK1), which controls the progression of cells 
from G2 to mitosis (Figure 1.2). In HeLa cells expressing a GRK5 short hairpin 
RNA (shRNA), phosphorylation of PLK1 was delayed and expression levels of 
phosphorylated AUKA were reduced by 50% compared to control shRNA 
expressing cells [48]. The G2/M arrest induced by GRK5 knockdown in HeLa cells 
is not only attributed to the abrogation of AUKA activity, but also to the upregulation 
of p53, which, as will be discussed in section 1.3.3.2, is negatively regulated by 
GRK5 [48, 49].  
 
GRK5 may also be promoting cell cycle progression via its role as a nucleophosmin 
1 (NPM1) kinase [50]. NPM1 is involved in cell cycle control, centrosomal 
duplication, mitosis as well as apoptosis and its phosphorylation by PLK1 at Ser4 is 
important for proper mitotic spindle assembly [50, 51]. While inhibition of PLK1 
ultimately results in apoptosis, it also causes elongated and fragmented nuclei, as 
does the overexpression of an NPM1 S4A mutant in HeLa cells, suggesting the 
PLK1-mediated phosphorylation of NPM1 at Ser4 is responsible for spindle 
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formation, defects of which result in improper cell division. GRK5 phosphorylates 
NPM1 at the same site as PLK1 as well as at Thr199, albeit to a lesser extent, and 
combined Ser4 and Thr199 phosphorylation of NPM1 regulates centrosome 
duplication. The Benovic group did not investigate the implications of GRK5-
mediated NPM1 phosphorylation on cell cycle control but instead focussed on the 
apoptotic phenotype. Their investigation into the functional consequence of GRK5 
activity towards NPM1 highlighted a role for GRK5 in compensating for loss of 
PLK1 activity. GRK5 knockdown in HeLa cells only enhanced apoptosis following 
the combined inhibition of PLK1 by the inhibitor, BI2536, and knockdown of GRK5 
only reduced Ser4 phosphorylation when combined with BI2536 treatment [50].  
 
This latter study by the Benovic group does not necessarily support a role for 
GRK5 in regulating the cell cycle, as the effect of GRK5 knockdown on spindle 
formation was not studied and GRK5 does not regulate centrosomal duplication 
despite phosphorylating both Ser4 and Thr199 on NPM1 [48, 50]. Instead, 
identifying NPM1 as a substrate and binding partner of GRK5 highlights a role for 
GRK5 in regulating apoptosis. Indeed, GRK5 phosphorylates p53, a key activator 
of apoptosis, which triggers its degradation [49]. Furthermore, NPM1 is a nuclear 
protein, therefore implying that the functional role of GRK5 extends beyond the 
plasma membrane and cytoplasm. The nuclear functions of GRK5 and the role of 
GRK5 in regulating apoptosis are discussed in section 1.3.3. 
1.3.3 Functions of GRK5 in the nucleus 
In addition to its established role at the plasma membrane, as well as its role 
regulating the cytoplasmic protein, tubulin, GRK5 can also translocate to the 
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nucleus. The nuclear localisation of GRK5 was first observed in spontaneously 
hypertensive heart failure rat myocytes by immunofluorescence [52] and contrasts 
with GRK2, which is excluded from the nucleus [53].  GRK5, as well as GRK4 and 
GRK6, contain functional NLSs and NESs when overexpressed and are present in 
the nucleus of Human epithelial cell line 2 (HEp2) cells under basal conditions [10]. 
Similarities in amino acid sequence of the NLS and its location within the kinase 
domain of GRK5 and GRK6 compared to GRK4, suggests potential specificities of 
GRK4 subfamily nuclear functions. Furthermore, the NLS of GRK5 and GRK6 bind 
DNA in vitro in contrast to GRK4, which does not [10]. Numerous nuclear 
substrates and binding partners of GRK5 have been identified, enhancing the 
appreciation of GRK5 as a key regulator of a variety of nuclear signalling pathways, 
which will be discussed in this section. 
 
The regulation of GRK5’s nuclear localisation is somewhat debated, particularly the 
mechanism of GRK5 nuclear import and export. CaM binding to GRK5 inhibits 
GRK5-mediated phosphorylation of GPCRs, by disrupting binding to membrane 
phospholipids and has also been proposed to trigger the nuclear localisation of the 
kinase [54, 55]. GRK5 contains two CaM binding sites located at either ends of the 
kinase, between residues 20–39, as well as between residues 540–578 [7]. The 
Koch group propose N-terminal CaM binding to be important for regulating GRK5 
nuclear import. Mutation of Trp30, located in the N-terminal GRK5 CaM binding site, 
to alanine (W30A) severely disrupts the nuclear localisation of the kinase in 
neonatal rat ventricular myocytes (NRVM) following stimulation by Gq or 
phenylephrine, causing the W30A mutant to adopt a very membranous localisation 
[56]. The Benovic group originally attributed N-terminal CaM binding to the 
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inhibition of GPCR phosphorylation by GRK5 [55], but a year later they showed that 
CaM binding to the C-terminal site is most important for inhibition of rhodopsin 
phosphorylation. When expressed in COS-1 cells, a GRK5 construct containing the 
W30A mutation phosphorylated rhodopsin to the same degree as wildtype GRK5 
and furthermore, CaM still inhibited the GRK5 W30A mutant-mediated 
phosphorylation of rhodopsin to the same efficacy as the wildtype kinase [57]. 
Based on these data I would predict that CaM should still be able to disrupt 
membrane binding of the W30A mutant, and, if CaM binding was responsible for 
sending GRK5 to the nucleus, this in turn should trigger relocalisation of the kinase. 
This, however, does not occur, as when the Koch group overexpressed the W30A 
mutant in NRVM, an immunofluorescence experiment showed the mutant to be 
membrane bound [56]. These conflicting results therefore suggest that CaM 
binding may not be responsible for stimulating the nuclear import of GRK5. 
 
In comparison to the Koch group’s immunofluorescence data, a GRK5 construct 
containing mutated polybasic residues in the N-terminal CaM binding site 
(GRK5!NTPB) has a nuclear localisation in HEp2 cells [58]. This GRK5 construct 
is not only unable to interact with CaM, but interactions with PIP2, whose binding 
site overlaps with the N-terminal CaM binding site, are also inhibited. Loss of PIP2 
binding may therefore potentially be responsible for triggering the relocalisation of 
GRK5 to the nucleus. This hypothesis fits with Koch’s data that shows GRK5’s 
nuclear localisation lies downstream of Gq. Following Gq activation, levels of PIP2 
fall due to the initiation of G protein signalling and the subsequent activation of PLC, 
which hydrolyses PIP2.  
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A similar mechanism of disrupted membrane association causing nuclear 
relocalisation has been proposed for GRK6A. The nuclear localisation of GRK6A is 
triggered by disrupting membrane binding through the use of the palmitoylation 
inhibitor, 2-bromopalmitate [59]. GRK6A is localised to the plasma membrane via 
an amphipathic helix as well as via the palmitoylation of cysteine residues located 
within the last 30 amino acids of the kinase [59, 60]. A C-terminal GRK6A deletion 
mutant is no longer plasma membrane localised but instead is redistribution to the 
cytoplasm and also to the nucleus [60].  
 
With loss of PIP2 binding regulating nuclear import, I propose CaM binding to 
regulate the nuclear export of GRK5 in coordination with the NES. Gq activation or 
treatment of HEp2 cells with the calcium ionophore, A23187, both of which 
increase intracellular Ca2+ concentrations, stimulates nuclear export of GRK5 [10]. 
While the overexpression of GRK5!NTPB in HEp2 cells was resistant to ionophore 
treatment, by comparison, mutating similar residues in the C-terminal polybasic 
domain (CTPB) of GRK5 to perturb C-terminal CaM binding did not affect A23187-
dependent nuclear export [11]. I thereby propose that binding of CaM to the N-
terminus of GRK5 therefore mediates Ca2+-dependent nuclear export of the kinase. 
N-terminal CaM binding to nuclear GRK5 is postulated to dissociate the NTPB as 
well as the NLS from DNA, triggering a conformational change to expose the NES, 
thereby triggering relocalisation of the kinase. In contrast, GRK6 is not exported 
following ionophore treatment, suggesting a differential means of nuclear export 
[11].  
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An obvious paradox with this proposed mechanism of nuclear export is that the 
Koch group observe Gq activation to stimulate nuclear localisation of GRK5 in 
NRVM whereas in HEp2 cells Gq activation causes nuclear exclusion of the kinase. 
The difference in observed subcellular localisation may be accounted for by 
differences in the levels of free CaM. In myocytes, most of the CaM is sequestered 
due to the number of calcium-binding proteins present, such that the concentration 
of free CaM is thus very low. According to the literature, concentrations of 
intracellular CaM range between 2–25 µM depending on the cell type. In myocytes 
50–75 nM is free, which is only approximately 1% of total cellular CaM [61]. By 
contrast, in HEK cells, 50% CaM is estimated to be free [61, 62]. In myocytes, I 
hypothesise that when PIP2 levels fall, GRK5 enters the nucleus and as levels of 
activated CaM are too low to promote its nuclear export, the kinase is observed to 
be nuclear by immunofluorescence. In HEp2 cells, however, activation of Gq-
coupled receptors sends GRK5 to the nucleus but it is rapidly exported due to 
relatively high levels of activated CaM, so following receptor activation GRK5 is 
seen by immunofluorescence to be excluded from the nucleus. Clearly more 
research is required to elucidate the regulatory mechanisms controlling the 
subcellular localisation of GRK5. 
 
Despite all GRK4 subfamily members containing a functional NLS, differences in 
their nuclear capabilities and subcellular regulation imply nuclear specific functions 
of the kinases. While nuclear functions of GRK6 and GRK4 are currently 
unreported, several GRK5 nuclear substrates and binding partners have been 
identified.  
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1.3.3.1 Nuclear factor kappa enhancer of activated B cells (NF!B) signaling 
The NF!B family of transcription factors function as multifaceted regulators of cell 
survival mechanisms, controlling the expression of genes that affect inflammation 
and immunity as well as proliferation, apoptosis and tissue remodelling. There are 
five members of the mammalian NF!B family of proteins, which form homo and 
heterodimers: p50 (NF!B1), p52 (NF!B2), p65 (RelA), RelB and c-Rel. Regulation 
of NF!B is mostly focused on the inhibitor of !B (I!B) proteins, which serve to bind 
and sequester NF!B dimers in the cytoplasm. I!B proteins include I!B", I!B#, I!B$, 
I!B%, B-cell lymphoma 3 (Bcl-3) and p105 and p100, which are the precursors of 
p50 and p52 respectively. Phosphorylation of I!B by the I!B kinase (IKK) at 
conserved “destruction box” serine residues, results in I!B ubiquitination and 
degradation and releases NF!B for translocation to the nucleus and subsequent 
upregulation of target genes [63].  
 
Figure 1.3 illustrates the two different NF!B pathways and the roles played by 
GRK5 in the canonical signalling pathway. Activation of the canonical NF!B 
pathway (Figure 1.3A) ensues following stimulation of, among others, tumour 
necrosis factor receptors (TNFRs), toll-like receptor 4 (TLR4) and the interleukin 
receptor-1. Instigation of signalling cascades culminates in the activation of IKK# 
(IKK2), which resides in complex with IKK" (IKK1) and the regulator, IKK& (NEMO). 
Substrates of IKK# include I!B". The identification of NLS and NES domains in the 
I!B"/p65/p50 complex suggests its continual nuclear-cytoplasmic shuttling. The 
complex, however, remains cytoplasmic in the steady state due to the combined 
exposure of the NES on I!B", as well as masking of the NLS on p65 [64]. In 
contrast, the non-canonical signalling pathway (Figure 1.3B) involves activation of 
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IKK!, is independent of NEMO and results in the proteolysis of p100, which leaves 
p52/RelB heterodimers free to shuttle to the nucleus. Phosphorylation of IKK! is 
catalysed by NF"B inducing kinase. IKK! and IKK# can also mediate crosstalk with 
other signalling pathways including MAPKs, which are activated by GPCRs as well 
as toll-like receptors. 
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Figure 1.3 NF!B signalling network 
A. The classical pathway is mediated by IKK! and results in phosphorylation of I"B#. GRK5 can 
phosphorylate I"B# following the activation of TNFRs but it binds and inhibits I"B# 
phosphorylation following TLR4 stimulation. B. The non-canonical pathway begins with IKK# 
phosphorylation by NF"B inducing kinase (NIK) and results in degradation of the I"B protein, 
p100. p52/RelB heterodimers then translocate to the nucleus. Adapted from [64].  
 
The link between GRKs and NF"B regulation stemmed from the identification of 
arrestin proteins as indirect NF"B signalling mediators. The elucidation of novel 
functions of the GRKs distinct from receptor phosphorylation sparked the 
expansion of these studies to identify whether the GRKs could also feature in the 
NF"B pathway and indeed, GRK5 is an important regulator of NF"B activity. 
Mechanistically, this is due to interactions of GRK5 with I"B and in some cases 
GRK5-mediated I"B phosphorylation, the functional consequences of which may 
depend on the cell type, the initiating stimulus and the I"B isoform involved (Figure 
1.2). 
 
Work by the Iaccarino group has shown GRK5 to bind directly to I"B# in endothelial 
cells, triggering translocation of the complex to the nucleus, which thereby reduces 
NF"B-mediated transcription. Interestingly, GRK5 binds to the N-terminus of I"B#, 
which may mask the NES located in its C-terminus, thus sequestering I"B#/NF"B 
in the nucleus. The GRK5/I"B# relocalisation can be triggered by isoproterenol, 
which activates !-adrenergic receptors, suggesting that GRK5 regulates I"B# 
following GPCR activation. The GRK5/I"B# interaction alone is responsible for 
inhibiting NF"B, rather than GRK5 kinase activity; overexpression of a kinase dead 
GRK5 mutant, GRK5$K215R, in bovine aortic endothelial cells, behaved like GRK5 
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wildtype with regards to I!B" nuclear accumulation and the phosphorylation state 
of I!B" remained constant following wildtype GRK5 overexpression. The binding 
site on I!B" has been mapped to the RH domain in the N-terminus of GRK5 and 
the overexpression of this domain alone (GRK5-RH) resulted in reduced NF!B 
stimulation following lipopolysaccharide (LPS) stimulation of TLR4.  GRK2 can also 
co-immunoprecipitate with I!B" but fails to regulate NF!B-mediated transcription 
[65]. 
 
Combined studies by the Benovic and Parameswaran groups have identified 
contrasting roles for GRK5 in regulating NF!B signalling pathways. In keeping with 
findings by the Iaccarino group, Benovic and Parameswaran showed GRK5 to 
negatively regulate TLR4-induced ERK activation by inhibiting the phosphorylation 
of the NF!B precursor, p105, in macrophages [66]. The MAPK kinase kinase 
protein, tumour progression locus 2 (TPL2) is sequestered by p105 in an inactive 
state; following phosphorylation and subsequent degradation of p105, TPL2 is free 
to initiate the MAPK signalling cascade that culminates in ERK1/2 activation [67]. 
GRK5 binds directly to the C-terminus of p105 at I!B#, blocking its phosphorylation 
by IKK. GRK2 is also capable of p105 binding but specific to GRK5 is its ability to 
regulate p105 phosphorylation; knockdown of GRK5 as opposed to GRK2 
increases p105 phosphorylation in vitro, which correlates with increased ERK1/2 
activation [66]. GRK2 has been shown to negatively regulate the NF!B p105-ERK 
pathway in vivo. GRK2 deletion in myeloid cells of mice increases inflammatory 
cytokine and chemokine production following LPS stimulation and macrophages 
derived from these mice show reduced ERK1/2 phosphorylation following LPS and 
IKK inhibitor treatment [68]. Furthermore, GRK2 may work in concert with GRK5 to 
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inhibit this pathway, as GRK5 knockout mice only displayed marginally enhanced 
p105-ERK signalling, suggesting that perhaps GRK2 compensates for loss of 
GRK5 [69]. 
 
Contrasting with the inhibition of p105 by GRK5 following TLR4-stimulation in 
macrophages, a major role for GRK5 in positively regulating I!B"-NF!B signalling 
via TLR4 activation has been identified from in vivo studies performed by the 
Parameswaran group. Cytokine and chemokine production was largely attenuated 
in GRK5 knockout mice and p65 nuclear translocation and I!B" phosphorylation 
were significantly reduced in LPS treated GRK5-/- macrophages, compared to 
GRK5+/+ macrophages [69]. GRK5 also positively regulates the NF!B pathway 
invoked following tumour necrosis factor " (TNF") stimulation, as does GRK2 [70]. 
Knockdown of GRK2 and GRK5 inhibited I!B" phosphorylation, nuclear 
translocation of p65/p50 and NF!B transcriptional activity in macrophages following 
TNF" treatment. Both kinases bind and phosphorylate I!B", but the sites of 
phosphorylation are different; GRK5 but not GRK2 phosphorylates I!B" at 
Ser32/Ser36, the same sites as IKK#. An I!B" S32A/S36A mutant exhibited 
approximately 60% reduced in vitro GRK5-mediated phosphorylation, compared to 
wildtype I!B". GRK2, however, phosphorylated both wildtype and mutant I!B" to 
the same degree. GRK5 and GRK2 therefore regulate I!B" differently following 
TNF" stimulation and furthermore, GRK5 regulates I!B" in opposing manners 
depending on the cell type [65, 70]. Additionally, the positive regulation of NF!B by 
GRK5 may be evolutionarily conserved. Gprk2, the Drosophila equivalent of 
mammalian GRK5, activates NF!B following bacterial stimulation. This mechanism 
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is also conserved in zebrafish and in HeLa cells, as knockdown of Gprk2 or GRK5 
impaired NF!B transcriptional activity [71]. 
 
The regulation of NF!B-mediated gene expression is therefore extremely complex, 
with the activation of different receptors initiating alternative signalling pathways 
that involve different methods of NF!B regulation in different cell types. Activation 
of TLR4 via LPS causes GRK5 to bind and stabilise p105 in macrophages, making 
the complex less susceptible to IKK phosphorylation, thereby inhibiting NF!B [66]. 
GRK5 differentially regulates I!B" depending on the stimulus and cell type. LPS 
induces an interaction between the kinase and I!B", which stabilises the 
I!B"/NF!B complex in the nucleus of endothelial cells, thereby preventing NF!B-
mediated transcription [65]. In macrophages however, GRK5 positively regulates 
LPS-induced NF!B signalling by phosphorylating I!B" [69] and a similar 
mechanism has been shown to occur following TNFR stimulation; TNF" causes 
GRK5 phosphorylation of I!B" at sites overlapping with IKK#, thereby relieving 
NF!B inhibition [70]. The method of GRK5-mediated NF!B regulation therefore 
varies depending on the stimulus, cell type and I!B" isoform, with GRK5 playing a 
dual role in regulating NF!B signalling. The implications of the GRK5-mediated 
NF!B regulation are vast due to the plethora of transcriptional targets of NF!B, 
including not only cytokines and chemokines but also negative regulators of 
apoptosis, including B cell lymphoma 2 (Bcl-2), whose role in apoptosis and 
disease is discussed in sections 1.3.3.2 and 1.4 respectively. Furthermore, 
deregulation of NF!B signalling is involved in many diseases, with upregulated 
activity common to colon cancer and pathological cardiac hypertrophy, which are 
discussed in section 1.4.  
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1.3.3.2 Apoptosis 
DNA damage results in two possible outcomes: delay to cell cycle progression 
allowing for effective repair, or programmed cell death if the damage is deemed 
irreparable. Double stranded breaks (DSB) in DNA activate kinases ataxia 
telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR), to 
trigger a phosphorylation cascade that can result in DNA repair, checkpoint control 
or apoptosis depending on the extent of the damage. The tumour suppressor 
protein, p53, is a major determinant of cell fate, whose phosphorylation and 
stabilisation by ATM controls the switch between apoptosis and growth arrest. The 
extent of DNA damage affects the sensitivity to p53 levels, which regulates the 
response to DNA damage by activating different signalling pathways. Following 
minor DSB only a small fraction of p53 is needed to drive the expression of p21, 
which halts cell cycle progression by eliciting arrest in G1. This high sensitivity to 
p53 promotes DNA repair pathways, which would have time to act due to the p53-
mediated inhibition of cell growth. In contrast, major DSB result in a higher 
concentration of p53 accumulating, which in turn leads to the activation of apoptotic 
pathways [72]. The difference in p53 sensitivity in relation to the severity of DNA 
damage thereby regulates cell fate. 
 
P53 is crucial in determining the cellular response to stress, not only by inducing 
apoptosis but by also having a role in growth arrest. Induction of p53-dependent 
apoptosis occurs via extrinsic or intrinsic pathways depending on apoptosis signals 
and converges on the activation of caspase proteins (Figure 1.4). Following DNA 
damage, the intrinsic apoptotic pathway is activated, whereby cytochrome C is 
released from mitochondria and forms a complex with apoptosis protease-
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activating factor 1 (Apaf1). Seven Apaf1 monomers oligomerise in complex with 
cytochrome C and bind to pro-caspase 9, to form a complex known as the 
apoptosome. The apoptosome forms a platform for caspase 9 activation, recruiting 
the pro-caspase 9 zymogen and catalysing its cleavage and thus activation, which 
in turn triggers a caspase cascade, resulting in the cleavage and activation of 
effector caspases 3, 6 and 7 [73]. The intrinsic apoptotic pathway is controlled by 
the Bcl-2 family of proteins, which comprise both pro- and anti-apoptotic members, 
which regulate the release of cytochrome C from mitochondria. There are three 
main classes of Bcl-2 proteins: Bcl-2 and its structurally related protein, B cell 
lymphoma-extra large (Bcl-xl), are anti-apoptotic proteins with a pro-survival 
phenotype, inhibiting pro-apoptotic Bcl-2 family members, Bax and Bak. Bax and 
Bak permeabilise the outer mitochondrial membrane, thereby enabling release of 
cytochrome C, as illustrated in Figure 1.4. All four proteins are structurally similar 
and contain four Bcl-2 homology (BH) domains. The final group of Bcl-2 family 
proteins are structurally dissimilar, BH3 only proteins that comprise this BH domain 
alone and work in a pro-apoptotic manner by binding and inhibiting anti-apoptotic 
Bcl-2 family members. Examples of BH3 only proteins include Bid, Bad, PUMA and 
NOXA [74]. Through binding and sequestering Bcl-2 and Bcl-xl, BH3 only proteins 
relieve the inhibition of pro-apoptotic Bcl-2 family proteins. The extrinsic and 
intrinsic pathways are linked by the BH3 only protein, Bid, which, as shown in 
Figure 1.4, is activated by caspase 8, which itself is activated following receptor 
stimulation that occurs in the extrinsic pathway. Cleavage of Bid exposes an N-
terminal glycine residue to myristoylation, which results in its relocalisation to 
mitochondria where it activates Bax and Bak [73]. 
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P53 triggers the expression of Apaf1 and BH3 proteins and upregulates caspase 
expression. P53 also upregulates the expression of extrinsic pathway receptors, 
Fas, DR5 and PERP, by increasing mRNA levels, and promotes trafficking of the 
Fas receptor to the cell surface from the Golgi. As shown in Figure 1.4, Fas is 
activated by its ligand, FasL, following tissue specific !-radiation. The death-domain 
containing receptor, DR5, is stimulated by its ligand, TRAIL, following DNA damage. 
PERP is expressed in mouse embryonic fibroblasts (MEFs) but its mechanism of 
p53-mediated apoptosis is currently unidentified. Initiator caspases 8 and 10 are 
activated by these receptors and cleave the pro-caspase 3 zymogen, as well as Bid 
[73]. 
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Figure 1.4 Intrinsic and extrinsic apoptosis pathways  
DSB are detected namely by ATM and ATR, which activate p53. Once activated, p53 enhances 
both the intrinsic and extrinsic apoptotic pathways by upregulating the expression of key 
proteins involved in both pathways, shown in red. P53 can also localise to mitochondria to 
promote a transcription-independent mechanism of apoptosis via cytochrome C release. Taken 
from [73]. 
 
The Ma group showed GRK5 to phosphorylate p53 in vitro and in vivo at Thr55, 
which results in reduced p53 levels. Treatment with the proteasome inhibitor, 
MG132, prevented the reduction in p53, thus confirming its degradation is via the 
proteasome. GRK5 knockout mice displayed tissue-wide aberrant upregulation of 
p53 implying that GRK5 negatively regulates p53 in vivo. GRK5-mediated p53 
degradation directly affects apoptosis, as knockdown of GRK5 in the osteosarcoma 
cell line, U2OS, increases apoptosis by 40% following cisplatin treatment. 
Apoptosis of Saos-2 cells, which are p53 null, were unaffected following GRK5 
knockdown, thus suggesting that GRK5 induces apoptosis via p53 [49]. 
 
Activation of p53 involves its release from repressors, its stabilisation and DNA 
binding to trigger the upregulation of target genes. Phosphorylation of p53 is crucial 
for its stabilisation. N-terminal phosphorylation occurs rapidly after DNA damage 
and is catalysed by a range of kinases including ATM and ATR. Phosphorylation 
serves to activate p53 and inhibit the interaction with the E3-ubiquitin ligase, mouse 
double minute 2 (Mdm2). Mdm2 is the principal ubiquitin ligase that acts on p53, 
triggering its destruction by the proteasome, but Mdm2-independent pathways of 
p53 destruction can also occur via other ubiquitin ligases, such as COP1. 
Phosphorylation of Ser15 and Ser20 are considered most important for activating 
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p53 and inhibiting Mdm2 binding, yet knockin mouse models with mutated residues 
Ser18 and Ser23, the mouse equivalent of Ser15 and Ser20, question the 
importance of these residues. Mutation of either residue to alanine only slightly 
reduced p53 levels in vivo and severe effects in double S18/23A mutant mice were 
only noted in specific tissues [75]. Either phosphorylation of additional residues is 
necessary to regulate p53 stability or the mechanism of p53 regulation is far more 
complex.  
 
Phosphorylation of Thr55 by GRK5 enhances the interaction of p53 with Mdm2 and 
thus its degradation [49] (Figure 1.2). The interaction between Mdm2 and p53 
takes place in the nucleus, as does p53 ubiquitination. Mdm2 promotes the nuclear 
export of ubiquitinated p53, which leads to its degradation in the cytoplasm [76]. 
Whether p53 is a nuclear GRK5 substrate is yet to be confirmed but this is highly 
likely considering the mechanism of p53 regulation. Phosphorylation at Thr55 
induces the association of p53 with the nuclear export factor, chromosome region 
maintenance 1 protein (CRM1) and the promotion of this interaction by Mdm2 is 
dependent on Thr55 phosphorylation [77]. P53 phosphorylation by GRK5 is 
therefore likely to occur in the nucleus and may function to catalyse the cytoplasmic 
shuttling of ubiquitinated p53, to mediate its degradation by the proteasome by 
enhancing its interaction with Mdm2 and thus CRM1. A functional consequence of 
Thr55 phosphorylation has been studied in the breast cancer cell line, MCF7; 
ERK2 phosphorylation of p53 at Thr55 increases sensitivity of cells to the 
chemotherapeutic drug, doxorubicin (DOXO) [78]. 
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It is worth noting that apoptosis is not solely induced by p53. Over 50% of tumours 
have mutated p53 proteins, and one of the most common mutations is at Arg273, 
which renders the protein unable to bind DNA and therefore inactive. While 
chemotherapy and radiotherapy can induce apoptosis in these cells, potentially via 
p53 homologues, p63 and p73, or via alternative apoptotic pathways such as NF!B 
activation, the challenge of inducing apoptosis is much greater if cells are deficient 
in wildtype p53 [79].  
 
Through its phosphorylation of p53 at Thr55, GRK5 acts to inhibit p53-mediated 
apoptosis by upregulating p53 degradation via the proteasome. Conversely, GRK5 
has been shown to negatively regulate Bcl-2 transcription in SHSY5Y cells, which 
is predicted to increase cell death, although the impact of this regulation on 
apoptosis has not been examined prior to my thesis work [80]. Deregulated 
apoptosis plays a key role in many diseases. In cancer, p53 is often mutated and 
apoptosis is downregulated in order to promote unprecedented cell growth. 
Conversely, in cardiovascular diseases, apoptosis is often prevalent, causing 
cardiac myocyte cell death. GRK5 expression levels vary in disease states 
including cancer and cardiac hypertrophy and may thereby differentially regulate 
apoptosis. The contribution of apoptosis and GRK5 to disease progression, 
including cancer and pathological cardiac hypertrophy, will be discussed in more 
detail in section 1.4. 
1.3.3.3 Histone deacetylase (HDAC) 5 phosphorylation  
Subjecting mice to cardiomyocyte-specific overexpression of wildtype GRK5 and 
inducing hypertrophy via transverse aortic constriction (TAC), results in 
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exaggerated pathological hypertrophy, premature heart failure and death. Mice 
overexpressing GRK5!NLS, however, behave like control littermates [81]. The 
elucidation of a mechanism whereby nuclear GRK5 causes hypertrophy led to the 
identification of the first nuclear substrate of the kinase, HDAC5. 
 
Nuclear activation of the transcription factor, myocyte enhancing factor 2 (MEF2), 
downstream of Gq-GPCRs, involves the regulation of class II HDACs, of which 
HDAC5 is a member. HDAC5 binds and sequesters MEF2 in the nucleus under 
basal conditions. Phosphorylation of HDAC5 triggers its release of MEF2 and its 
concurrent nuclear export via the recruitment of 14-3-3 proteins. MEF2 is 
subsequently able to activate pro-hypertrophic foetal cardiac genes, which are 
aberrantly expressed in pathological hypertrophy [82, 83], such as atrial natriuretic 
factor (ANF) whose transcriptional upregulation is illustrated in Figure 1.2. This 
cardiac remodelling, switching from the adult to foetal gene program, occurs 
following various stress triggers including volume or pressure overload, myocardial 
infarction and hypertension. By identifying HDAC5 as a GRK5 substrate, the Koch 
group identified the first nuclear function of GRK5. GRK5 was identified as a novel 
HDAC5 kinase, phosphorylating HDAC5 at Ser259 and Ser498, the same sites 
targeted by previously identified HDAC5 kinases, CaM kinase II (CaMKII) and 
protein kinase D (PKD) [81, 83, 84]. GRK5 binds HDAC5 in NRVM and 
phosphorylates HDAC5 in vitro. The kinase activity of GRK5, as well as its nuclear 
localisation is therefore important for the resultant upregulation of MEF2 activity 
[81]. The implications of this mechanism of GRK5-mediated pathological cardiac 
hypertrophy will be discussed in more detail in section 1.4.1, where the role of 
GRK5 in cardiovascular disease is explained in depth. 
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1.4 GRK5 in disease 
The altered expression of GRKs is associated with many disease states including 
cardiovascular disease (CVD), cancer and psychiatric disorders. 
1.4.1 Pathological cardiac hypertrophy 
GRK5 and GRK2 are the primary GRK members expressed in the heart. A 
hallmark of human heart failure is impaired !-adrenergic receptor signalling. GRK2 
is the predominant kinase responsible for !-adrenergic receptor phosphorylation, 
such that GRK2 upregulation and increased activity have long been known to play 
a causative role in CVDs, particularly hypertension [85, 86]. GRK5 is upregulated in 
patients with left ventricular overload disease, which is associated with hypertrophic 
cardiomyopathy (HCM) but the role of GRK5 in cardiac myocyte signalling has 
been less understood until recently [87, 88]. The significance of elevated GRK5 
levels were only appreciated when mice with cardiac specific overexpression of 
GRK5 were stressed by TAC during experiments performed by the Koch group to 
investigate whether elevated GRK5 levels influenced the myocardial response to 
pressure overload and affected the development of pathological hypertrophy [81]. 
The murine TAC model mimics pressure overload and is used extensively as a tool 
to model human CVD and to probe the mechanism behind cardiac hypertrophy and 
the development of heart failure in vivo [89]. Patients with ventricular overload 
disease have elevated cardiac expression of GRK5, such that transgenic mice 
overexpressing GRK5 are predicted to model the disease [88, 90]. It was only by 
stressing the transgenic mice that the contribution of GRK5 to pathogenesis was 
understood. Compared to littermate control mice and GRK2 transgenic mice that 
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behaved in a similar manner, subjecting mice to cardiac myocyte-specific 
overexpression of wildtype GRK5 resulted in exaggerated pathological hypertrophy, 
premature heart failure and death in response to TAC. This response was 
abrogated in GRK5!NLS transgenic mice, implicating nuclear GRK5 as a 
causative factor in disease pathology. Investigating the mechanism in NRVM, the 
Koch group found GRK5 to accumulate in nuclei in response to hypertrophic stimuli, 
such as overexpression of Gq coupled GPCRs. A potential mechanism by which 
nuclear GRK5 exaggerates hypertrophy development is by acting as an HDAC5 
kinase, whose phosphorylation triggers its nuclear export, relieving the inhibition of 
MEF2 and thus resulting in the upregulation of pro-hypertrophic foetal cardiac 
genes [81]. These data therefore implicate GRK5 in a pro-hypertrophic mechanism, 
suggesting a causative role for the kinase in progression towards heart failure.  
 
The Iaccarino group has shown an N-terminal GRK5 peptide to be cardioprotective 
in vitro and in vivo. As previously discussed, the N-terminal domain of GRK5 
inhibits NF"B mediated transcription, as the RH domain interacts with inhibitory 
subunit, I"B#, preventing its phosphorylation and subsequent degradation in 
endothelial cells [65]. NF"B activity is activated in human failing hearts and in vitro 
studies have demonstrate the requirement of this transcription factor for 
hypertrophic growth of cardiac myocytes in response to GPCR agonists [91, 92]. In 
vivo and in vitro expression of an adenovirus that encodes for the RH domain 
within the amino terminal of GRK5 (AdGRK5-NT) prevented left ventricular 
hypertrophy [93]. These data therefore suggest that the N-terminus of GRK5 
functions in an anti-hypertrophic manner, in contrast to the role of nuclear GRK5 as 
an HDAC5 kinase, which has a pro-hypertrophic function. The effect of the intact 
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kinase on NF!B-mediated cardiac hypertrophy, however, has not been studied. 
Since mice lacking endogenous cardiac GRK5 are protected from TAC-induced 
hypertrophy, I predict GRK5 to be acting in a dominant pro-hypertrophic manner. 
 
GRK5 is further implicated in hypertrophy, potentially via its canonical role in 
receptor desensitisation. A cardioprotective GRK5 Gln41Leu polymorphism has 
been found among the African American community [14]. The Liggett group 
attributed the beneficial effects mediated by the Leu41 polymorphism to 
augmentation of "-adrenergic receptor desensitisation, based on in vitro studies 
and on transfected cells and transgenic mice overexpressing the Gln41Leu GRK5 
mutant [94, 95]. A study in humans, however, contests this theory and showed the 
GRK5 polymorphism did not affect sensitivity to the "-adrenergic receptor blocker, 
atenolol, following acute adrenergic stimulation [96]. This discrepancy may be due 
to the acute stimulus used in the human study, as prolonged adrenergic stimulation 
is more likely to enhance receptor desensitisation.  
 
The role of GRK5 in pathological cardiac hypertrophy is therefore extremely 
complex. While the N-terminal RH domain of GRK5 appears to have a 
cardioprotective function, the intact kinase exacerbates pathological cardiac 
hypertrophy. Upregulation of GRK2 occurs to a greater degree than GRK5 in heart 
failure patients and, as such, the physiological role and regulation of GRK5 in 
cardiovascular diseases has not been extensively characterised. Studies by the 
Koch group have greatly advanced the appreciation of GRK5 as a causative 
component of pathological cardiac hypertrophy. Elucidation of the mechanisms 
regulating GRK5 nuclear localisation and activity may thus lead to important 
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therapeutic advances. 
1.4.2 Neurodegenerative disease 
Alzheimer’s disease (AD) represents one of the most common forms of dementia. 
Most patients with Parkinson’s disease (PD) develop dementia in later stages of 
the disease, but the hallmark of PD is degeneration of the central nervous system. 
GRK5 has been implicated in the pathology of both of these neurodegenerative 
diseases. 
 
AD is a neurodegenerative disease pathologically associated with the accumulation 
of !-amyloid plaques and neurofibrillary tangles, which are composed of 
phosphorylated tau, in neurons. Imbalanced neuronal signal transduction is a 
hallmark of the disease and is attributed to hyperactive G protein signalling, which 
can arise due to impaired GPCR desensitisation. In the context of AD, perturbed 
receptor desensitisation potentially results from !-amyloid-induced relocalisation of 
GRK5 to the cytoplasm. Pre-treatment of microglia with !-amyloid enhanced 
thrombin induced GPCR activity and significantly reduced interactions of GRK5 
with the GPCR, PAR1. While thrombin treatment stimulated the GRK5/PAR1 
interaction, as would be expected following GPCR activation, pre-treatment with !-
amyloid reduced the binding of GRK5 by approximately 80%. Immunofluorescence 
experiments attributed the loss of GRK5 binding to GPCRs to the !-amyloid 
stimulated cytoplasmic re-localisation of GRK5. In vivo work using AD transgenic 
mice showed this relocalisation occurs at the early stages of disease pathogenesis, 
prior to cognitive decline and persists into the later stages of the disease [97]. This 
suggests that loss of GRK5 at the membrane may be a causative factor, 
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contributing to AD pathogenesis. Aged GRK5 knockout mice displayed mild 
cognitive impairment, with short-term memory deficiencies and hypoalertness, as 
well as increased axonal defects. Clusters of axonal swellings were also noted, 
which included elevated levels of total and phosphorylated tau, as well as !-
amyloid [98].  
 
The mechanism by which GRK5 plays a causative role in AD is unclear but the 
GRK5 deficiency at the plasma membrane links both the cholinergic and !-amyloid 
hypotheses of AD pathogenesis.  These hypotheses attribute the cognitive decline 
associated with AD to !-amyloid accumulation, which is toxic to neurons, or 
deregulated cholinergic signalling, respectively [99]. Presynaptic hypercholinergic 
dysfunction reduces acetylcholine release resulting in post-synaptic 
hypocholinergic signalling, both of which are detected in cortex and hippocampal 
tissues of AD patients, along with a reduced activity of choline acetyltransferase, 
which catalyses acetylcholine production [100]. Instead of conflicting, the two 
hypotheses rather emphasise different aspects of disease pathology and are likely 
to integrate to some degree. Indeed, post-synaptic hypocholinergic activity 
promotes the processing of the !-amyloid precursor protein, which thus promotes 
!-amyloid accumulation. Furthermore, !-amyloid is the main cause of GRK5 
cytoplasmic relocalisation and it is the relocalisation of the kinase that impairs 
cholinergic desensitisation [99].  
 
PD pathology involves the degeneration of dopaminergic neurons in the substantia 
nigra and the accumulation of phosphorylated "-synuclein proteins in Lewy bodies, 
which are neuronally toxic. Synucleins are soluble proteins expressed primarily in 
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neurons and no discernable function has been identified for either !-, "- or #-
synuclein. Via interactions with tubulin, there is potential for !-synuclein to be a 
microtubule associated protein and it may play a role in blocking endoplasmic 
reticulum-to-Golgi trafficking in PD [45, 101]. GRK5 co-localises with !-synuclein in 
neurons of PD patients, accumulating in Lewy bodies where it functions as an !-
synuclein kinase. Overexpression of GRK5 in HEK293 cells stably expressing !-
synuclein and treated with a phosphatase inhibitor resulted in significant 
phosphorylation of !-synuclein at Ser129, which increased with increasing 
concentration of OA, a protein phosphatase 1/2A inhibitor. In the Drosophila model 
of PD, phosphorylation of !-synuclein at Ser129 renders the protein toxic to 
dopaminergic neurons, potentially by inducing the aggregation of !-synuclein 
monomers [102, 103]. The Qin group in China, however, showed that knockdown 
of GRK5 in the neuroblastoma cell line, SHSY5Y, did not affect Ser129 
phosphorylation levels [80]. This latter finding implies that while !-synuclein is a 
GRK5 substrate, GRK5 is not the sole kinase involved in catalysing Ser129 
phosphorylation and suggests that other kinases can compensate for the loss of 
GRK5. The group went on to show that GRK5 expression levels are upregulated in 
!-synuclein stably expressing mice and that the kinase upregulates HDAC activity 
in these cells compared to SHSY5Y cells. !-Synuclein stably expressing cells, 
which have higher GRK5 expression levels compared to SHSY5Y cells, also have 
lower Bcl-2 protein levels and the same is true for !-synuclein stably expressing 
mice compared to control, nontransgenic mice. Reverse transcription – polymerase 
chain reaction (RT-PCR) experiments showed knockdown of GRK5 in SHSY5Y 
cells to slightly but significantly increase Bcl-2 mRNA levels [80]. Additionally, post-
mortem studies illustrated that PD patients have increased GRK5 protein and 
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mRNA levels [104]. So while GRK5 may not have a crucial role as an !-synuclein 
kinase, upregulation of GRK5 in PD is likely to play a causative role in 
pathogenesis, potentially by inducing transcriptional repression of Bcl-2 by 
upregulating HDAC activity, whose function is discussed in detail in section 1.5. 
The consequence of GRK5-mediated Bcl-2 inhibition on PD progression is 
currently uncertain, but may suggest a role for apoptosis in disease pathology. 
1.4.3 Cancer 
Aberrant activation and/or expression of GPCRs are associated with many 
malignancies, which thereby implicates GRKs in cancer pathology. Unprecedented 
cell growth and proliferation, angiogenesis and suppression of apoptosis are 
common cellular features of cancer cells. The role of GRK5 in cell cycle regulation 
and apoptosis, as discussed in section 1.3.2.1 and 1.3.3.2, respectively, implicates 
GRK5 in cancer pathogenesis beyond its role as a GPCR kinase. Moreover, 
findings by the Qin group that GRK5 upregulates HDAC activity, suggests an 
additional function for GRK5 in promoting gene repression and considering cancer 
is associated with aberrant gene expression, reinforces a potential role for GRK5 in 
this collection of diseases, which is the main focus of my thesis. 
1.4.3.1 Prostate cancer 
GRK5 has been directly implicated in prostate cancer pathogenesis, as knockdown 
of the kinase in the prostate cancer cell line, PC3, attenuated proliferation. Stable 
knockdown of GRK5 using a shRNA construct also reduced tumour growth rates 
following the implantation of these cells into immunodeficient mice. A kinase-
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dependent function of GRK5 in regulating prostate tumour growth is implied, as 
tumour growth rates were restored following the overexpression of wildtype but not 
kinase dead GRK5 and kinase activity is important in regulating cell cycle 
progression of PC3 cells [12].  
 
GRK5 knockdown in PC3 cells caused an accumulation of cells in G2/M, with a 
concomitant decrease of cells in G1 phase of the cell cycle. Consistent with these 
findings, levels of the cell cycle markers, cyclin D1 (G1-phase marker) and 
phosphorylated histone H3 (G2/M marker), were reduced and elevated respectively 
[12]. As explained in section 1.3.2.1, GRK5 is implicated in cell cycle regulation via 
interactions with tubulin, its localisation at centrosomes and its promotion of 
centrosome nucleation. GRK5 knockdown in HeLa cells leads to G2/M cell cycle 
arrest [48] and a similar finding in PC3 cells reinforces the role played by GRK5 not 
only in cancer pathogenesis but also in cell cycle regulation. A possible 
mechanistic explanation of GRK5-mediated regulation of prostate cancer cell 
proliferation is via the phosphorylation of retinoblastoma protein (Rb). Rb 
hyperphosphorylation is detected in the early stages of G1 in rapidly proliferating 
cancer cells, as the phosphorylated protein relieves inhibition of the transcription 
factor, E2F1. Knockdown of GRK5 resulted in a hypophosphorylated form of Rb, 
and abrogated expression of E2F1 target genes [12]. The role of GRK5 in 
regulating cell cycle progression thereby highlights a role for GRK5 in prostate 
cancer pathology.  
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1.4.3.2 Glioblastoma multiforme (GBM) 
GRK5 has also been implicated in the proliferation of GBMs, which are the most 
common brain tumours in adults. These tumours are thought to arise from GBM 
initiating cells with stem cell markers (GSC). A role for GRK5 in GBM has been 
elucidated, with expression levels of the kinase being highest in primary GBMs and 
positively correlating with the aggressiveness of the tumour. Furthermore, GRK5 is 
more highly expressed in GSC, which, compared to non-GSC or differentiated 
GBM cells, are more resistant to treatment [105]. While the cause and mechanistic 
implications of altered GRK5 expression are yet to be elucidated, GRK5 has been 
shown to regulate GBM proliferation. Stable knockdown of GRK5 in GBM cells 
significantly reduced proliferation rates [105].  
1.4.3.3 Thyroid carcinoma 
GRK5 and GRK2 are the predominant GRK isoforms in human thyroid, playing a 
role in regulating thyroid stimulating hormone (TSH) receptors [106, 107]. TSH 
receptor stimulation is linked to elevated levels of cyclic AMP (cAMP) and basal 
levels of cAMP have been found to be significantly higher in differentiated thyroid 
carcinoma (DTC) compared to normal thyroid tissue (NTT) [108, 109]. Reduced 
GRK5-mediated TSH desensitisation is thought to play a role in disease 
pathogenesis.   
 
Despite the involvement of both kinases in TSH receptor desensitisation, 
expression of GRK5 but not GRK2 was significantly reduced in DTC in comparison 
to NTT. In contrast, rhodopsin-directed GRK activity was upregulated in DTC [110]. 
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The enhanced TSH activity could be attributed to the reduced GRK5 levels, while 
the increased GRK activity is likely to be GRK2 dependent. All samples assayed for 
GRK activity were tested for GRK2 protein expression levels and while no 
significant difference in GRK2 expression levels were detected overall by Western 
blotting, two patients out of the ten had paired samples showing relatively higher 
GRK2 protein expression compared to their normal tissues. A positive correlation 
was observed for GRK2 expression levels and GRK activity and considering 
rhodopsin is a preferred substrate of GRK2 compared to GRK5, GRK2 
upregulation is the likely cause of the increased GRK activity [110]. 
 
TSH downregulates GRK5 protein and mRNA levels in rat thyroid cells and the 
reduced TSH desensitisation in DTC compared to NTT suggests that GRK5 may 
also regulate receptor signalling [106, 110]. GRK5 expression may therefore 
account for the perturbed TSH receptor desensitisation and subsequent 
upregulation of cAMP levels in thyroid tumours. 
1.4.3.4 Colorectal cancer (CRC) 
Considering CRC is a main focal point of my thesis, I will explain the disease 
pathogenesis in more detail compared to the other diseases mentioned thus far. 
CRC is the second largest cause of cancer mortality in the United States; it is 
estimated that more than 100,000 new cases were diagnosed in 2010 alone, half of 
which resulted in death [111].  Patient prognosis correlates with the stage at which 
the disease is detected; survival of patients five years post diagnosis ranges from 
74–93.2% for those diagnosed with stage I cancers, which are confined to the 
colon, but is only 5.7–8.1% for those with stage IV, metastatic disease [112]. It is 
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estimated that 60% of CRC related deaths could be prevented if screening 
methods were more widely utilised [113]. Stage I cancers can be cured by 
aggressive surgery, yet only 39% of patients present with such tumours at the time 
of diagnosis [American Cancer Society, Cancer Facts and Figures, 2012]. Once the 
cancer spreads beyond the inner lining of the colon and metastasises to the lymph 
nodes, patients can be treated post surgery with adjuvant chemotherapy agents 
such as 5-fluorouracil (5-FU), which acts as the backbone in most combinatorial 
therapeutic approaches. One combinatorial therapeutic study in stage II and III 
CRC patients treated with 5-FU, leucovorin and oxaliplatin resulted in a 78.2% 
survival rate three years post treatment [114]. Treatment of stage IV metastatic 
CRCs represents a more serious clinical problem particularly if secondary tumours 
are not resectable, as such late stage cancers are often chemo-resistant. 
 
Over 50% of CRCs arise from large, pre-existing adenomas, or polyps, whose 
benign cells undergo transformation over a series of years and thus become 
malignant [115]. Transformation ensues following the accumulation of four to seven 
genetic mutations that result in altered cellular proliferation. 60–80% of 
adenomatous polyps show loss of heterozygosity in the APC gene, which is 
believed to be one of the earliest acquired mutations in the development of CRC 
[115, 116]. A collection of mutations in key oncogenes and tumour suppressor 
genes including MLH-1, K-Ras and p53, arise in a non-linear fashion, causing the 
adenomatous polyp to progress into a carcinoma. Additionally, overexpression of 
the anti-apoptotic protein, Bcl-2, is associated with early development of CRCs 
[116]. Bcl-2 is a key regulator of the intrinsic apoptotic pathway, such that its 
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overexpression may, at least in part, be responsible for apoptosis resistance, the 
hallmark of cancerous cells.  
 
A whole genome association study, published in a patent application by Dr Stephen 
Gruber at the University of Michigan, identified a single nucleotide polymorphism 
(SNP) in the intron of GRK5 to be associated with a 35% increased risk of 
developing CRC [Patent publication number: WO2009046422 A2]. It is currently 
unknown whether this SNP affects GRK5 expression levels, but a recent 
microarray study of gene expression profiles of patients with colorectal liver 
metastases identified GRK5 as being significantly under expressed in higher-risk 
patients [Chung, J., 2013; personal communication]. There is, therefore, potential 
for GRK5 to act as a biomarker for CRC, with levels of the kinase possibly 
indicating the stage of disease. Moreover, GRK5 has also been shown to 
negatively regulate Bcl-2 transcription in SHSY5Y cells, levels of which, as 
previously mentioned, are upregulated in colon cancer [80]. It therefore feasible 
that GRK5 may be playing a causative role in colon cancer progression to a 
metastatic state; down-regulation of the kinase may relieve Bcl-2 transcriptional 
inhibition and render cells resistant to pro-apoptotic stimuli, thus accelerating 
cancerous cell growth. 
 
Chapter 5 of my thesis explains a potential mechanism whereby GRK5 may 
increase the sensitivity of the colon cancer cell line, HT-29, to apoptosis induced by 
5-FU in an HDAC-dependent manner. 
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1.5 HDACs and repressor complexes 
HDACs are key to the regulation of gene expression and act characteristically to 
silence genes while their functional counterparts, histone acetyltransferases (HATs), 
promote transcription [117]. These repressor proteins were first identified in yeast, 
as HDAC complexes, HDA and HDB. Further characterisation identified two related 
transcriptional regulators known as Hda1p and Rpd3p, which are responsible for 
the deacetylation function that correlates with heterochromatin and genetically 
‘silenced’ genes [118, 119]. Control of gene expression by HATs and HDACs is via 
the addition and removal of acetyl groups. HATs catalyse the acetylation of lysine 
residues on histone carboxyl terminal tails, which reduces the strength of the 
electrostatic interaction between the histone and DNA in the nucleosome unit. The 
resulting chromatin relaxation accommodates transcriptional machinery, thus 
promoting gene expression. The removal of acetyl groups by HDACs condenses 
the chromatin and therefore promotes transcriptional repression [120].  
 
A total of eighteen HDACs have been identified in mammals, which are categorised 
into four classes based on structure and homology to equivalent enzymes in yeast. 
The yeast HDACs, Hda1p and Rpd3p, represent archetypal members of classical 
mammalian class I and class II HDAC families, which comprise HDACs 1, 2, 3, 8, 
and 4, 5, 6, 7, 9, 10 respectively. These HDACs share a conserved catalytic, 
deacetylase domain, as does the class IV HDAC, HDAC11 (Figure 1.5). Class III 
HDACs, also known as sirtuins, share no homology with the other HDAC classes, 
as their deacetylase activity depends on NAD+ as opposed to zinc ions [117]. Class 
I, II and IV HDACs catalyse histone deacetylation via a charge-relay system that is 
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mediated via conserved residues in the catalytic domain and is coordinated by zinc 
ions [117].  
 
Class I and II are known as classical HDACs and are depicted in Figure 1.5. Class I 
HDACs are ubiquitously expressed in mammalian cells, while class II HDACs, 
which are further divided into class IIa (HDACs 4, 5, 7, 9) and IIb (HDACs 6 and 
10), are considered to have more specialised functions, as they are expressed only 
in the brain, skeletal muscle and heart [117]. Class I HDACs have a predominant 
nuclear localisation whereas class II are subject to stimulus-induced cytoplasmic-
nuclear shuttling [121]. The nuclear export of HDACs 4, 5 and 7 to the cytoplasm 
occurs during muscle differentiation, following phosphorylation by CaMK [117]. 
Phosphorylation is a key method of HDAC regulation and while both class I and 
class II are subject to this post-translational modification, phosphorylation controls 
different aspects of HDAC function. Whereas phosphorylation of class II HDACs 
regulates their cellular localisation, which indirectly affects their enzymatic activity, 
class I HDAC phosphorylation directly promotes their deacetylase function, except 
for HDAC8, which is inhibited by phosphorylation. Furthermore, the extent of class I 
HDAC phosphorylation provides an additional method of regulation, with HDAC1 
and HDAC2 existing in three different phosphorylation states: hypophosphorylated, 
basally phosphorylated and hyperphosphorylated. In addition to phosphorylation, 
both classes of classical HDACs are also regulated by sumoylation and 
polyubiquitination, with HDAC2 also modified by s-nitrosylation and HDAC1 by 
acetylation [121, 122]. HDAC regulation is further controlled at the transcriptional 
level, as well as via the association with other transcriptional proteins. Furthermore, 
Chapter 1: Introduction 
! 69 
class I HDACs are often found in large multiprotein complexes, which bring 
specificity to their deacetylase function and mediate their localisation to DNA. 
 
 
 
Figure 1.5 Class I and class II HDACs 
Organisation of HDAC subfamilies is illustrated in the schematic. Catalytic domains are 
coloured in green and nuclear localisation signals in purple. HDAC cellular localisation is also 
given. Taken from [121]. 
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Class I and II HDACs have been implicated in many diseases including CVD and 
cancer. Pan-HDAC inhibitors that reversibly block HDAC activity, including 
trichostatin A (TSA) and sodium butyrate (NaB), are often used in research and two 
such inhibitors, SAHA and depsipeptide, are FDA approved as anti-cancer 
treatments. Both class I and II HDAC members are upregulated in different cancers, 
yet class I-specific HDAC inhibitors are considered by many to be the most relevant 
anti-cancer targets due to their potency in inhibiting proliferation and inducing 
apoptosis [123]. The class I HDAC inhibitor, MS-275, has been used to treat 
patients with leukaemia, lymphoma or solid tumours in phase I and II clinical trials 
[124]. Treatment with TSA suppresses in vitro and in vivo models of cardiac 
hypertrophy [125, 126]. HDACs are considered important integrators of the 
divergent stress response signalling pathways that are activated during cardiac 
remodelling in response to hypertrophic stimuli [127]. Class IIa HDACs are the 
best-characterised class in terms of their role in hypertrophy, with HDAC5 acting in 
an anti-hypertrophic manner by physically inhibiting MEF2. The cardioprotective 
effect of TSA treatment therefore presents a paradox in terms of HDAC contribution 
to cardiac hypertrophy, which has been reconciled by opposing functions attributed 
to class I and class II HDACs. While class II HDACs are anti-hypertrophic, class I 
are pro-hypertrophic. TSA thereby inhibits class I pro-hypertrophic activity and the 
anti-hypertrophic effects of HDAC5 remain unaffected, as they are independent of 
deacetylase action [128]. Indeed, following hypertrophic induction, disease 
development was significantly reduced in mice treated with the class I specific 
HDAC inhibitor, SK-7041 [129]. 
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Class I HDACs rarely function independently, but instead work as part of a 
repressor complex, the association of which acts as another method of regulating 
HDAC enzymatic activity. Indeed, HDAC1 and HDAC2 only display maximal 
catalytic activity when involved in a repressor complex [117, 130]. Moreover, the 
distinct roles played by HATs and HDACs are now considered to be an 
oversimplification of transcriptional regulation in vivo and instead, the outcome may 
depend on the repressor complex involved [131]. A variety of mammalian 
repressors have been characterised to recruit both of these HDACs: RE1 silencing 
transcription factor (REST), which is also known as neural restricted silencing 
factor and its co-repressor, Co-REST, nuclear receptor co-repressor (N-CoR) and 
silencing mediator of retinoic and thyroid hormone receptors (SMRT), nucleosome 
remodelling and deacetylating complex (NuRD) and the mammalian Swi-
independent 3 (Sin3) protein [130, 132-134]. These repressors have overlapping as 
well as distinct binding partners, to coordinate different methods of gene repression, 
including ATP-dependent chromatin remodelling, histone deacetylation and DNA 
methylation. Figure 1.6 illustrates the multiple complexes formed by each of these 
repressors. 
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Figure 1.6 Mammalian repressor complexes  
The four mammalian transcriptional repressor complexes and their associated proteins. Taken 
from [90]. A. Co-REST complex, currently identified as two distinguishable Co-REST complexes, 
each of which contains a polyamie-oxidase-like protein as well as HDAC1 and/or HDAC2. i. 
Two interchangable Co-REST complexes have been identified, comprising either HDAC1 or 
HDAC2, as well as p37, which are able to dimerise [135]. ii. Co-REST and polyamie-oxidase-
like protein have also been purified with proteins ZNF217, a Sox-like protein and p80 [132]. B. 
N-CoR/SMRT complex, currently purified as six different macromolecule complexes identified 
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by three separate groups. i. Identified from HeLa cells, one N-CoR/SMRT complex contains the 
transducin "-like protein 1 (TBL1), HDAC3 and a protein of 37 kDa, p37 [136]. ii. iii. iv. Three 
further N-CoR/SMRT complexes were identified from Xenopus egg extracts. ii. The canonical 
mechanism of N-CoR/SMRT-mediated repression is reliant on Sin3A, its associated protein, 
RbAp48 (RBBP4) and HDAC1 (Rpd3). Additional proteins in the complex include p110, p30, 
p100 and p70 iii. A Sin3A-independent N-CoR/SMRT complex has also been identified to 
comprise p115, p60 and p52. iv. A N-CoR/SMRT complex comprising p120, p65 and p29 does 
not posses HDAC activity [137]. C. The NuRD repressor complex comprises HDAC1 and 2, 
along with RbAp46 and 48, Mi-2, MTA1-3 proteins and MBD2/3. i. The potential association of 
the NuRD complex with polyamine-oxygenase-like protein suggests a potential role for the 
NuRD complex in redox reactions [138]. ii. Differential Mi-2 complexes may also exist, similar to 
Co-REST, involving either HDAC1 or HDAC2 monomers, which can subsequently dimerise 
depending on the association with MBD2 [135]. D. The Sin3 core complex comprises HDACs 1 
and 2 along with Rb-associated proteins, RbAp48 and RbAp46, SAP30 and SAP18 [139]. 
 
1.5.1 REST/Co-REST 
The transcription factor, REST, comprises eight zinc fingers and is composed of 
two domains. The N-terminus recruits the Sin3 complex, which helps mediate gene 
repression, while the C-terminus binds to its co-repressor, Co-REST. [140]. The 
complex thereby regulates transcription via two distinct mechanisms.  
 
Co-REST comprises two 50-amino acid SANT domains, named for their presence 
in Swi3, Ada2, N-CoR, and TFIIB. The N-terminal SANT domain is responsible for 
binding HDACs and is therefore important for repressor activity [90, 132]. Co-REST 
binds HDAC1 and HDAC2 in a complex distinct from REST and Sin3, as shown in 
Figure 1.6A [132]. Two major HDAC1/2-containing Co-REST complexes were 
identified in HeLa cells, both containing the transcriptional co-repressor, CoREST, 
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a protein homologous to a polyamine-oxidase, which is an FAD-dependent 
enzyme, as well as a protein of 37 kDa (p37) of unknown function. Under native 
conditions, these complexes, as shown in Figure 1.6Ai, may contain either HDAC1, 
or HDAC2. A general model for interaction between HDAC1 and HDAC2 is 
suggested via dimerisation [135].   
 
Immunoprecipitation of Co-REST from T-Ag Jurkat cells detected both HDACs as 
interactors of Co-REST, but instead of detecting an interaction with REST, another 
eight zinc-fingered transcription factor, termed ZNF217, was identified. As shown in 
Figure 1.6Aii, this Co-REST complex also comprises a 40 kDa Sox-like protein, the 
polyamine-oxidase-like protein, and p80, a protein of unknown function [132].  
1.5.2 SMRT/N-CoR 
N-CoR and SMRT are homologous proteins, identified by their association with 
unliganded retinoic acid (RAR) and thyroid hormone (T3R) nuclear receptors [141, 
142]. RAR- and T3R-mediated repression occurs independently of agonist binding, 
with the assistance of N-CoR and SMRT, which have preferential action towards 
T3R and RAR respectively [143]. Aside from this difference, N-CoR and SMRT are 
known to have homologous functions and will, therefore, subsequently be referred 
to as N-CoR/SMRT.  
 
The mechanism of N-CoR/SMRT repression is most commonly reliant upon Sin3 
and HDAC1, but the proteins can also interact directly with HDAC3, HDAC4, 
HDAC5 and HDAC7 and form a variety of other complexes, as illustrated in Figure 
1.6B. Indeed, multiple N-Co-R/SMRT complexes have been identified. A novel N-
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CoR/SMRT-containing complex, isolated from HeLa cells, incorporates the 
transducin "-like protein 1 (TBL1), as well as HDAC3 and another protein of 37 
kDa, p37 (Figure 1.6Bi) [136]. Three distinguishable macromolecular complexes 
were identified in 2001 from Xenopus egg extract; one contains Sin3A, the yeast 
HDAC1 homologue, Rpd3, and the Sin3A-associated protein, RbAp48 (RBBP4) 
(Figure 1.6Bii); the second possesses Sin3A-independent HDAC activity (Figure 
1.6Biii) and the third complex lacks HDAC activity entirely (Figure 1.6Biv) [137]. 
The Sin3A-associated N-CoR/SMRT complex (Figure 1.6Bii) purifies as an eight-
protein complex including: p110, p30, p100, p70, RbAp48, Rpd3, Sin3A and N-
CoR/SMRT itself. Rpd3 and RbAp48 are more abundant than the other accessory 
proteins, in a ratio of 2:1 and 4:1, respectively, with N-CoR/SMRT, which may 
suggest these proteins function as the catalytic subunit and histone-interacting 
subunit, respectively. Complex two (Figure 1.6Biii), consists of four polypeptides, 
p115, p60, p52 and N-CoR/SMRT, with a stoichiometry of 1:1:2:4, respectively. No 
HDAC has been identified in the core complex, suggesting deacetylase activity 
may arise from an indirect association with an HDAC that escaped purification. 
Complex three (Figure 1.6Biv) also consists of four polypeptides: N-CoR/SMRT, 
p120, p65 and p29, with a stoichiometry of 2:3:1:1, respectively, predicting a mass 
of 1 MDa. The role of multiple N-CoR/SMRT subunits may indicate that the 
complexes must interact with multiple targeting proteins or additional co-repressor 
complexes in vivo [137].  
 
Using mass spectrometry and Western blotting techniques, additional novel 
components of the N-CoR/SMRT complex have been identified, including the 
SWI/SNF-related proteins BRG1, BAF 170, BAF 155, BAF 47, and the co-
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repressor KAP-1 that is involved in silencing heterochromatin [144] (Figure 1.6Bv).  
While this N-CoR/SMRT complex contains only HDAC3, another N-CoR/SMRT 
complex identified by the same group contained predominantly HDAC1 and 
HDAC2, as well as several other subunits that are found in the Sin3A/HDAC 
complex (Figure 1.6Bvi) [144]. While multiple N-CoR/SMRT complexes have been 
identified, additional biochemical studies are necessary to elucidate the full 
repertoire of biological functions and mechanisms. 
 
The mechanism of N-CoR/SMRT repression is dependent on the N-terminus of the 
protein, which contains two SANT domains, while the majority of transcription factor 
binding occurs in the C-terminus of the protein [90]. N-CoR/SMRT function is not 
confined to T3R and RAR; they confer repressor activity on many transcription 
factors, including NF#B and activator protein-1, which stimulates proliferation. 
Identification of an increasing number of binding partners suggests these 
repressors are involved in regulating a variety of cellular processes, including not 
only proliferation, but also development and apoptosis. Hormone binding regulates 
N-CoR/SMRT complexes and their association with nuclear receptors, but 
additional cell signalling pathways, including ERK and PKA-mediated signalling, 
can also culminate with N-CoR/SMRT regulation. Indeed, treatment of L-throxine to 
activate the ERK MAPK signalling pathway caused SMRT dissociation from the 
thyroid hormone receptor, TR"1, in a hormone-independent manner [145]. 
Depending on the binding partner or signalling pathway initiated, the repressors 
can be degraded or relocalised to the cytoplasm to modulate access to 
transcription factors [90]. 
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1.5.3 NuRD 
NuRD is an ATP-dependent repressor protein. In addition to binding HDAC1 and 
HDAC2, Rb associated proteins, RBBP4 (RbAp48) and RBBP7 (RbAp46), the 
ATPases, Mi-2, either the !- or –" isoform, also form part of the core complex. 
These proteins catalyse ATP hydrolysis to initiate chromatin remodelling and 
deacetylase activity and therefore play a key role in gene regulation [131]. The 
NuRD repressor complex also involves the methyl-CpG-binding domain proteins, 
MBD2 and/or MBD3 (p32) and metastasis-associated proteins, MTA1–3 (Figure 
1.6Ci) [135]. 
 
The MBD family of proteins mediate interactions with methylated CpG 
dinucleotides, except for MBD3 (p32), which contains two point mutations to 
prevent nucleotide binding. The methylation state of DNA is related to 
transcriptional activity, with nucleotides in silenced genes often possessing this 
post-translational modification [135]. MBD2 and MBD3 can dimerise but also 
mediate additional protein-protein interactions to further modulate gene targeting of 
the complex.  
 
MTA2 is constitutively expressed and is therefore considered to mediate NuRD 
housekeeping gene regulation, whereas MTA3 and MTA1 (p70) are expressed in a 
tissue-specific manner, generating more specialised roles for the repressor 
complex [90]. The binding of accessory proteins further modulates NuRD function 
and interactions of transcription factors with particular core NuRD complex 
components is also responsible for tissue and cell-specific functions [131].  
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Mi-2! and Mi-2" have distinct functions, but they can also co-exist within the same 
NuRD complex [131]. As shown in Figure 1.6Cii, the binding of two Mi-2-containing 
complexes, as a dimer, may be dependent on the dissociation of MBD3 (p32). 
Furthermore, Mi-2 isoforms may also associate with either HDAC1 or HDAC2, 
which can subsequently dimerise [138, 146]. 
 
Purification of an endogenous HDAC2 complex from HeLa cell extracts by 
immunoaffinity chromatography identified a previously uncharacterised protein of 
110 kDa. Sequence analysis by peptide mass spectrometry, identified significant 
homology of this protein to polyamine oxygenase. The potential association of the 
NuRD complex with polyamine-oxygenase-like protein, shown in Figure 1.6Ci by a 
reversible reaction, suggests a potential role for the NuRD complex in redox 
reactions [138]. 
1.5.4 Sin3 
Mammalian Sin3 exists as three isoforms generated from two different genes, 
SIN3A and SIN3B and is considered to be a master scaffold, binding and 
coordinating a series of core proteins in order to repress transcription [139]. Sin3 
comprises four highly conserved paired amphipathic helix (PAH) domains, which 
mediate protein-protein interactions and are essential for full repressor function, as 
well as an HDAC interaction domain (HID) and a highly conserved region (HCR) in 
the C-terminus, which is less well characterised [147]. Sin3 itself has no intrinsic 
DNA binding ability and therefore relies upon binding different transcription factors 
in order to regulate specific genes. The enzymatic activity of the complex arises 
from binding HDAC1 and HDAC2, which along with five other proteins comprise the 
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core mammalian Sin3 complex, which is shown in Figure 1.6D and Figure 1.7 [148]. 
Included in the core complex are SAP30, SAP18, and SDS3 as well as RBBP4 
(RbAp48) and RBBP7 (RbAp46), which are also components of the NuRD complex. 
These repressors therefore have a similar core unit, to which the addition of 
repressor-specific proteins enables more specialised functions. Sin3 also recruits 
other repressor complexes, including SMRT, N-CoR and REST/Co-REST, which 
bind to PAH1 [149-151]. 
 
 
 
Figure 1.7 Sin3 structure and binding partners  
Sin3A comprises six domains. The core repressor complex, shown in green, binds at the HID, 
with paired-amphipathic helix (PAH) domains mediating protein-protein interactions with 
associated co-repressors and co-factors. The highly conserved region (HCR) remains poorly 
characterised. The core Sin3 complex comprises HDAC1, HDAC2, RBB4 and 7, SDS3, SAP 18 
and SAP30, which can also bind HDAC3 and HDAC4 as accessory proteins [139]. 
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Providing a functional platform for class I HDAC activity means repressor 
complexes, like HDACs themselves, play important roles in physiological and 
pathophysiological processes by regulating gene expression. The recruitment of 
HDACs and transcription factors to form a multi-protein repressor complex allows 
for additional layers of transcriptional regulation. The interplay between 
transcriptional activation and repression of specific genes is crucial in 
developmental processes and is often disrupted in disease. During pathological 
cardiac hypertrophy, cardiac remodelling ensues following the repression of adult 
cardiac genes and the upregulation of foetal genes. Cancer is often associated with 
repression of pro-apoptotic proteins, as well as proliferation inhibitors, such as p21. 
The involvement of HDACs and their repressor complexes in these processes are 
therefore implied and the identification of GRK5 as an HDAC activator, suggests 
the kinase may also participate in HDAC regulation. Furthermore, the involvement 
of both HDAC repressor complexes and GRK5 in cardiac hypertrophy and cancer 
suggests their potential coordination in disease pathogenesis.  
1.6 Aims of my thesis 
In light of the discovery of the NLSs and NESs of GRK5, numerous nuclear 
substrates of the kinase have been identified. HDAC5 was the first nuclear 
substrate to be discovered, whose GRK5-mediated phosphorylation acts in a pro-
hypertrophic manner and results in the upregulation of MEF2 transcriptional activity. 
Given the role of HDACs in gene repression, I aimed to investigate whether GRK5 
could regulate transcription in a direct manner. Many diseases are associated with 
aberrant gene expression and GRK5 expression levels vary in disease states. We 
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therefore hypothesised that GRK5 regulates transcription and could thereby 
influence disease pathogenesis.  
 
In this thesis I identify class I HDACs and the transcriptional repressor protein, 
Sin3A, as novel binding partners of GRK5. I explain attempts to map the binding 
sites of HDAC1 and Sin3A on GRK5 and explore the potential role of GRK5 as a 
transcriptional regulator in the context of colon cancer. I elucidate a novel GRK5-
dependent mechanism of Bcl-2 transcriptional repression in the colon cancer cell 
line, HT-29, which increases sensitivity to apoptosis-promoting chemotherapeutic 
agents.  
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Chapter 2. Materials and methods 
Tissue culture dishes were obtained from Nunc, culture medium from Gibco BRL, 
plastic-ware from Falcon or Sterilin and other reagents from Sigma, unless 
otherwise stated. Buffer ingredients, antibodies, cDNAs, small inhibiting RNAs 
(siRNAs) and micro RNAs (miRNAs) referred to in this report are listed in Tables 
2.1–2.4.  
2.1 Cell culture 
All cell lines (HeLa, HEp2, HT-29, SW620, OVCAR3, IGROV-1, A2780 and PC3) 
were cultured in Dulbecco’s modified Eagle medium (DMEM) containing 10% calf 
serum and penicillin (100 IU/ml)/ streptomycin (100 µg/ml). Cells were maintained 
in a humidified incubator at 37°C, 5% CO2. Confluent monolayers were passaged 
every 3–4 days by trypsinising and replating at a ratio of 1:10. Cell freezing and 
thawing: To freeze cell stocks, two 70% confluent 9 cm plates were trypsinised 
and resuspended per 1 ml of freezing medium (DMEM, 20% foetal calf serum, 10% 
dimethylsulphoxide (DMSO) and penicillin (100 IU/ml)/ streptomycin (100 µg/ml)). 
After 1 week at -80°C, cells were transferred to liquid nitrogen. To recover stocks, 
aliquots were rapidly thawed at 37°C and plated onto a 9 cm plate in 15 ml culture 
medium. 
2.2 Transfection of cDNA, siRNA and miRNAs 
Cells were transiently transfected using Fugene HD (Roche). cDNAs, siRNAs or 
miRNAs were added to 100 µl of serum-free DMEM along with 3 µl of Fugene per 1 
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µg DNA. Samples were mixed by gentle agitation and incubated at room 
temperature for 20 minutes. The media/cDNA/Fugene mixes were then added 
drop-wise to 50% confluent cells and unless otherwise stated, 24 hours was 
allowed for protein expression.  
2.3 Preparation of cell lysates and nuclear extracts 
Cells in 9 cm dishes were washed twice with cold phosphate buffered saline (PBS) 
on ice and lysed by addition of 1 ml of the appropriate chilled lysis buffer. A cell 
scraper was used to remove cell material from the dishes and lysates were 
transferred to a 1.5 ml tube. After 15 seconds sonication (Branson Sonifier 450, 
setting 6), lysates were cleared by centrifugation at 14,000 rpm (Heltich bench top 
centrifuge Mikro 20) for 5 minutes. Protein concentrations were determined using 
the BioRad protein assay according to manufacturer’s instructions and lysates were 
stored at -20°C. For preparation of nuclear extracts: cells were harvested in 1 ml 
cold nuclear lysis buffer, vortexed for 10 seconds and incubated on ice for 15 
minutes. Nuclei were isolated by spinning the lysates through 4 ml cold sucrose 
cushion at 1300 g for 10 minutes at 4°C (Sorvall TC-6 centrifuge). The nuclei pellet 
was then resuspended in 1 ml cold Tris-HCL, pH7.5, containing 10 mM NaCl and 
clarified by centrifugation at 1300 g for 10 minutes at 4°C (Sorvall TC-6 centrifuge). 
Nuclei were extracted by suspension in 100–200 µl of extraction buffer and 
sonicated for 30 seconds before incubation on ice for 30 minutes. Samples were 
centrifuged at 10,000 g for 10 minutes at 4°C (Sorvall TC-6 centrifuge) and the 
supernatants containing crude nuclear extracts stored at -80°C until use. 
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2.4 Co-Immunoprecipitation 
Volumes of cell lysates harvested in GTPase buffer, containing 200 µg protein, 
were incubated with the appropriate antibody for 1 hour rotating at 4°C. Protein A/G 
sepharose beads (Santa Cruz) were washed in GTPase lysis buffer and 30 µl of a 
50% suspension was added to each sample before incubation for a further hour, 
rotating at 4°C. The samples were then spun down at 200 g (1500 rpm Heltich 
bench top centrifuge Mikro 20) for 2 minutes, the supernatant aspirated and 1 ml 
GTPase lysis buffer added to wash the beads. This wash cycle was repeated 3 
times before adding 25 µl sodium dodecyl sulphate (SDS) reducing buffer to each 
sample in preparation for analysis by SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE).  
2.5 Immunofluorescent labeling 
Coverslips with cell monolayers were fixed in 4% paraformaldehyde (TAAB)/ PBS 
for 20 minutes before quenching for 10 minutes in 0.27% NH4Cl/ 0.37% glycine in 
PBS. 1% bovine serum albumin (BSA) (First Link UK Ltd.)/ 0.2% Saponin/ PBS 
was then added for 30 minutes to block and permeabilise fixed cells. Primary 
antibody incubations were performed for 1 hour at room temperature in 1% BSA/ 
0.2% Saponin. Cells were subsequently washed 3 times with 1% BSA/ 0.2% 
Saponin before incubation with the appropriate secondary antibody for 30 minutes 
at room temperature. Following 3 more washes in 1% BSA/ 0.2% Saponin, cells 
were washed twice in PBS and coverslips were mounted on slides in 90% glycerol/ 
PBS/ 3% N-propyl-galate. Confocal images were taken at room temperature with 
Leica ACS Apo 40x and 63x oil immersion lenses. A Leica TCS SPE confocal 
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microscope and LAS AF software was used to acquire the images. Images were 
optimised for contrast in Adobe Photoshop but no further manipulations were made. 
For HEp2 cells: 24–48 hours post-transfection, cells were treated or not with 25 
µM Ca2+ ionophore, A23187 (Calbiochem) for 15 minutes in medium supplemented 
with 2 mM CaCl2 at 37°C, 5% CO2. Cells were stained as detailed above.  
2.6 Direct binding assay 
10 µl purified glutathione S-transferase (GST) or GST-HDAC1, GST-HDAC3 or 
GST-HDAC8 was immobilised on glutathione sepharose beads (GE Healthcare) in 
200 µl protein binding buffer. 10 µl of GRK5 purified from SF9 cells was added and 
samples incubated, rotating, for 1 hour at 4°C. Beads were then washed 4 times in 
protein binding buffer before adding 25 µl SDS reducing buffer to each sample 
ready for analysis by SDS-PAGE. GRK5 binding was detected using an anti-GRK4-
6 antibody. For GST-Sin3A deletion mutant pull downs (Figure 3.6) and for 
screening GRK5 mutants for direct binding to HDAC1 and Sin3A (Figure 4.7 
and 4.8): Wildtype or mutant GRK5 (M1: E355A/V356A, M2: D485A, M3: D486A, 
M4: D487A, M5: D485/486/487A or GRK5%NLS) was in vitro translated and 
radiolabelled with [35S]-methionine using the Promega quick-coupled transcription/ 
translation system according to manufacturer’s instructions. 10 µl in vitro translated 
wildtype GRK5 was incubated with GST or GST-Sin3A deletion mutants for Sin3A 
pull downs (Figure 3.6). For the GRK5 mutant pull-downs, 10 µl in vitro translated 
wildtype or mutant GRK5 was incubated with GST, GST-HDAC1 or GST-Sin3A-
545-1157 (Figure 4.7 and 4.8). The incubations and subsequent washing steps 
were carried out in 200 µl protein binding buffer. SDS-PAGE gels were incubated 
with Autofluor (National Diagnostics), the Autoradiographic Image Intensifier, as per 
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instructions, for an hour, and then placed on 2 sheets of filter paper, covered with 
Saran wrap and dried using a Model 583 Gel Dryer (BioRad) at 80°C for 90 
minutes before being exposed to film (Biomax ML, Kodak) at -70°C overnight.  Film 
was developed using an Agfa automatic film processor. For direct binding of 
HDAC1 and HDAC2 to GRK5 (Figure 3.4): 10 µl in vitro translated Flag-HDAC1 
or Flag-HDAC2 was incubated with GST or GST-GRK5 in 200 µl NETN buffer. 
Subsequent washing steps were carried out in H Buffer. SDS-PAGE gels were 
dried down and analysed by autoradiography. 
2.7 Peptide array overlays 
The GRK5 peptide arrays were kindly received from Dr George Baillie (Glasgow 
University). GRK5 peptide libraries of overlapping 25-mer peptides each shifted 
along by five amino acids were produced by automatic SPOT™ synthesis onto 
Whatman 50 cellulose membranes using 9-fluorenylmethyloxycarbonyl chemistry 
with the AutoSpot-Robot ASS 222 (Intavis Bioanalytical Instruments) [119, 120]. 
The arrays were activated by immersion in 100% ethanol, rinsed in Tween/Tris-
buffered saline (TTBS) and incubated in blocking buffer for one hour at room 
temperature. The interaction of spotted peptides with target proteins was 
investigated by overlaying the membranes with 10 µg/ml recombinant fusion 
protein in 1–5% blocking buffer overnight at 4°C. Detection of bound fusion proteins 
is as per Western blotting, using an anti-GST primary antibody and the relevant 
secondary antibody. For alanine scanning substitution arrays: Alanine scanning 
substitution analyses were performed to determine specific amino acid residue(s) 
important for mediating the binding event. Amino acid residues from selected 
peptide sequences were replaced with alanine one at a time unless the indicated 
Chapter 2: Materials and methods !
! 88 
amino acid was alanine, when it would be substituted for aspartate. Control spots 
(*) consisting of full length, unmutated peptides known to bind to the protein of 
interest were also included for comparative purposes. The arrays were 
immunolabeled and detected by autoradiography, as described above. 
2.8 Gal4 luciferase reporter assay 
Gal4 transcriptional activity was recorded using the Dual-Luciferase® Reporter 
Assay system (Promega), according to the manufacturer’s instructions. Briefly, the 
minimal promoter-luciferase reporter containing a GAL4 DNA-binding domain 
(DBD) alone (GAL4-DBD), or fused to a GRK5 construct (Gal4-DBD-GRK5), which 
were kindly received from Dr Mark Scott, were transfected into HT-29 cells in 6 well 
plates. The cells were additionally co-transfected with pFR-luc, a firefly luciferase 
expression plasmid in the cytomegalovirus (CMV) vector under the control of the 
Gal4-DBD, and pRL-CMV, a constitutively expressed Renilla luciferase CMV 
plasmid, as a measure of transfection efficiency. Luciferase activities were 
determined 24 hours post transfection according to manufacturer’s instructions. 
The cells were harvested on ice in 250 µl passive lysis buffer (Promega) and 20 µl 
cell lysate incubated with 100 µl luciferase assay substrate and firefly luminescence 
recorded for 15 seconds using a Turner TD-20e luminometer. 100 µl Stop and 
GloTM reagent was added and the specific luminescence from Renilla luciferase 
was recorded for an additional 10 seconds. The experiment was repeated as a 
triplicate and the average firefly luminescence calculated relative to that of Renilla. 
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2.9 PCR 
2.9.1 Site directed mutagenesis  
The QuikChange! site-directed mutagenesis kit (Stratagene) was used according 
to manufacturer’s instructions to make point mutants in the potential HDAC1 and 
HDAC1/Sin3A binding sites on GRK5. A bovine GRK5 construct (pRK5-GRK5) was 
used as template to create the mutants M1–5, as outlined in Table 4.2. GRK5 
sequencing primers, to enable sequencing of the entire GRK5 cDNA following 
PCR/mutagenesis are as follows:  
 
GRK5seqF1  400 – CTTCAGAAACCCTGCAAAGA – 419 
GRK5seqF2  814 – AAGTTCCACATTTACAACAT – 833 
GRK5seqF3 1201 – GTGTTGGAGACAGAGGAGGT – 1220 
GRK5seqF4 1556 – AGTGCTTTAAGGAGCTGAAC – 1575 
 
To create the potential GRK5%HDAC1 mutant (M1), amino acids 55 and 56 were 
mutated to alanine residues using the following primers; sense primer 5’–C  GTT 
GGC TAC ATG GCT CCA GCG GCC CTG AAC AAC CAG AGG TAT GG–3’, anti-
sense primer 5’–CC ATA CCT CTG GTT GTT CAG GGC CGC TGG AGC CAT 
GTA GCC AAC G–3’. To create the potential GRK5%HDAC1%Sin3A mutants, 
amino acids 485 (M2), 486 (M3), 487 (M4) or 485–487 (M5) were mutated to 
alanine residues to produce mutants M2–M4 using the following primers; M2: 
sense primer 5’–C CTG GAC CAC ACG GCC GAC GAC TTC TAC TCC–3’, anti-
sense primer 5’–GGA GTA GAA GTC GTC GGC CGT GTG GTC CAG G–3’; M3: 
sense primer 5’–C CTG GAC CAC ACG GAC GCC GAC TTC TAC TCC–3’, anti-
sense primer 5’–GGA GTA GAA GTC GGC GTC CGT GTG GTC CAG G–3’; M4: 
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sense primer 5’–GAC CAC ACG GAC GAC GCC TTC TAC TCC AAG TTC TCC–3’, 
anti-sense primer 5’–GGA GAA CTT GGA GTA GAA GGC GTC GTC CGT GTG 
GTC–3’; M5: sense primer 5’–GGC GTC AAC CTG GAC CAC ACG GCC GCC 
GCC TTC TAC TCC AAG TTC TCC–3’, anti-sense primer 5’–GGA GAA CTT GGA 
GTA GAA GGC GGC GGC CGT GTG GTC CAG GTT GAC GCC–3’. Nucleotides 
in bold encode the mutated amino acids. 
 
PCR was carried out as follows: 
2 µl Template (10 ng) 
5 µl 10X Reaction buffer 
1.25 µl Sense primer (100 ng/µl) 
1.25 µl Anti-sense primer (100 ng/µl) 
1 µl dNTPs (10 mM) 
1 µl Pfu polymerase 
38.5 dH20 
____________________________ 
50 µl 
 
PCRs were cycled in a PTC-2000 Peltier Thermal Cycler (MJ Research) as 
followed:  
1. 95°C, 30 seconds 
2. 95°, 30 seconds 
3. 55°C, 60 seconds 
4. 68°C, 11 minutes 
5. Return to step 2 for 17 more cycles then step 6. 
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6. 4°C forever. 
 
Following PCR, 1 µl DpnI was added to the reaction and incubated at 37°C for 1 
hour to cleave methylated parent DNA. 5 µl of each PCR reaction was then 
transformed into competent Escherichia coli (E. coli) as detailed in section 2.11.4. 
2.9.2 Quantitative RT-PCR (qRT-PCR)  
HT-29 cells were transfected with 10 µg GRK5 siRNA or scrambled control for 72 
hours. RNA was then extracted from cells using the QIAGEN RNAeasy kit with 
cells homogenised using the QIAshredder kit (QIAGEN), according to 
manufacturer’s instructions. Prepared RNA samples were reverse-transcribed into 
cDNA using SuperScript® Reverse Transcriptase II (Invitrogen) according to the 
manufacturer’s instructions. 6.25 µl cDNA samples at 150 ng/µl were then amplified 
by qPCR using the DyNAmo flash SYBER green QPCR kit (Thermo Scientific). 
12.5 µl SYBER green was added to the cDNA along with 6.25 µl primer pairs (1.2 
µM). mRNA levels of GRK5, Bcl-2 and actin were analysed using appropriate 
forward and reverse primer pairs (IDT Technologies). GRK5: forward primer 5’–
GAC CAC ACA GAC GAC GAC TCC–3’, reverse primer 5’–CGT TCA GCT CCT 
TAA AGC ATT–3’; Bcl-2: forward primer 5’–GCG ACT CCT GAT TCA TTG–3’, 
reverse primer 5’–AGG TGC GTT TCC CTG TA–3’; actin: forward primer 5’– TTG 
TGG TGA AGC TGT AGC C–3’, reverse primer 5’–GCG AGA AGA TGA CCC AGA 
T–3’. PCR reactions were performed using the Eppendorf Mastercycler® ep 
realplex2 with 40 cycles of the following condition: 
 
95°C for 10 seconds 
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55°C for 15 seconds 
72°C for 15 seconds 
 
Results were analysed using the Realplex software. 
2.10  Fluorescence-activated cell sorting (FACS) 
HT-29 cells were split into 12-well plates and transfected and treated 24 hours later, 
as indicated in Figure 5.8. Cells were harvested by trypsinisation and recovered in 
500 µl DMEM. Cells were spun down at 1000 rpm (Heltich bench top centrifuge 
Mikro 20) for 5 minutes and the cell pellets resuspended in 500 µl DMEM 
containing 0.25 µg 7-aminoactinomycin D Viability Staining Solution (7-AAD, e-
Bioscience). 7-AAD is a fluorescent DNA intercalator that is selectively excluded 
from live cells and is therefore used as an indicator of cell death. Samples were 
analysed within 30 minutes of incubation using a BD LSR II cytometer. The 
percentage of cells positively stained with 7-AAD was recorded, with 10,000 cells 
analysed per sample. Unstained cells were used as negative controls.  
2.11  Other techniques 
2.11.1  SDS-PAGE  
SDS-PAGE was performed using the Hoefer Scientific Instruments vertical slab gel 
unit SE 600 gel system. 10% separating gel was cast between two glass plates by 
polymerising 30% (v/v) acrylamide in 0.375 M Tris-HCl pH8.8 and 1% SDS, using 
0.3% (v/v) ammonium persulphate and 0.07% (v/v) N, N, N’, N’-tetramethyl-
ethylenediamine (TEMED). A 4% stacking gel was cast above the separating gel 
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by polymerising 4% (v/v) acrylamide in 0.12 M Tris-HCl pH6.8 and 1% SDS, using 
0.1% (v/v) ammonium persulphate and 0.1% (v/v) TEMED. Samples were prepared 
by addition of 25 µl SDS reducing buffer to 10 µg of lysate or immunoprecipitate 
and heated at 60°C for 10 minutes. Samples were loaded onto the gels and the 
gels were subjected to a constant voltage of 300 V for 1 hour in gel running buffer. 
For direct binding experiments, radioactive gels were dried onto 3mm Whatman 
paper overnight and exposed to film at -80°C for 48 hours. 
2.11.2  Western blotting and immunodetection  
Proteins separated on SDS-PAGE gels were transferred onto nitrocellulose 
membrane (Hybond-ECL, Amersham) using a semi-dry electrophoretic transfer unit 
(V20-SDB). The gel and membrane were soaked in transfer buffer, placed between 
6 soaked pieces of filter paper and subjected to a constant current of 0.8 mA per 
cm2 membrane for 1 hour 45 minutes. Membranes were then incubated in blocking 
buffer for 1 hour at room temperature followed by incubation for 1 hour with the 
appropriate primary antibody diluted in blocking buffer, or overnight at 4°C. 
Following 5 washes over a 30 minute period in TTBS, a horseradish peroxidase-
conjugated secondary antibody (Amersham), diluted in TTBS, was added to the 
immunoblots for 1 hour. The blots were then washed as before. Sufficient ECL 
reagent (Amersham) was added to cover the membrane and incubated for 1 min. 
Bound antibody was detected by exposing the immunoblot to film (Biomax ML, 
Kodak) for the required time and the film was developed using an Agfa automatic 
film processor and quantified using a BioRad densitometer.  
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2.11.3  Coomassie staining of SDS-PAGE gels 
To stain proteins, the SDS-PAGE gel was covered in Coomassie stain, heated for 1 
minute at 750W in a microwave and allowed to cool at room temperature on a 
shaker. The gel was then de-stained using Coomassie de-stain until proteins were 
visible and identifiable by comparison to molecular weight markers.  
2.11.4  Bacterial transformation and plasmid DNA purification 
TOP10 (Invitrogen) chemically competent E. coli were thawed on ice and mixed by 
hand. 20 µl of cells were aliquoted into a pre-chilled 1.5 ml Eppendorf tube 
containing 50 ng of plasmid cDNA and incubated on ice for 30 minutes. The 
bacteria were then heat shocked at 37°C for 5 minutes before incubation on ice for 
2 minutes. 1 ml pre-warmed super-optimal broth with catabolite repression (SOC) 
medium (Invitrogen) was added and the bacteria were incubated at 37°C for 1 hour 
with shaking at 200 rpm (Kuhner ISF-1-W bacterial incubator). The bacteria were 
then plated onto Luria Broth (LB) agar plates containing 100 µg/ml ampicillin or 25 
µg/ml kanamycin, as appropriate, and incubated at 37°C overnight. The next day, 
single colonies were picked from the plate and grown overnight at 37°C, shaking at 
200 rpm (Kuhner ISF-1-W bacterial incubator), in 500 ml of LB medium containing 
100 µg/ml ampicillin or 25 µg/ml kanamycin as appropriate. The following day, the 
bacteria were pelleted and the plasmid DNA was extracted using a QIAprep Spin 
Maxiprep kit (QIAGEN). The concentration of the plasmid DNA was determined by 
measuring A260 using an Ultraspec 2000 spectrophotometer (Pharmacia Biotech). 
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2.11.5  Purification of GRK5 
GRK5 was overexpressed in baculovirus-infected SF9 cells by Dr Julie Pitcher. Cell 
pellets were thawed, supplemented with fresh protease inhibitors (40 µg/ml 
phenylmethanesulfonyl fluoride (PMSF), 1 mM benzamidine), and homogenised 
with 10 strokes of a tightglass Dounce homogeniser on ice. All subsequent 
manipulations were performed at 4°C and all buffers contained protease inhibitors 
as above. The homogenate was spun at 43,000 g for 20 minutes and the resulting 
pellet was re-homogenised with 50 ml of purification buffer with 20 mM NaCl and 
spun as before. The two supernatants were pooled and passed through a 10 ml 
column of S-Sepharose (Pharmacia) at a flow rate of 1 ml/min. Most proteins failed 
to bind to the resin. The column was washed with 50 ml of buffer A with 20 mM 
NaCl and eluted with a linear 100 ml gradient of 20–750 mM NaCl in purification 
buffer. Fractions were assessed for GRK5 and contamination by Coomassie 
staining of 10% SDS-PAGE gels and those containing GRK5 and the fewest 
protein contaminants were pooled (20 ml), diluted with buffer A to below 100 mM 
NaCl, and applied to a 10 ml column of heparin-Sepharose (Pharmacia) at 1 ml/min. 
The column was washed with 50 ml of purification buffer with 150 mM NaCl and 
eluted with a linear 100 ml gradient of 15–1500 mM NaCl in purification buffer. 
Fractions containing purified GRK5, as assessed by SDS-PAGE Coomassie 
staining, were pooled and concentrated to 1 ml in a Centriprep 30 spin concentrator 
(Amicon). Purified GRK5 was stored at 4°C or at -20°C in 50% glycerol. Final purity 
of purified GRK5 was assessed by Coomassie staining.  
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2.11.6  GST-GRK5, GST-HDAC and GST-Sin3A deletion mutant fusion 
protein purification 
BL21 (Invitrogen) E. coli were transformed as described for TOP10. 100 ml starter 
cultures were diluted 1/10 in room temperature LB and left at 37°C shaking for an 
hour before being moved to 20°C for 1 hour, shaking at 200 rpm. Isopropyl-"-D-
thio-galactoside (IPTG) was then added to the final concentration of 0.03 mM for 18 
hours to induce fusion protein expression. After pelleting, the bacteria were 
resuspended in 25 ml PBS containing the protease inhibitors 40 µg/ml PMSF and 
1mM benzamidine. Lysates were sonicated twice for 2 minutes, on ice. 1% Triton 
X-100 was then added to the lysates before being cleared by centrifugation for 30 
minutes at 39,500 g, at 4°C. 1 ml of 50% glutathione sepharose beads (GE 
healthcare) was added to the supernatants and incubated for 2 hours at 4°C on a 
rotating wheel. The beads were then washed 3 times with cold 50 mM Tris pH8.0, 
1% Tween, 1% Triton X-100 and once with cold 50 mM Tris pH8.0. For the peptide 
arrays, GST-fusion proteins were eluted from the glutathione sepharose beads with 
25 mM glutathione in 50 mM Tris pH8.0 containing protease inhibitors and dialysed 
overnight in TTBS. Samples were run on a Coomassie gel with BSA standards to 
determine fusion protein purity and concentration.  
2.11.7  In vitro translation 
For direct binding experiments, proteins were in vitro translated and radiolabelled 
with [35S]-methionine using the Promega quick-coupled transcription/translation 
system according to manufacturer’s instructions. The RNA polymerase, nucleotides, 
salts and Recombinant RNasin® Ribonuclease Inhibitor were combined with rabbit 
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reticulocyte lysate to form a single TnT® Quick Master Mix. The TNT® Quick 
Coupled Transcription/Translation System is available in two configurations for 
transcription and translation of genes cloned downstream from either the T7 or SP6 
RNA polymerase promoters. The SP6 or T7 TnT® Quick Master Mix was rapidly 
thawed after removing from storage at -70ºC and placed on ice. 0.2–2.0 µg cDNA 
was incubated with 40 µl TnT® Quick Master Mix along with 2 µl [35S]-methionine 
(1,000 Ci/mmol at 10 mCi/ml) for 30–60 minutes. The in vitro translated proteins 
were then stored at -80°C until use. 
2.12  Statistical analysis 
Results were analyzed using the student’s two-sample T-test to determine whether 
measurements made on two populations were different from each other. The null 
hypothesis proposed that the two populations were the same in every case. 
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Table 2.1 Primary antibodies 
 
Antigen Source Product 
number 
Dilution 
for 
Western 
Volume 
for IP 
(µl) 
Dilution for 
Immunofluorescence 
"-Actin Mouse Santa Cruz 
SC-81178 
   
Bcl-2 Mouse Santa Cruz 
SC-130308 
1:1000   
Active 
cleaved 
caspase 
3 
Rabbit Cell 
Signaling 
Technology 
9661S 
  1:100 
Cleaved 
PARP-1 
Rabbit Santa Cruz 
SC-23461 
1:1000   
ERK Rabbit Sigma 
M5670 
1:20,000   
Flag Mouse Sigma 
F3165 
1:1000 3  
GRK2 Rabbit Santa Cruz 
SC-562 
1:500   
GRK4-6 Mouse Upstate 05-
466 
1:1000  1:300 
GRK5 Rabbit Santa Cruz 
SC-565 
1:1000  1:50 
GST Rabbit Sigma 
Aldrich 
G7781 
1:8000   
HA Rat Roche 
1867423 
1:1000   
HDAC1 Mouse Santa Cruz 
SC-81598 
1:1000   
HDAC2 Mouse Santa Cruz 1:1000   
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SC-81599 
RBBP4 Rabbit Abcam 
ab1765 
1:1000   
Sin3A  Mouse Santa Cruz 
SC-5299 
1:1000 5  
Myc Mouse Millipore 05-
724 
1:1000  1:100 
 
 
Anti-mouse and anti-rabbit IgG HRP-conjugated secondary antibodies were from 
Sigma (sourced from sheep, 1:20,000). For immunofluorescence, anti-mouse and 
anti-rabbit IgG Alexa Fluor® 488 and 594 conjugated secondary antibodies were 
from Molecular Probes (sourced from donkey, 1:700). 
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Table 2.2 Buffers 
 
Buffer Name Ingredients 
Blocking buffer 5% skimmed milk powder made up in TTBS 
Buffer A 34% sucrose w/w 
65 mM NaCl 
2 mM MgCl2 
10 mM Tris-acetate buffer, pH 7.4 
0.1 mM EDTA 
500 µM PMSF 
1 µM Leupeptin 
1 µM Pepstatin 
Coomassie stain 40% MeOH 
10% acetic acid 
0.05% Brilliant Blue G 
Coomassie de-stain 40% MeOH 
10% acetic acid 
Extraction buffer 50 mM HEPES pH 7.5 
420 mM NaCl 
0.5 mM EDTA 
0.1 mM EGTA 
10% glycerol 
Gel running buffer 2 M glycine 
0.25 M Tris-HCl 
0.03 M SDS 
GTPase lysis buffer 10% glycerol 
50 mM Tris-HCl pH8 
150 mM NaCl 
1% TX-100 
2 mM EDTA 
40 µg/ml PMSF 
H buffer 20 mM HEPES pH7.7 
50 mM KCl 
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20% glycerol 
0.1% NP-40 
NETN buffer 20 mM Tris pH8.0 
100 mM NaCl 
1 mM EDTA 
0.5% NP-40 
Nuclear lysis buffer 10 mM Tris pH7.5 
10 mM NaCl 
15 mM MgCl2 
250 mM sucrose 
0.5% NP-40 
0.1 mM EGTA 
PBS 137 mM NaCl 
2.7 mM KCl 
4.3 mM Na2HPO4 
1.47 mM KH2PO4 
Adjust to a final pH of 7.4. 
Protein binding buffer 20 mM HEPES pH7.8 
1 mM MgCl2 
10 µM ZnCl2 
2 mM DTT 
10% glycerol 
0.05% Triton X-100 
100 mM KCl 
40 µg/µl BSA 
Purification buffer 20 mM HEPES 
2 mM EDTA 
0.02% Triton X-100 
pH7.2 
SDS reducing buffer 25 mM Tris-HCl pH6.5 
10% glycerol 
8% SDS 
5% "-mercaptoethanol 
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A few grains of Brilliant Blue G 
Sucrose cushion 30% sucrose 
10 mM Tris pH7.5 
10 mM NaCl 
3 mM MgCl2 
Transfer buffer 0.05 M Tris-HCl 
0.04 M glycine 
0.01 M SDS 
20% MeOH 
TTBS 50 mM NaCl 
20 mM Tris-HCl pH8.0 
0.1% Tween-20 
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Table 2.3 cDNA constructs 
 
Construct Name cDNA Supplier Reference 
GRKs 
GRK5 GRK5-pRK5 Dr Robert 
Lefkowitz 
[152] 
GRK5 M1 
GRK5 M2 
GRK5 M3 
GRK5 M4 
GRK5 M5 
GRK5-pRK5 Miss K Lester  
GST-GRK5 pGEX-GRK5 Prof J Benovic [57] 
Gal4-DBD-GRK5 pFA-CMV-GAL4-DBD Dr M Scott [153] 
HDACs 
Flag-HDAC1 
Flag-HDAC2 
Flag-HDAC3 
pcDNA3.1-Flag-hHDAC Dr Stephane 
Emiliani 
[154] 
Flag-HDAC8 pCEP4F-Flag-HDAC8 Prof. Antonella 
Riccio 
[155] 
HA-HDAC4 
HA-HDAC5 
HA-HDAC6 
HA-HDAC7 
HA-HDAC9 
HA-HDAC10 
pcDNA-HA3.1 -HA-
HDAC 
Dr Saadi 
Khochbin 
 [156-158] 
GST-HDAC1 
GST-HDAC2 
GST-HDAC3 
GST-HDAC8 
pGEX-KG-HDAC Prof. Antonella 
Riccio 
[159, 160] 
Sin3A 
Sin3A-N205 
Sin3A-N479 
pCS2+MT-mSin3A Dr R Eisenman [161] 
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Sin3A-N680 
Sin3A-N1015 
GST-Sin3A 57-215 
GST-Sin3A 215-404 
GST-Sin3A 404-545 
GST-Sin3A 545-1157 
pGEX-KG-mSin3A Dr. Martin 
Privalsky 
[162] 
Other 
GST pGEX6p1-EV Dr. S Nurrish [163] 
Gal4 pFA-CMV-GAL4-DBD Dr M Scott  
Renilla luciferase pRL.CMV Dr M Scott  
Firefly luciferase pFR-luc Dr M Scott  
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Table 2.4 siRNA and miRNA constructs 
 
Construct name Sequence Supplier 
GRK5 siRNA 5’–AAG CCG UGC AAA GAA CUC UUU–3’ Thermo 
Scientific 
miR-135a-5p 
mirVana® miRNA 
mimic 
5’–UAUGGCUUUUUAUUCCUAUGUGA–3’ Invitrogen 
miR-135a- 5p 
mirVana® miRNA 
inhibitor 
5’–UAUGGCUUUUUAUUCCUAUGUGA–3’ Invitrogen 
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Chapter 3. Class I HDACs and Sin3A are novel 
binding partners of GRK5 
3.1 GRK5 interacts directly with class I HDACs 
The GRKs are known canonically for their role in phosphorylating GPCRs, 
preventing coupling to heterotrimeric G proteins and triggering receptor 
desensitisation. As discussed in detail in chapter 1, GRKs are becoming 
increasingly recognised for their role in mediating G protein-independent signalling. 
The discovery that GRK5, and the other GRK4 subfamily members, contain a 
functional NLS and NES prompted research into a role for the kinase in the nucleus. 
The first nuclear substrate of GRK5 to be identified was HDAC5, whose 
phosphorylation stimulates its nuclear export [81]. HDACs regulate gene 
expression by catalysing the deacetylation of lysine residues on histones and work 
in concert with repressor complexes to target their enzymatic activity to specific 
genes. The phosphorylation of HDAC5 by GRK5 relieves the inhibition of the pro-
hypertrophic transcription factor, MEF2, thus resulting in the upregulation of MEF2 
target genes and the progression towards pathological cardiac hypertrophy [81].  
 
The study of HDACs in the heart is largely concerned with their role as regulators 
of cardiac hypertrophy. Treatment with a pan-HDAC catalytic inhibitor, TSA, 
suppresses in vitro and in vivo models of cardiac hypertrophy [125, 126]. Despite 
targeting both classes of HDAC, the effect of TSA on cardiac hypertrophy is 
considered to be due to its action on class I HDACs, which are pro-hypertrophic 
and dominate over the anti-hypertrophic action mediated by class II HDACs [128, 
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164]. Indeed, treatment with the class I specific HDAC inhibitor, SK-7041, 
significantly reduces hypertrophic development in mice [129]. 
 
GRK5 is upregulated in patients with left ventricular overload disease, which is 
associated with HCM [87]. Moreover, the cardiac specific overexpression of GRK5 
in mice potentiates pressure-overload induced hypertrophy and GRK5 knockout 
mice show delayed hypertrophy and preserved cardiac function. GRK5 is therefore 
playing a causative role in disease progression possibly via its role as an HDAC5 
kinase [81, 165].  The NLS of GRK5 contains a functional DNA binding site, thus 
suggesting the kinase could also be playing a more direct role in controlling 
transcription [11]. In light of the causative roles played by both GRK5 and class I 
HDACs in hypertrophy, I wanted to investigate whether GRK5 could also contribute 
to disease progression in a class I HDAC-dependent fashion.  
 
To test this hypothesis I performed co-immunoprecipitation experiments in HeLa 
cells, as this cell line is easy to maintain and transfect. I over expressed Flag-
tagged class I HDACs or HA-tagged class II HDACs in HeLa cells with or without 
GRK5 and used an antibody against the epitope tag to immunoprecipitate the 
HDACs. GRK5 binding was detected by Western blotting using an anti-GRK5 
antibody. Figure 3.1 clearly shows that GRK5 binds to class I HDACs, HDAC1, 
HDAC3 and HDAC8 (Figure 3.1A) relative to HDAC2 and all class II HDACs 
(Figure 3.1B).  
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GRK5 is an HDAC5 kinase [81], but as compared to class I HDACs, the interaction 
between GRK5 and HDAC5 is relatively weak (Figure 3.1B). Relationships 
between substrates and kinases are often transient, with dissociation occurring 
promptly after the phosphorylation event, thus ensuring the kinase is able to target 
multiple substrates. Such interactions can therefore be difficult to capture, 
particularly by co-immunoprecipitation. The poor interaction of GRK5 with class II 
HDACs, as shown in Figure 3.1, is therefore typical of a substrate/kinase 
relationship [166], thus suggesting that the GRK5-mediated regulation of this class 
may not extend beyond phosphorylation.  
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Figure 3.1 GRK5 binds class I HDACs 
A. Representative Western blot showing the co-immunoprecipitation of Flag-tagged class I 
HDACs with GRK5. HeLa cells were transfected as indicated and protein expression confirmed 
by Western blotting (lysates) using an anti-Flag or anti-GRK5 antibody to detect HDACs or 
GRK5 respectively. Flag-tagged class I HDACs were immunoprecipitated (IP) and the amount 
of GRK5 bound to immunoprecipitated Flag-HDAC was detected by immunoblotting (IB). The 
blots shown are representatives of 3 separate experiments. B. Data quantified from co-
immunoprecipitations involving class I and class II HDACs. The percentage of GRK5 co-
immunoprecipitated per unit HDAC immunoprecipitated is normalised to the amount of co-
immunoprecipitation seen for HDAC1. Error bars represent standard error of the mean from 
three separate experiments, with *P<0.001; **P<0.05 relative to the amount of the GRK5 co-
immunoprecipitated with HDAC1 . H1, HDAC2; H2, HDAC2; H3, HDAC3; H8, HDAC8. These 
experiments were performed by Laura Johnson. 
 
Although indicative, co-immunoprecipitation experiments do not confirm whether an 
interaction between two proteins is direct; it is possible that accessory proteins in 
the cell lysate bridge the gap between the proteins of interest. In order to ascertain 
whether GRK5 interacts directly with class I HDACs, HDAC1, HDAC3 and HDAC8, 
I performed direct binding assays using GST-HDACs purified from bacteria, which 
were immobilised on glutathione sepharose beads and incubated with GRK5 
purified from SF9 cells. The samples were run on a SDS-PAGE gel and the amount 
of GRK5 binding directly to the fusion protein was detected by Western blotting 
using an anti-GRK4-6 antibody. GRK5 was pulled down with each of the three 
GST-HDACs but not with the GST negative control, thus suggesting that the kinase 
does indeed bind directly and specifically to HDAC1, HDAC3 and HDAC8 (Figure 
3.2A). Quantification of multiple pull-down experiments shows GRK5 binds directly, 
and most strongly, to HDAC8 (Figure 3.2B), a pattern that is supported by the co-
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immunoprecipitation data in Figure 3.1B. The weakest of the three interactions of 
GRK5 is that with HDAC3. 
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Figure 3.2 GRK5 binds class I HDACs directly 
A. GST or GST-tagged class I HDACs were used to pull-down purified GRK5 from SF9 cells. 
Samples were run on SDS-PAGE gels and GRK5 binding detected by Western blotting, using 
an anti-GRK4-6 antibody (IB). The fusion protein inputs were checked by running equal 
amounts of GST and GST-HDACs on SDS-PAGE gels before Coomassie staining (Fusion 
protein input). The Western blot is a representative from 3 separate experiments. B. 
Quantification of A. The percentage of GRK5 bound to GST-HDAC per unit INPUT was 
quantified relative to the amount of GRK5 bound to GST and normalised to the percentage of 
GRK5 bound to HDAC8. Error bars represent standard error of the mean. *P<0.05, **P<0.005 
relative to GST. H1 = HDAC1, H2 = HDAC2 etc. 
3.2 GRK5 fails to interact with HDAC2 
HDAC1 and HDAC2 are highly homologous proteins that share 85% sequence 
identity at the amino acid level, can heterodimerise and are often found in the same 
repressor complexes [167]. Several HDAC1/HDAC2 knockdown and knockout 
studies have highlighted redundant and compensatory roles for these HDACs. That 
being said, the global and targeted deletion of HDAC1 in mice results in early 
embryonic lethal death and a down-regulation of cellular HDAC activity is reported 
in HDAC1-null embryonic stem cells, despite the compensatory upregulation of 
HDAC2 [168]. HDAC1 therefore has certain autonomous roles that cannot be 
compensated for by HDAC2. Similarly, a role specific to HDAC2 has been reported 
with regards to apoptosis; selective inhibition of HDAC2 but not HDAC1 increased 
the sensitivity of breast cancer cells to tamoxifen treatment [169]. Co-
immunoprecipitation of Flag-tagged HDACs with GRK5 identified an interaction 
specific to HDAC1 and not HDAC2 (section 3.1).  To confirm the specificity of 
HDAC binding, I performed an immunofluorescence experiment to study whether 
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the cellular localisation of the HDAC could be influenced by GRK5, which would 
suggest a potential interaction between the HDAC and the kinase in a cellular 
setting. 
 
The nuclear export of GRK5 can be stimulated in HEp2 cells by treatment with the 
calcium ionophore, A23187. GRK5 binds to Ca2+/CaM with a high affinity at its N-
terminus, which promotes the nuclear export of the kinase [10]. To extend this 
investigation, HEp2 cells were treated with A23187 and monitored as to whether 
HDAC nuclear export could be influenced by the presence of GRK5. When 
overexpressed individually in HEp2 cells, both HDAC1 and HDAC2 remain 
exclusively nuclear following A23187 treatment (Figure 3.3, panels a–d). Upon co-
transfection of GRK5 with HDAC1, ionophore treatment promotes nuclear export of 
not only GRK5, (Figure 3.3, compare panels f to j and h to l) but also HDAC1 
(Figure 3.3, panels e and i). In contrast, in cells expressing both GRK5 and HDAC2, 
HDAC2 remains exclusively nuclear following ionophore treatment (Figure 3.3, 
panels g and k). These data thus support the data obtained in the co-
immunoprecipitation experiments, that GRK5 binds to HDAC1 but not HDAC2.
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Figure 3.3 GRK5 stimulates nuclear export of HDAC1 but not HDAC2 following A23187 treatment 
HEp2 cells were transfected as indicated and treated or not with the calcium ionophore, A23187 (+ A23187; 25 mM, 15 min). The subcellular 
distribution of GRK5 and HDAC1 or HDAC2 was subsequently visualised by indirect immunofluorescence using anti-GRK5 and anti-Flag 
antibodies to detect GRK5 and HDACs respectively. Scale bars 10 µm. These experiments were performed by Laura Johnson. 
 
C
hapter 3: R
esults 
Chapter 3: Results !
! 114 
Data in Figure 3.2 shows the interaction between HDAC1 and GRK5 to be direct. 
As an additional test of the binding specificity of GRK5 with HDAC1 and HDAC2, I 
performed a direct binding assay with GST-GRK5 or GST (negative control) 
purified from bacteria and immobilised on glutathione sepharose beads, with which 
I incubated in vitro translated [35S]-methionine labelled Flag-HDAC1 or Flag-
HDAC2.  The samples were washed, run on a SDS-PAGE gel and the gels dried 
down and exposed to X-ray film. Figure 3.4 confirms a direct interaction between 
GRK5 and HDAC1 and shows HDAC2 fails to interact directly with GRK5. Both the 
immunofluorescence (Figure 3.3) and pull-down data (Figure 3.4) confirm the 
findings from Figure 3.1 that indeed, GRK5 binds directly and specifically to 
HDAC1 but not HDAC2 in cells, cell lysates and in vitro.  
 
Comparison of the HDAC1 and HDAC2 sequence alignments highlights a potential 
GRK5 binding site in the C-terminus of HDAC1. HDAC1 and HDAC2 share a 91% 
sequence identity in the combined N- and catalytic- domains, while the remaining 
approximately 40 amino acids of the C-termini are only around 34% identical [170]. 
Differences in HDAC1 and HDAC2 function may possibly be due to the interactions 
mediated by their C-termini, which, for HDAC1, is likely to include the binding site 
of GRK5. 
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Figure 3.4 GRK5 does not bind HDAC2 directly  
GST or GST-GRK5 was used to pull down in vitro translated, radiolabelled, Flag-tagged HDAC1 
or HDAC2. Samples were run on a SDS-PAGE gel alongside 0.5 µl of HDAC1 or HDAC2 
(INPUT). The fusion protein inputs were checked by running equal amounts on SDS-PAGE gels 
and detected by Coomassie staining. A. Representative Western blot from three separate 
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experiments. B. Quantification of A. HDAC binding (%) was quantified relative to INPUT. Error 
bars represent standard error of the mean from three separate experiments, *P<0.005. 
3.3 GRK5 interacts directly with the C-terminus of Sin3A 
HDACs are most commonly recognised for their role in regulating gene silencing, 
yet these proteins rarely function independently, as they lack a DNA binding 
domain. Instead, HDACs comprise the enzymatic components of multi-protein 
transcriptional repressor complexes. Indeed, HDAC1 and HDAC2 only display 
maximal catalytic activity when involved in such a complex [117, 130]. Numerous 
mammalian repressors have been characterised that recruit class I HDACs, as 
discussed in section 1.5 and include NuRD, REST/Co-REST, N-CoR/SMRT and 
Sin3 [130, 132-134]. Lan Ma’s group performed a mass spectrometry screen in 
2012 to identify novel interactors of GRK5. Flag-GRK5 was purified from the 
metastatic breast cancer cell line, MDA-MB-231, and samples run on SDS-PAGE 
gels. The screen identified and characterised damaged DNA-binding protein 1 
(DDB1), part of an E3 ligase complex, as a major binding partner of GRK5. Another 
hit from this screen, but one which was not pursued by the group, was Sin3A [171]. 
Sin3A, a global regulator of transcription, incorporates HDAC1 and HDAC2 in its 
core repressor complex. In order to investigate whether the binding of class I 
HDACs to GRK5 could have a functional role, I decided to explore this potential 
GRK5/Sin3A interaction, to study whether GRK5 could play a role in regulating 
HDAC1 function within the context of this transcriptional repressor.  
 
I extracted nuclei from HeLa cells, which are likely to be enriched in Sin3A, and 
compared the cellular localisation of endogenous GRK5 to that of Sin3A. Figure 
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3.5A shows, as would be expected, Sin3A and a few core components, HDAC1, 
HDAC2 and RBBP4, to be highly enriched in the nuclear fraction (N) compared to 
the whole cell lysate (W) and GRK5 has the same cellular distribution, while GRK2 
is excluded from the nucleus. Considering the proteins of interest are all enriched in 
the nucleus, I used the HeLa nuclear extract to perform co-immunoprecipitation 
experiments to determine whether GRK5 may be part of the Sin3A repressor 
complex. Using an anti-Sin3A antibody, endogenous Sin3A was 
immunoprecipitated and GRK5 binding was detected by Western blotting using an 
anti-GRK5 antibody. Figure 3.5B shows endogenous GRK5 to interact with 
endogenous Sin3A.  
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Figure 3.5 GRK5 interacts with Sin3A 
A. HeLa whole cell lysates (W) and nuclear extracts (N) were immunoblotted (IB) for the 
proteins indicated. B. Co-immunoprecipitation of endogenous Sin3A and GRK5 from HeLa cell 
nuclear extracts. GRK5 binding to immunoprecipitated (IP) Sin3A was detected by 
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immunoblotting (IB). Endogenous protein expression was confirmed by Western blotting 
(lysates) using an anti-Sin3A and anti-GRK5 antibody respectively. The Western blot is a 
representative from 3 separate experiments. 
 
Section 3.1 identified HDAC1 as a novel and direct interactor of GRK5. HDAC1 is a 
component of the Sin3A core complex and may therefore be responsible for 
recruiting GRK5 to Sin3A. In order to ascertain whether Sin3A is capable of 
interacting directly with GRK5 independently of HDAC1, I performed direct binding 
assays using immobilised GST-tagged Sin3A deletion mutants purified from 
bacteria and in vitro translated [35S]-methionine labelled GRK5. This enabled not 
only the elucidation of whether the interaction between Sin3A and GRK5 is direct, 
but also enabled the broad scale mapping of the GRK5 interaction site on Sin3A. 
The Sin3A deletion mutants, as illustrated in Figure 3.6A, encompass each of the 
PAH domains, which mediate protein-protein interactions. The largest C-terminal 
fragment of Sin3A incorporates not only PAH4 but also the HID onto which the core 
complex assembles and the HCR, which is less well characterised. Data in Figure 
3.6B demonstrates a direct interaction between the C terminal portion of Sin3A, 
encompassing residues 545–1157, and GRK5. Quantification of multiple 
experiments indicates binding to be exclusive to this portion of Sin3A (Figure 3.6C). 
The HCR and PAH4 domains of Sin3A are poorly characterised, with only a few 
protein interactions identified at these sites; most of the interactions that occur 
between residues 545–1157 involve the HID and the majority of the core Sin3A 
components bind to the region encompassing PAH3–HID [139]. GRK5 does not 
bind directly to the PAH3 domain but it is possible that, like HDAC1, GRK5 may 
bind to the HID of Sin3A, assembling in concert with, or in addition to, the Sin3A 
core complex proteins. 
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Figure 3.6 GRK5 interacts directly with the C-terminus of Sin3A 
A. A schematic representative of the GST-Sin3A deletion mutants used in the pull-down 
experiments. B. In vitro translated radiolabelled GRK5 was incubated with GST or GST-Sin3A 
deletion mutants. Samples were run on a SDS-PAGE gel alongside 10% of the amount of in 
vitro translated GRK5 used in the experiment (INPUT). The fusion protein inputs were checked 
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by running equal amounts on SDS-PAGE gels and detected by Coomassie staining (not shown). 
C. Quantification of the amount of in vitro translated GRK5 directly bound to GST or GST-Sin3A 
deletion mutants relative to INPUT and normalised to the percentage GRK5 bound to GST-545-
1157. Data is from three separate experiments and error bars represent standard error of the 
mean. *P<0.005 relative to GST. 
3.4 Summary 
This chapter describes the identification of novel GRK5 binding partners: class I 
HDACs and the repressor protein, Sin3A. 
• In HeLa cells, GRK5 binds class I HDACs, HDAC1, HDAC3 and HDAC8 by 
co-immunoprecipitation, but does not interact with HDAC2 or class II 
HDACs. 
• GRK5 binds HDAC1, HDAC3 and HDAC8 directly. 
• Following A23187 treatment, GRK5 triggers the nuclear export of HDAC1 
but not HDAC2 in HEp2 cells and binds to HDAC1 directly but not HDAC2 in 
in vitro direct binding assays. These data support the co-
immunoprecipitation data in Figure 3.1 that implies GRK5 binds HDAC1 but 
not HDAC2. 
• Endogenous GRK5 binds to the endogenous mammalian transcriptional 
repressor protein, Sin3A, by co-immunoprecipitation, in HeLa cells. 
• GRK5 binds directly and exclusively to the C-terminus of Sin3A, which 
encompasses the HID, PAH4 and the HCR. 
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Chapter 4. Mapping the binding sites of HDAC1 and 
Sin3A on GRK5 
4.1 GRK5 peptide arrays 
The previous chapter saw the identification of class I HDACs, HDAC1, HDAC3 and 
HDAC8 and the transcriptional repressor protein, Sin3A, as direct binding partners 
of GRK5. One method of investigating the functional relevance of protein-protein 
interactions and thus the functional relevance of GRK5/class I HDAC and 
GRK5/Sin3A complex formation, is to study the physiological effects brought about 
by preventing such binding events. My results from chapter 3 suggest that GRK5 
can interact both directly and indirectly with the Sin3A complex, via Sin3A itself but 
also via HDAC1. Preliminary in vitro mapping experiments or sequence analyses 
has enabled the broad-scale mapping of the GRK5 binding sites on Sin3A and 
HDAC1 respectively; direct binding assays identified GRK5 to bind to the C-
terminus of Sin3A and the differential binding of HDAC1 and HDAC2 with GRK5 
also suggests that GRK5 is likely to bind to the C-terminus of HDAC1, the region of 
the protein that varies most from HDAC2. To complement these findings and 
develop tools to ascertain the function of GRK5 as a binding partner of Sin3A and 
HDAC1, I wanted to map the binding sites of both proteins on GRK5.  
 
The mutation of binding sites for novel binding partners on target proteins is often 
used as a means of investigating the physiological implication of the interaction. In 
order to ascertain the role of a novel binding partner in concert with a well-
established protein complex, this new interactor should be the protein mutated in 
order to avoid disruption to the complex, which may have a variety of physiological 
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implications. Indeed, following the identification of growth factor receptor-bound 
protein 2 (Grb2) as a novel interactor of TNFR1, the binding site was mapped to 
the Src homology 3 domain on Grb2 and key residues mutated accordingly. 
Transfection of this TNFR1 binding deficient Grb2 mutant into HEK293 cells 
perturbed the TNF!-dependent activation of c-Raf-1, thus highlighting the specific 
importance of the interaction of TNFR1 with Grb2 in regulating this signalling 
pathway [172]. My aim, therefore, was to identify key residues on GRK5 that 
mediate the binding events with HDAC1 and Sin3A, the mutation of which would 
hopefully result in specific GRK5"HDAC1 and GRK5"Sin3A binding deficient 
mutants without completely disrupting the Sin3A complex. These GRK5 mutants 
would then enable me to test the importance of these interactions in controlling 
GRK5-mediated cellular phenotypes. 
 
SPOT™ immobilised peptide libraries of GRK5 were used in an attempt to map the 
binding sites of HDAC1 and Sin3A on the kinase. These peptide arrays are able to 
bind purified recombinant proteins and identify biologically active motifs. This 
technique, pioneered by Ronald Frank in the 1980s and first presented in 1990, 
involves multiple peptides synthesised and ‘spotted’ onto one membrane support. 
The technique utilises the concept that chemical reactions can proceed to 
completion only when enough reagent is used that can be taken up by the support 
material. Multiple reactions can therefore occur on one membrane as spot sizes 
are strictly controlled, such that peptides occupy distinct and isolated areas [173]. 
These membranes are used as tools to map binding sites, with one protein spotted 
as peptides onto the membrane, which is then overlaid with another protein of 
interest. For example, peptide arrays of #-arrestin 2 have been successfully utilised 
to identify the residues that mediate binding to family 4 cAMP-specific 
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phosphodiesterase, subfamily D, isoform 5 (PDE4D5) [174]. Moreover peptide 
array libraries of PDE4D5 showed that !-arrestin 2 and the receptor for activated C 
kinase 1 (RACK1) bind PDE4D5 at overlapping sites [175]. 
 
To increase the reliability of screening, the GRK5 arrays consist of overlapping 25-
mer peptides each sequentially shifting along by five amino acids to span the entire 
GRK5 sequence (Figure 4.1A). Additionally, the arrays are duplicates, with the 
same peptide sequence printed twice on one array. The method used to detect 
sites of protein-protein interactions are much like a Western blot and illustrated 
schematically in Figure 4.1; the arrays are overlaid with purified GST-tagged 
proteins and sites of protein-protein interaction detected using an anti-GST 
antibody and the relevant secondary antibody (Figure 4.1B). The arrays are 
subsequently developed and imaged using X-ray film, with dark spots illustrating 
sites of positive protein-protein interactions (Figure 4.1B).  
 
GRK5 peptides that replicate within and between experiments are subsequently 
selected for further mapping. These selected peptides are detected as strong spots 
on both sides of the duplicated array, as shown for peptide 3 on Figure 4.1B and 
similar patterns will have been detected in multiple experiments. Each amino acid 
of the chosen peptides are mutated sequentially to alanine and immobilised on an 
alanine scanning substitution array for incubation with target proteins (Figure 4.1C). 
Developing these arrays identifies residues important for mediating the binding 
events, as their mutation to alanine prevents these interactions from occurring, 
such that gaps appear in the developed array. 
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Figure 4.1 Schematic representation of mapping protein binding sites using GRK5 
peptide arrays  
A. The GRK5 protein sequence is divided into 25-mer peptides, each overlapping by 5 amino 
acids. Each circle represents 5 amino acids. B. GRK5 peptide array. The GRK5 peptides are 
immobilised onto the array and incubated with target protein (GST-HDAC1 shown here for 
illustrative purposes), primary then secondary antibodies. The array is then developed and dark 
spots highlight sites of protein-protein interactions. Based on repeat data within and between 
experiments, selected spots are chosen that correspond to specific GRK5 peptide sequences, 
e.g. peptide 3, as shown in the schematic. C. Peptides corresponding to intensely stained and 
replicated spots are selected and used in an alanine scanning array. The array comprises firstly 
the full-length peptide (*) and then each residue in the chosen peptide is mutated sequentially to 
alanine. The method of incubation with target GST-proteins and detection using specific 
antibodies is as described in B. Developing the array highlights key residues needed for binding 
to the target protein. 
4.2 Mapping the binding sites of HDAC1 and Sin3A on GRK5 
GRK5 peptide arrays were incubated with GST-HDAC1 or GST-Sin3A-545-1157, 
the Sin3A fragment shown in section 3.3 to bind directly to GRK5, or with GST as a 
negative control. The arrays were then probed with an anti-GST antibody before 
the appropriate secondary antibody and developed as per a Western blot. In 
comparison to the GST control arrays, which remain largely blank (Figure 4.2Ai), 
the arrays probed with GST-HDAC1 (Figure 4.2Aii) or GST-Sin3A-545-1157 
(Figure 4.2Aiii) display a series of dark spots, many of which are repeated on both 
sides of the array and in multiple experiments. Peptides that reproducibly bind 
GST-HDAC1 or GST-Sin3A are indicated in Figure 4.2Aii and iii by, respectively, 
blue and green circles. This colour coding holds true throughout, with blue and 
green corresponding to HDAC1 and Sin3A interacting peptides, respectively. The 
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location of these peptides within the sequence of GRK5 is shown in Figure 4.2B. 
The majority of these potential HDAC1 and Sin3A interacting peptides are located 
in the C-terminal portion of GRK5. 
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Figure 4.2 Mapping the sites of HDAC1 and Sin3A interactions on GRK5  
A. GRK5 peptide arrays were incubated with purified GST-HDAC1 (ii), GST-Sin3A-545-1157 
(iii) or GST (control) (i) and probed with an anti-GST antibody to detect sites of protein-protein 
interaction. Dark spots on the arrays indicate sites of positive interactions. Spots detected 
repeatedly on multiple arrays within and between experiments are circled in blue or green to 
indicate HDAC1 or Sin3A interacting peptides respectively. B. The sequences of the peptides 
circled in A. are mapped onto the GRK5 peptide sequence, with potential HDAC1 interacting 
peptides highlighted in blue and Sin3A interacting peptides in green.  
 
In an attempt to identify specific GRK5 residues important for binding HDAC1 and 
Sin3A, six peptides were incorporated into an alanine scanning substitution array. 
The peptides chosen reflect peptides repeatedly observed in multiple experiments 
to interact with target proteins. Unique to HDAC1 binding are peptides 69 and 112, 
highlighted in blue, and specific to Sin3A binding are peptides 76 and 106, which 
are highlighted in green (Figure 4.3A and B). Two additional peptides, 82 and 96, 
were also selected as being potentially involved in both HDAC1 and Sin3A binding 
events. The table in Figure 4.3C illustrates the sequences of the selected peptides 
and the location of the peptides within the GRK5 sequence is shown in Figure 4.4. 
The selected peptides span the C-terminal region of the catalytic domain as well as 
the C-terminus of the kinase. 
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Figure 4.3 Selecting potential HDAC1 and Sin3A GRK5 interacting peptides 
Six peptides that were detected on the GRK5 arrays from multiple experiments were selected 
for further mapping by alanine scanning. A and B. Selected peptides that interact with HDAC1 
(A, blue) and Sin3A (B, green) are circled and numbered. C. The peptide sequence is given for 
each of the six selected GRK5 peptides and coloured according to whether these peptides 
mediate interactions with HDAC1 (blue) or Sin3A (green) or both (blue and green). 
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Figure 4.4 GRK5 protein sequence with potential interacting peptides 
GRK5 peptides selected for the alanine scanning arrays are numbered and highlighted to show 
their potential interactions with HDAC1 (blue) and Sin3A (green) or both proteins (blue and 
green).  
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4.3 Identifying key residues for binding using Alanine 
scanning substitution arrays 
Having identified six GRK5 peptides that were indicated by array analysis to 
contain HDAC1 and/or Sin3A binding sites, I then wanted to map these binding 
sites further and identify the specific residues required for these interactions. The 
selected peptides were used on an alanine scanning array, whereby each residue 
of the chosen peptide is mutated sequentially to alanine and these libraries were 
once again probed with target proteins, GST-HDAC1 or GST-Sin3A-545-1157. The 
first peptide on the array is the full-length GRK5 peptide, which is expected to 
interact with the target protein based on previous array analysis and is indicated in 
Figure 4.5 by an asterisk. Lack of binding to a mutated peptide, denoted by an 
absence of signal on the array, would therefore highlight an important residue for 
the binding event (Figure 4.1C). 
 
GRK5 array results from Figure 4.3 suggest that peptides 69 and 112 are specific 
to mediating interactions with HDAC1. As shown in Figure 4.5A, mutation of each 
of the first 9 residues of peptide 69, Leu341–Val349, (L-I-R-G-R-V-G-T-V) to 
alanine increases the intensity of the interaction with GST-HDAC1, suggesting that 
this sequence may contain negative determinants in mediating the binding event. In 
contrast, mutating residues Gly350–Pro354 (G-Y-M-A-P) has little effect on binding 
compared to the full-length peptide. The intensity of the interaction with GST-
HDAC1 is modestly reduced in comparison to the full-length peptide following the 
mutation of each of the residues Glu355–Arg361 (E-V-L-N-N-Q-R) to alanine, thus 
suggesting these amino acids may be of particular importance in mediating binding 
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to HDAC1. I decided to select the first two amino acids in this sequence, Glu355 
and Val356, as residues to mutate in the full length GRK5 sequence to create a 
potential GRK5!HDAC1 binding mutant (Figure 4.5A, red box). The mutation of 
most of the residues in peptide 112 enhances the interaction between GRK5 and 
HDAC1 compared to the full-length peptide, with the possible exception of residues 
Gln358 and His359 (Figure 4.5A lower panel). Considering that mutating peptide 
69 displays a reduced intensity of HDAC1 binding that spans more residues and is 
thus more likely to represent a bona fide binding site than peptide 112, peptide 112 
was disregarded for any further analysis and only residues Glu355 and Val356 
from peptide 69 were selected for mutation to create a potential GRK5!HDAC1 
binding mutant. 
 
Important for both HDAC1 and Sin3A binding are GRK5 peptides 82 and 96 (Figure 
4.3). Binding of GRK5 peptide 82 to GST-HDAC1 is notably disrupted following the 
mutation of residues Lys411, Phe412, Glu414–Lys417 (E-E-A-K) and Lys421–
Gln430 (M-L-L-T-K-D-A-K-Q) (Figure 4.5C). When overlaid with GST-Sin3A-545-
1157 however, binding to even the full-length GRK5 peptide is very poor. The same 
is true for peptide 96. This may be due to a technical error with the alanine 
scanning array used in the Sin3A experiment, as only full-length peptide 76 has a 
significant interaction with GST-Sin3A-545-1157 (Figure 4.5B and C), which is not 
in keeping with data from Figure 4.3. I decided, therefore, to focus on the 
interactions of peptides 82 and 96 with GST-HDAC1 when selecting residues to 
mutate. Despite the reduced binding observed in the alanine scanning array of 
peptide 82, the alanine mutations of residues Asp485–Tyr489 (D-D-D-F-Y) in 
peptide 96 appeared to completely abolish binding to HDAC1 (Figure 4.5C). 
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Moreover, although the array may be unreliable, binding to Sin3A is also abolished 
following the mutation of the same residues, in comparison to the full-length 
peptide. I decided to select the first three residues in this sequence, Asp485–
Asp487, to create a GRK5!HDAC1 and potentially a GRK5!HDAC1!Sin3A 
binding mutant.  
 
Chapter 4: Results !
! 135 
 
 
Figure 4.5 Mapping the sites of HDAC1 and Sin3A interactions on GRK5 using a GRK5 
alanine scanning array 
Individual residues in the selected peptides were mutated sequentially to alanine. * indicates the 
full length peptide with no mutations. The peptide sequence above the array indicates which 
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residue in that spot was mutated to alanine. GRK5 residues chosen to mutate are highlighted in 
red boxes.  A and B. Arrays incubated with GST-HDAC1 or Sin3A are shown in blue and green 
respectively. C. Peptides 82 and 96 were incubated with both GST-HDAC1 and GST-Sin3A. 
 
Specific to Sin3A binding are GRK5 peptides 76 and 106. As previously mentioned, 
on developing these alanine scanning arrays, full-length peptide 76 interacts 
stronger with Sin3A compared to peptide 106 (Figure 4.5, *). I therefore decided to 
focus on selecting residues to mutate from peptide 76. Sin3A binding to the peptide 
was reduced following the mutation of residues Ser383 and Pro384, the series 
Arg386–Asp398 (R-G-R-K-E-K-V-K-R-E-E-V-D), as well as the final residue in the 
peptide, Arg400. I decided to focus on the series of 12 residues whose interaction 
with Sin3A is reduced following mutation to alanine, as the likelihood is that multiple 
residues are involved in the binding event. In this sequence, residues Arg388 and 
Lys389 were noted as being the most important residues in the sequence for 
binding, as their mutation results in the weakest interaction with Sin3A-545-1157 
(Figure 4.5B). These amino acids were therefore selected for mutation. 
 
To summarise, of the six GRK5 peptides chosen for the alanine scanning arrays, 
residues from three peptides were selected for mutation, as highlighted in bold in 
Table 4.1. Out of the two peptides chosen for specificity towards HDAC1 binding, 
both peptides 69 and 112 contain residues that are negative determinants in the 
binding event, as strength of the interactions increases following their mutation to 
alanine. Peptide 69 contains more residues than peptide 112 that appear to be 
important for the binding event. The first two residues in this sequence, Glu355 and 
Val356, were selected for mutation. Considering full-length peptide 76 binds GST-
Sin3A-545-1157 on the alanine scanning arrays stronger than full-length peptide 
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106, residues from this peptide were chosen for mutation. The first two amino acids 
in a series whose mutation to alanine reduces binding to Sin3A were selected: 
Arg388 and Lys389. When analysing the binding of HDAC1 and Sin3A to peptides 
82 and 96, binding is abolished following the mutation of residues Asp485–Tyr489 
(D-D-D-F-Y) of peptide 96. The first three amino acids in this sequence, Asp485–
Asp487 were chosen for mutation. A summary of the residues selected for mutation 
is shown in Table 4.1. 
 
Peptide Peptide sequence with mutated residues highlighted 
Potential 
binding mutant 
69 L-I-R-G-R-V-G-T-V-G-Y-M-A-P-E-V-L-N-N-Q-R-Y-G-L-S GRK5!HDAC1 
76 Y-E-M-I-E-G-Q-S-P-F-R-G-R-K-E-K-V-K-R-E-E-V-D-R-R GRK5!Sin3A 
96 D-V-L-D-I-E-Q-F-S-T-V-K-G-V-N-L-D-H-T-D-D-D-F-Y-S 
GRK5!HDAC1!
Sin3A 
 
Table 4.1 GRK5 residues chosen for mutation based on alanine scanning array data  
The GRK5 peptides selected for mutation are shown, along with the specific residues chosen to 
mutate (bold). The potential resultant GRK5 binding mutant is also given. 
 
The residues selected for mutation were mapped onto the crystal structure of 
GRK6 in complex with AMP in order to confirm their location within the protein’s 
tertiary structure. GRK5 and GRK6 share 70.1% amino acid sequence identity [24], 
such that the crystal structure of GRK6 was used to infer the position of the 
residues in GRK5, for which no crystal structure has been generated.  
 
Figure 4.6 depicts the 3D ribbon structure (Figure 4.6A), and solvent exposed 
surface area (Figure 4.6B and C) of the GRK6 dimer. A sequence alignment of 
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GRK5 and GRK6 reveals residues Glu355 and Val356, a potential HDAC1 binding 
site on GRK5, are present at the same residue positions in GRK6. These residues 
are highlighted and labelled in blue in Figure 4.6A. The GRK5 region predicted to 
be involved in both HDAC1 and Sin3A interactions, Asp485–Asp486–Asp487, 
maps to a sequence on GRK6 ten residues along: Asp495–Gln496–Asp497. These 
residues are highlighted and labelled in sea green in Figure 4.6A and, as can be 
seen clearly in Figure 4.6B and C, lie on the surface of GRK6. The solvent exposed 
surface area of each of the residues, Asp495, Gln496 and Asp497 are 15.1, 107.4. 
and 108.0 Å, respectively, suggesting that Gln496 and Asp497 are extremely 
accessible to solvents and binding partners. In contrast, Glu355 and Val356 have a 
solvent accessible surface area of only 4.0 Å and 4.4 Å, respectively, and lie in a 
groove on the surface of GRK6 (Figure 4.6B and C). Residues Arg388 and Lys389 
are not shown on the crystal structure but these residues are involved in the NLS of 
GRK5 and GRK6, which are known to be solvent exposed, as a GRK5!NLS 
mutant has been well characterised [10]. 
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Figure 4.6 GRK6 crystal structure with selected residues  
The crystal structure of the GRK6 dimer with each monomer coloured in a different shade of 
orange. Residues 485–487, representing potential Sin3A and HDAC1 binding sites, are 
coloured in sea green.  Residues 355 and 356, representing a potential HDAC1 binding site are 
coloured in blue. A. The 3D ribbon structure of GRK6 with labelled residues in the appropriate 
colours. B. The solvent exposed surface area of the GRK6 dimer is shown with circled residues 
corresponding to those labelled in A. C. The solvent exposed surface area of the GRK6 dimer is 
shown in a different orientation, highlighting the groove that contains residues 355 and 356.   
 
While it is worthwhile knowing the location of the selected residues in the protein’s 
tertiary structure, a potential conformational change may ensue upon interacting 
with a binding partner to alter the position of amino acids. The involvement of 
residues Glu355 and Val356 in mediating intermolecular interactions does, 
therefore, remain a possibility, particularly as these amino acids lie on the surface 
of GRK6. Furthermore, a GRK6 monomeric crystal structure may differ from the 
dimer crystal structure. While I do hypothesise GRK5 to dimerise in certain cellular 
settings, it may bind HDAC1 and Sin3A as a monomer and the selected residues 
may be more exposed in its monomeric form. Differences between GRK5 and 
GRK6 also mean that while the GRK6 crystal structure is informative, one cannot 
be certain that the same residues in GRK5 adopt a similar conformation. With this 
in mind I continued with this investigation and mutated the selected residues 
summarised in Table 4.1 to form potential GRK5 binding deficient mutants. 
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4.4 GRK5!NLS has a weaker interaction with HDAC1 and 
compared to wildtype GRK5 
As described above and in Figure 4.5 and Table 4.1, three regions of the GRK5 
protein sequence were identified as potential binding sites: Glu355 and Val356, 
and Arg388 and Lys389, specific to the binding of HDAC1 and Sin3A respectively, 
and Asp485–Asp487, which I predict to be important for both binding events. In 
order to test whether the residues identified are indeed important for HDAC1 and/or 
Sin3A binding, I mutated the GRK5 wildtype sequence to alanine at the selected 
sites and tested the ability of these mutants to bind to HDAC1 and Sin3A by 
performing direct binding assays. The mutated residues of a GRK5!NLS mutant 
include Arg388 and Lys389, the residues hypothesised to be necessary for the 
Sin3A/GRK5 interaction [10]. I therefore tested this GRK5!NLS mutant as a 
potential GRK5!Sin3A binding deficient mutant and mutated Glu355 and Val356 
and Asp485–Asp487 to alanine as a potential GRK5!HDAC1 (M1) and 
GRK5!HDAC1!Sin3A binding mutants (M2–5) respectively, as shown in Table 4.2. 
To try and determine whether the three aspartic acid residues, Asp485–Asp487, 
work cooperatively or independently to mediate binding to HDAC1 and Sin3A, I 
decided to mutate each of these residues to alanine individually (M2–4) as well as 
together (M5) (Table 4.2). 
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Table 4.2 GRK5 mutants  
The GRK5 mutants are described, showing the mutations made and the peptides from which 
these residues were chosen, as a result of the peptide array experiments. Additionally, the 
potential GRK5 binding mutant generated from these mutations is also given.  
 
I tested the ability of these GRK5 mutants to bind Sin3A and HDAC1 by in vitro 
translating the mutants with [35S]-methionine, for use in direct binding assays with 
immobilised GST-HDAC1, GST-Sin3A-545-1157 or GST as a control (Figure 4.7). 
The potential GRK5!HDAC1 binding mutant, M1, behaves like wildtype GRK5 and 
binds similarly to HDAC1. I also tested this mutant for Sin3A binding and again, M1 
behaves like wildtype kinase, as expected. The potential GRK5!HDAC1!Sin3A 
mutants, M2, M3, and M5, bind HDAC1 and Sin3A to a similar degree as wildtype 
GRK5. From quantification of three independent experiments, mutant M4, 
encompassing a single alanine mutation at residue Asp487 (Table 4.2), has a 
stronger interaction with HDAC1 and Sin3A compared to wildtype GRK5 (Figure 
4.7B). This aspartic acid residue may act as a negative determinant of HDAC1 and 
Sin3A binding when incorporated into the tertiary GRK5 structure, but this is likely 
to be is likely due to an experimental error from one ambiguous result.  
Mutant name Peptide Mutation Potential binding mutant 
M1 69 E355A/V356A GRK5!HDAC1 
M2 96 D485A GRK5!HDAC1!Sin3A 
M3 96 D486A GRK5!HDAC1!Sin3A 
M4 96 D487A GRK5!HDAC1!Sin3A 
M5 96 D485/486/487A GRK5!HDAC1!Sin3A 
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Figure 4.7 GRK5 mutants interact with HDAC1 and Sin3A  
GST (control), GST-HDAC1 or GST-Sin3A-545-1157 were immobilised and incubated with in 
vitro translated, radiolabelled GRK5 wildtype (WT) or mutants (M1–5). Samples were run on 
SDS-PAGE gels, dried down and exposed to film. The fusion protein inputs were checked by 
running equal amounts of protein on SDS-PAGE gels before Coomassie staining. A. 
Representative Western blot of 3 separate experiments. B. Quantification of A. The bar graph 
shows percentage of GRK5 bound to fusion proteins per unit GRK5 INPUT. Error bars 
represent standard error of the mean from three separate experiments. *P<0.5 relative to GRK5 
WT. 
 
The GRK5!NLS mutant, tested as a potential GRK5!Sin3A mutant, binds 
approximately 50% less well to both HDAC1 and Sin3A, compared to wildtype 
GRK5 (Figure 4.8B and C). The NLS of GRK5 encompasses residues Arg388–
Glu395 (R-K-E-K-V-K-R-E), with arginine and lysine residues of this sequence 
mutated to form the GRK5!NLS construct (A-A-E-A-V-A-A-E), as shown in Figure 
4.8A, where mutated residues are in red boxes. While the suspected residues that 
mediate the interaction with Sin3A, Arg388 and Lys389, are mutated in this 
GRK5!NLS mutant, we cannot rule out the possibility that the loss of binding to 
HDAC1 and Sin3A could be due to the additional mutations in the sequence, which 
exclude the kinase from the nucleus. 
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Figure 4.8 GRK5!NLS interacts with HDAC1 and Sin3A 
A. Comparison of residues mutated in the GRK5!NLS mutant (bottom line) to the residues 
selected to mutate from the alanine scanning array of peptide 76, to potentially create a Sin3A 
binding deficient mutant (top line). Mutated residues are boxed in red. B. GST (control), GST-
HDAC1 or GST-Sin3A-545-1157 were immobilised and incubated with in vitro translated, 
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radiolabelled GRK5 wildtype (WT) or NLS mutant (GRK5!NLS). Samples were run on SDS-
PAGE gels, dried down and exposed to film. The fusion protein inputs were checked by running 
equal amounts of protein on SDS-PAGE gels before Coomassie staining. Shown is a 
representative Western blot of 4 separate experiments. C. Quantification of A. The bar graph 
shows percentage of GRK5 bound to fusion proteins per unit GRK5 INPUT. Error bars 
represent standard error of the mean from four separate experiments. *P<0.05 relative to GRK5. 
4.5 Summary 
In this chapter I attempted to map the HDAC1 and Sin3A binding sites on GRK5.  
• Using GRK5 peptide arrays comprising 25mer immobilised peptides, I 
attempted to identify specific GRK5 peptides that mediate binding to HDAC1 
and Sin3A.  
• Following the analysis of arrays developed from multiple experiments, 
specific peptides were selected based on repeat binding patterns to the 
target proteins, as shown in Table 4.3. These residues were incorporated 
into alanine scanning arrays and selected residues chosen to mutate. 
 
Peptide Potentially 
binds to 
Alanine scanning arrays Residues to 
mutate 
69 HDAC1 More residues act as positive binding 
determinants than peptide 112. 
Glu355 and 
Val356  
112 HDAC1 Many residues act as negative 
determinants. 
 
76 Sin3A Full-length peptide binds Sin3A stronger 
than peptide 106. 
Arg388 and 
Lys389 
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(GRK5!NLS) 
106 Sin3A Full-length peptide did not strongly 
interact with Sin3A. 
 
82 HDAC1 
and Sin3A 
Loss of binding is not as great as that 
shown in peptide 96. 
 
96 HDAC1 
and Sin3A 
Mutation of certain residues totally 
abolishes binding to target proteins. 
Asp485–
Asp487  
 
Table 4.3 Summary of peptide array results  
The table describes the peptides chosen for use in the alanine scanning arrays and summarises 
the results of these arrays. Residues from selected peptides chosen to mutate are also 
displayed. 
 
• Mapping the selected residues onto the crystal structure of GRK6 shows 
Asp485–Asp487 are located on the surface of the kinase, accessible to 
solvent and binding partners. Residues Glu355 and Val356 lie in a groove 
on the surface of GRK6 and are unlikely to mediate intermolecular 
interactions in the given conformation, but conformational changes that 
occur upon protein binding and discrepancies between the GRK5 and GRK6 
amino acid sequence, and thus potentially their tertiary structures, means 
these residues may still be involved in mediating protein-protein interactions. 
• The following GRK5 mutants were made based on analysis of the alanine 
scans: E355A/V356A, D485A, D486A, D487A and D485/486/487A, which 
are referred to as mutants M1–M5, as shown in Table 4.2. None of the 
mutants disrupt binding to the fusion proteins compared to wildtype GRK5, 
as shown by direct binding assays.  
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• Mutant M4, D487A, displayed enhanced binding capabilities to both HDAC1 
and Sin3A. 
• A pre-existing GRK5!NLS mutant encompassing the R388A/K389A 
mutation was tested as a potential GRK5!Sin3A binding mutant. Indeed, 
binding of the GRK5!NLS to both HDAC1 and Sin3A was perturbed in 
comparison to wildtype GRK5.  
• Despite this result, the GRK5!NLS mutant will not be used to further 
investigate a physiological role for the GRK5/Sin3A or GRK5/HDAC1 
interactions, as this mutant is excluded from the nucleus. Any functional 
differences observed with this mutant in comparison to wildtype GRK5 
cannot, therefore, be solely attributed to perturbing the protein-protein 
interactions between GRK5!NLS and Sin3A or HDAC1, but may also be 
due to mislocalisation of GRK5.  
 
In light of my inability to identify GRK5 mutants deficient in HDAC1 and/or Sin3A 
binding, I decided to investigate a functional role for nuclear GRK5 in coordination 
with HDAC1 and the Sin3A complex through the use of HDAC and Sin3A inhibitors. 
The following chapter describes these findings in detail.  
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Chapter 5. GRK5 represses Bcl-2 transcription to 
increase the sensitivity of HT-29 cells to 
chemotherapeutic agents 
GRKs play a part in disease pathogenesis through their role as GPCR kinases. As 
increasing numbers of non-receptor GRK substrates and binding partners are 
being identified, their effector portfolio in both physiological and pathophysiological 
processes has greatly expanded beyond that of receptor desensitisation. Indeed, 
nuclear GRK5 has been implicated in pathological cardiac hypertrophy through, at 
least in part, relieving the inhibition of the pro-hypertrophic transcription factor, 
MEF2, by acting as an HDAC5 kinase [81].  
 
Chapter 3 saw the identification of class I HDACs and Sin3A as novel GRK5 
binding partners. I outlined in chapter 4 a method used to attempt to map the 
binding sites for these proteins on GRK5, with the aim of making GRK5 binding 
deficient mutants. Identification of these novel GRK5 binding partners suggests a 
role for the kinase in transcriptional repression, but the only identified HDAC1 and 
Sin3A binding deficient mutant, GRK5!NLS, is exclusively cytoplasmic. Disrupted 
protein binding cannot be distinguished from the mutant’s mislocalisation, thus 
preventing further use of the GRK5!NLS construct in investigating a functional role 
for the GRK5/HDAC1 and GRK5/Sin3A interactions. An alternative approach to 
probing the physiological implications of protein-protein interactions is through the 
use of signalling inhibitors and protein knockdown. Both of these techniques were 
employed to investigate a potential role for GRK5, in concert with HDAC1 and 
Sin3A, in a model of colon cancer. 
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The aberrant growth of cancerous cells is due to the accumulation of multiple 
genetic mutations that render cells resistant to cell cycle control checkpoints and 
many environmental cues. The progression of tissues from benign to malignant 
involves the deregulation of multiple genes and altered gene expression 
accordingly. Aberrant activation or expression of GPCRs is associated with tumour 
growth and cancer progression. GRK5 is implicated in cancer pathogenesis not 
only due to its role as a GPCR kinase, but also in a more direct manner, via its 
ability to phosphorylate nuclear substrates, including p53. GRK5 is involved in the 
pathogenesis of GBM, thyroid, prostate and colon cancer, as discussed in section 
1.4.  
 
Colon cancer is one of the leading causes of cancer deaths worldwide and GRK5 
has recently been implicated in the disease pathogenesis: a whole genome 
association study identified a SNP in the intron of GRK5 to be associated with a 
35% increased risk of developing CRC [Dr Stephen Gruber, Patent publication 
number: WO2009046422 A2]. Whether this SNP affects the expression levels of 
GRK5 is yet to be determined, but a recent microarray study of gene expression 
profiles of patients with colorectal liver metastases identified GRK5 as being 
significantly under expressed in higher-risk patients [Chung, J., 2013; personal 
communication]. GRK5 expression is positively regulated by the tumour suppressor 
protein, tazarotene-induced gene 1 (TIG1), which inhibits cell growth and is 
downregulated in metastatic colon cancer cells. Furthermore, GRK5 suppression is 
responsible for TIG1-mediated growth regulation in colon cancer cells [176]. There 
is, therefore, potential for GRK5 to act as a biomarker for CRC, with levels of the 
kinase possibly indicating the stage of disease.    
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5.1 GRK5 levels vary across cancer cell lines 
There is considerable evidence that GRK5 is downregulated in colon cancer. To 
investigate whether this down-regulation contributes to disease progression and to 
investigate a potential function of the GRK5/HDAC1 and GRK5/Sin3A interactions 
in this process, I sought a model cellular system to use. I screened a range of 
cancer cell lines to compare how GRK5 protein expression levels vary in different 
cancers and whether kinase levels in colon cancer are notably lower. GRK5 is 
expressed in the cervical cancer cell line, HeLa, as well as in the prostate cancer 
cell line, PC3, as mentioned in sections 3.3 and 1.4.3.1 respectively. In addition to 
these two cell lines, three ovarian cancer cell lines, OVCAR3, IGROV-1 and A2780 
as well as two colon cancer cell lines, SW620 and HT-29, were tested for 
endogenous GRK5 protein expression levels. 
 
Cell nuclear extracts were prepared from the range of cancer cell lines and run 
together with the whole cell lysate on a SDS-PAGE gel and probed with an anti-
GRK5 antibody. Figure 5.1 shows GRK5 to be enriched in nuclear extracts but is 
barely detectable in the remaining cell lysate. Furthermore, nuclear GRK5 levels 
vary greatly between different cancers cell lines. For comparison purposes, the 
amount of nuclear GRK5 per unit actin expression, as shown in the bar graph of 
Figure 5.1, is arbitrarily set to 100% for HeLa cells. All three ovarian cancer cell 
lines have the highest nuclear GRK5 expression levels and the lowest expression 
is found in colon cancer cells, HT-29 and SW620. These cell lines are derived from 
colon adenocarcinomas; HT-29 cells are primary colon epithelial cells from a grade 
II tumour, localised only to the bowl and are yet to metastasise. By contrast, 
SW620 are metastatic colon cancer cells taken from lymph nodes. Relative to 
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HeLa cells, nuclear GRK5 protein levels in HT-29 and SW620 cells are 12.1% ± 2.1 
and 14.0% ± 0.2 respectively (Figure 5.1B). OVCAR3 cells have approximately 10-
fold more GRK5 compared to the colon cancer cells. In contrast to GRK5, which is 
enriched in the nucleus, GRK2 is largely cytoplasmic (Figure 5.1A). This is hardly 
surprising, as the GRK2 subfamily lack the NLS. The detection of small amounts of 
nuclear GRK2 could result from cytoplasmic contamination of the nuclear extract. 
Considering both colon cancer cell lines have by far the lowest GRK5 protein levels, 
these data support the hypothesis that GRK5 levels may be downregulated in colon 
cancer. HT-29 cells were chosen as a model cell line, as they are widely used as 
an in vitro model of colon cancer. As described, these cells are derived from a 
lower grade colon cancer tumour compared to SW620, yet the cells already show a 
resistance to apoptosis, suggesting a trend towards metastasis [177]. Using HT-29 
cells for further studies rather than SW620 cells could identify whether GRK5 is 
having a causative role at the earlier stages of disease pathogenesis and may even 
highlight a potential role for GRK5 as a colon cancer biomarker. 
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Figure 5.1 GRK5 levels are lowest in colon cancer  
A. Nuclear extracts were prepared from a range of cancer cell lines. The coloured fonts indicate 
the type of cancer with red (HeLa) as cervical cancer, yellow (SW620 and HT-29) as colon 
cancer, green (OVCAR3, IGROV-1 and A2780) as ovarian cancer and purple (PC3) as prostate 
cancer. Nuclear extracts (N) and whole cell lysates (W) were run on SDS-PAGE gels and 
immunoblotted (IB) with an anti-GRK5 or anti-GRK2 antibody and an anti-!-actin antibody, as a 
loading control. B. Quantification of mean levels of GRK5 in nuclear extracts relative to !-actin 
and normalised to GRK5 levels in HeLa cells. Error bars are standard deviation of the mean 
from three separate experiments. *P<0.05 relative to the amount of GRK5 in HeLa cells, which 
is arbitrarily set to 100%. 
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5.2 GRK5 represses Bcl-2 in a class I HDAC-dependent manner 
Levels of the anti-apoptotic protein, Bcl-2, are upregulated during the early stages 
of progression of an adenomatous polyp to a colorectal carcinoma. GRK5 has been 
shown to negatively regulate Bcl-2 transcription in SHSY5Y cells [80]. It is therefore 
feasible that GRK5 may be playing a causative role in colon cancer progression to 
a metastatic state; down-regulation of the kinase may relieve Bcl-2 inhibition and 
render cells resistant to apoptosis, thus accelerating cancer cell growth. I 
overexpressed increasing amounts of GRK5 in HT-29 cells and by Western blotting, 
probing with an anti-Bcl-2 antibody, I detected whether GRK5 could alter Bcl-2 
protein levels. Figure 5.2A indicates that indeed, GRK5 and Bcl-2 protein levels 
have a reciprocal relationship; increasing GRK5 expression levels causes a 
simultaneous reduction in Bcl-2 protein by up to 54% ± 7.02 (n = 3; P<0.005) 
(Figure 5.2B). In an initial experiment, knocking-down endogenous GRK5 by 
transfecting a GRK5 small inhibiting RNA (siRNA) into HT-29 cells causes the 
opposite pattern and results in a significant increase in Bcl-2 protein levels by 
70.8% (Figure 5.2C). These data therefore suggest that GRK5 does, indeed, 
negatively regulate Bcl-2 protein levels.  
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Figure 5.2 GRK5 reduces Bcl-2 protein levels in HT-29 cells 
A. HT-29 cells were transfected with increasing amounts of GRK5 and Bcl-2 protein was 
detected by Western blot with an anti-GRK5 and anti-Bcl-2 antibody respectively. Endogenous 
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ERK expression was immunoblotted (IB) as a control. The Western blot shown is a 
representative from 3 separate experiments. B. Quantification of A. The bar graph represents 
average Bcl-2 levels from three separate experiments normalised relative to ERK expression 
levels. Error bars represent standard error of the mean from three separate experiments; 
*P<0.005 relative to 0 µg GRK5 transfected. C. HT-29 cells were transfected with a GRK5 
siRNA or a scrambled control and 48 hours later cells were harvested and lysates run on SDS-
PAGE gels to detect GRK5 and Bcl-2 protein expression levels. N = 1. 
 
In order to investigate the mechanism by which GRK5 is regulating the levels of 
Bcl-2 expression, I treated HT-29 cells at the time of transfection with a pan-HDAC 
inhibitor, NaB, or a class I specific HDAC inhibitor, MS-275, or DMSO as a control. 
Treatment with either inhibitor abolishes the GRK5-dependent reduction of Bcl-2 
protein levels, as shown in Figure 5.3, and in fact causes a marginal but significant 
increase in protein levels compared to controls. This suggests that the regulation of 
Bcl-2 by GRK5 is HDAC dependent. Data in chapter 3 identified class I HDACs as 
novel binding partners of GRK5 and, as shown in Figure 5.3, class I HDAC inhibitor 
treatment abolishes the GRK5-mediated regulation of Bcl-2 expression. The 
regulation of Bcl-2 by GRK5 is therefore likely to be class I HDAC-dependent, the 
first functional connection reported between GRK5 and class I HDACs. 
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Figure 5.3 GRK5 represses Bcl-2 in an HDAC dependent manner 
HT-29 cells were transfected as indicated and treated with DMSO (mock), sodium butyrate 
(NaB, 10 mM) or the class I specific HDAC inhibitor, MS-275 (10 µM) for 24 hours, and Bcl-2 
protein expression detected by Western blot. The bar graph represents average Bcl-2 protein 
expression levels detected by Western blot, quantified relative to ERK expression levels, as a 
loading control and normalised to mock. Error bars represent standard error of the mean from 
three independent experiments. **P<0.05; *P<0.5. 
5.3 GRK5 represses transcription 
Chapter 3 identified class I HDACs and Sin3A as novel GRK5 binding partners. 
Moreover, data suggesting that GRK5 represses transcription of Bcl-2 in SHSY5Y 
cells has previously been reported [80]. In order to test whether GRK5 can act as a 
transcriptional regulator in HT-29 cells and whether the interaction of GRK5 with 
HDAC1 and Sin3A is required for transcriptional repression, I used a modified 
GRK5 construct in a pre-existing Gal4 luciferase assay. This assay utilises a firefly 
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luciferase reporter gene that is under the control of the Gal4 transcription factor. I 
compared firefly luminescence when the reporter gene was co-transfected with a 
Gal4 DNA binding domain (Gal4-DBD) that activates transcription, to that obtained 
when a Gal4-DBD-GRK5 (GRK5) fusion protein was expressed. A Renilla 
luciferase under the control of a constitutively active, cytomegalovirus (CMV) 
promoter, was also co-transfected in each condition as a measure of transfection 
efficiency. Figure 5.4 shows the average luminescence normalised relative to 
mock-transfected cells. GRK5 represses Gal4 mediated transcription, as the 
average luminescence fell from 452.8% ± 66.8 when Gal4-DBD was expressed, to 
166.3% ± 18.7 when Gal4-DBD-GRK5 was expressed. 
 
 
Figure 5.4. GRK5 represses Gal4 mediated transcription  
HT-29 cells were transfected with either a mock, Gal4-DBD (Gal4) or Gal4-DBD-GRK5 (GRK5) 
construct. Cells were co-transfected with a firefly luciferase expression plasmid for Gal4 and a 
constitutively expressed Renilla luciferase plasmid and subjected to the luciferase assay 24 
hours post transfection. Average luminescence is normalised to mock transfected cells. Error 
Chapter 5: Results !
! 159 
bars represent standard error of the mean from three separate experiments; *P<0.05; 
**P<0.005 relative to mock. 
 
In an attempt to determine whether the GRK5-mediated regulation of Gal4 
controlled transcription is Sin3A dependent, I aimed to simultaneously knockdown 
Sin3A and overexpress Gal4-DBD-GRK5 and study the corresponding effects on 
transcription. Knocking down Sin3A by transfecting as well as nucleofecting Sin3A 
siRNA did not work, such that an alternative approach was used based on the 
competitive inhibition of the GRK5/Sin3A interaction. I co-expressed Gal4-DBD-
GRK5 and the luciferase constructs with Myc-tagged mouse C-terminal Sin3A 
deletion mutants, as shown in Figure 5.5, and measured Gal4 mediated 
transcription 24 hours later. I hypothesised that interacting with overexpressed 
Sin3A may prevent Gal4-DBD-GRK5 from interacting with the endogenous Sin3A 
repressor complex and would thus prevent GRK5-dependent repression of the 
Gal4 luciferase target gene if this was a Sin3A-dependent event. A similar 
experiment has been performed to test the functional role of the interaction 
between Sin3A and the co-repressor, Alien. Transfection of Sin3A deletion 
fragments 545–678 (HID) and 1001–1337, both of which were previously shown to 
bind Alien directly, inhibited the Alien-mediated luciferase transcriptional repression 
by up to approximately 33% [178]. 
 
Figure 5.5A illustrates the Myc-tagged Sin3A deletion mutants used in the 
luciferase assay compared to the GST-tagged deletion fragments used in chapter 3 
in direct binding assays. The C-terminal GST-Sin3A mutant encompassing 
residues 545–1157 (GST-545-1157) binds to GRK5 directly (Figure 3.6) and is 
highlighted in grey. The direct binding of GRK5 exclusively to this mutant suggests 
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that the interaction occurs somewhere between the HID and C-terminus of Sin3A. 
GRK5 would thus be predicted to bind to Sin3A N1015 and presumably Sin3A 
N680 if the HID represents the GRK5 binding site. Data in Figure 5.5B suggests 
that the GRK5-mediated repression of Gal4-mediated transcription is slightly but 
significantly relieved by these Sin3A fragments. Co-transfection of Gal4DBD-GRK5 
with either N205 or N479 does not affect GRK5-mediated transcriptional repression, 
which is not surprising given that these fragments do not interact with GRK5 
(Figure 5.5B).  
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Figure 5.5 GRK5-mediated Gal4 transcriptional repression is Sin3A dependent  
HT-29 cells were transfected with either Gal4-DBD (Gal4) or wildtype GRK5 fused to the Gal4-
DBD (GRK5) and the mouse Myc-tagged Sin3A deletion mutant indicated (N205, N479, N680 
or N1015). Cells were additionally co-transfected with a firefly luciferase expression plasmid for 
Gal4 and a constitutively expressed Renilla luciferase plasmid and subjected to the luciferase 
assay 24 hours post transfection. A. The schematic shows full length Sin3A and Sin3A deletion 
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mutants and the domains they encompass. The Myc tagged mutants used in the Gal4 luciferase 
assay are shown in comparison to the GST-tagged mutants used in chapter 3, with the mutant 
shown to interact directly with GRK5 highlighted in grey. B. The bar graph shows the 
percentage of GRK5-mediated repression of the luciferase reporter gene, calculated as the 
percentage reduction in luminescence relative to the luminescence reading following the 
overexpression of the Gal4 construct. Error bars are standard error of the mean from three 
separate experiments; *P<0.05 relative to GRK5. 
 
Data from the two previous figures highlights a potential role for GRK5 in regulating 
transcription in a Sin3A-dependent manner. The Gal4 assay, however, is an 
artificial model of transcription and the possibility exists that the Gal4-DBD-GRK5 
fusion protein may be inhibiting luciferase expression indirectly by, for example, 
sterically inhibiting the Gal4-DBD from interacting with the promoter. In order to 
ascertain directly whether GRK5 is capable of regulating transcription, I performed 
RT-PCR experiments to quantify mRNA levels of both GRK5 and Bcl-2, following 
transfection of GRK5 siRNA or control siRNA into HeLa cells. HeLa cells rather 
than HT-29 cells were used for these experiments, since HT-29 cells have 
extremely low levels of GRK5, whereas levels of the kinase are almost 7-fold 
higher in HeLa cells (Figure 5.1). Detecting GRK5 mRNA in HT-29 cells and, 
furthermore, detecting a reduction in mRNA levels following siRNA transfection, 
proved technically difficult. Figure 5.6 shows that knocking down GRK5 by 93% ± 
0.01 causes a simultaneous increase in Bcl-2 mRNA levels of 22% ± 0.1. These 
data are consistent with findings in SHSY5Y cells, where GRK5 knockdown by 
approximately 70% caused a slight but significant increase in Bcl-2 mRNA by 
approximately 10%.  
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Figure 5.6 GRK5 represses Bcl-2 transcription 
HeLa cells were transfected with GRK5 siRNA or scrambled siRNA and left 48–72 hours before 
RNA was extracted and purified. mRNA levels of GRK5 and Bcl-2 were quantified by RT-PCR 
relative to !-actin. This bar graph shows mean GRK5 and Bcl-2 mRNA levels relative to !-actin 
normalised to scrambled siRNA in each case. Error bars represent standard error of the mean 
from three separate experiments; *P<0.5, **P<0.05. 
 
To summarise this section, GRK5-mediated down-regulation of Bcl-2 protein levels 
is sensitive to class I HDAC inhibitors, suggesting regulation is class I HDAC 
dependent. A Gal4-DBD-GRK5 construct inhibits Gal4 mediated transcription, 
which is modestly relieved by co-transfecting Sin3A mutants that are likely to bind 
to the kinase, implying that GRK5 represses transcription in vitro in a Sin3A-
dependent manner. Furthermore, GRK5 negatively regulates Bcl-2 transcription in 
HeLa cells. Taken as a whole, these data suggest a role for GRK5 in regulating 
transcription, potentially in a HDAC and Sin3A dependent manner. 
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5.4 GRK5 increases apoptosis sensitivity 
As previously explained, levels of the anti-apoptotic protein, Bcl-2, are upregulated 
in many cancers, including colorectal. Bcl-2 overexpression has also been related 
to chemotherapy resistance. Sections 5.1–5.3 show GRK5 to negatively regulate 
Bcl-2 protein and mRNA levels in cancerous cell lines. Considering the crucial role 
Bcl-2 plays in regulating apoptosis and how these mechanisms are altered in 
cancerous tissues, I wanted to investigate whether GRK5 is capable of influencing 
apoptosis in HT-29 cells. Figure 5.1 shows GRK5 levels to vary across a range of 
cancer cell lines, with OVCAR3 and HT-29 cells having the highest and lowest 
kinase levels respectively. Considering endogenous levels of GRK5 differ so 
greatly in these two cell lines, I wanted to ascertain whether this difference is 
reflected in different sensitivities to treatment with apoptosis-promoting agents. I 
treated both cell lines with increasing amounts of DOXO, a chemotherapeutic agent 
commonly used in many cancer treatment regimes, including that of ovarian cancer 
patients. Cells were harvested 24 hours post treatment and expression levels of 
cleaved-poly (ADP-ribose) polymerase-1 (PARP-1) detected by Western blot, as a 
measure of apoptosis. The induction of apoptosis results in the activation of 
caspases, which go on to degrade various cellular protein targets. The first of such 
caspase targets to be described was the nuclear protein, PARP-1, which is cleaved 
from its 116kDa form to fragments of 89 and 24kDa [179]. PARP-1 catalyses the 
synthesis of (ADP)-ribose polymers and this post-translational modification plays a 
key role in DNA repair and defence mechanisms against DNA damage [180, 181]. 
Caspase-mediated cell death is achieved by the cleavage of proteins like PARP-1, 
which are required for cell survival. The appearance of cleaved PARP-1 fragments 
thereby serves as a biomarker for apoptosis.  
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An initial experiment shows that increasing the concentration of DOXO results in 
increased levels of cleaved PARP-1 in both OVCAR3 and HT-29 cells, as indicated 
by Western blotting using an antibody specific to the 89kDa PARP-1 fragment 
(Figure 5.7). Interestingly, there is a positive correlation between endogenous 
GRK5 levels and the amount of cleaved PARP-1. OVCAR3 cells, which have 
approximately 10-fold more endogenous GRK5 (Figure 5.1) also have considerably 
more cleaved PARP-1 following DOXO treatment, compared to HT-29 cells (Figure 
5.7). Considering GRK5 expression alone has little effect on cleaved PARP-1 
levels, these data suggest that GRK5 may therefore be playing a role in regulating 
apoptosis in response to DOXO treatment.  
 
 
 
Figure 5.7 OVCAR3 cells express more cleaved PARP-1 following DOXO treatment 
compared to HT-29 cells 
OVCAR3 and HT-29 cells were treated with increasing amounts of doxorubicin (DOXO) as 
indicated. Cells were harvested 24 hours later and lysates immunoblotted (IB) with an antibody 
against the 89kDa cleaved PARP-1 fragment. N = 1.  
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DOXO treatment is commonly given to ovarian cancer patients, whereas 5-FU is 
the backbone drug used to treat colon cancer. In order to further investigate 
whether GRK5 may enhance apoptosis sensitivity in colon cancer, I first wanted to 
test whether GRK5 could sensitise HT-29 cells to 5-FU treatment. I overexpressed 
GRK5, as indicated in Figure 5.8, and treated cells 24 hours later with 200 µM 5-FU. 
Apoptosis was measured 24 hours post treatment by two different assays: cells 
were stained with the viability dye, 7-aminoactinomycin D (7-AAD) and counted by 
fluorescence-activated cell sorting (FACS) (Figure 5.8A), and an 
immunofluorescence apoptosis assay was also performed, staining for cleaved 
caspase 3 expression levels (Figure 5.8B).  
 
HT-29 cells were either mock transfected using pcDNA3 or transfected with 
increasing amounts of GRK5. Cells were treated with 5-FU or DMSO 24 hours post 
transfection and assayed 24 hours later. Cells were pelleted and incubated with 7-
AAD, which inserts itself between successive cytosine/guanine bases, thus staining 
the DNA of apoptotic cells, as the chromatin is accessible. In an initial experiment, 
10,000 cells were counted by flow-cytometry, with the percentage of cells stained 
with 7-AAD giving an indication of cell death. As can be seen in Figure 5.8A, GRK5 
overexpression has some effect on DMSO treated cells, with cell death increasing 
from 9.4% in untransfected cells, to 19.5% when 7 µg GRK5 is transfected. The 
combination of GRK5 overexpression and treatment with 5-FU, however, causes 
an increase in cell death from 4.9% in untransfected cells to 30.1% when 7 µg 
GRK5 is transfected. Although this assay looked promising and suggested that 
GRK5 expression sensitises cells to 5-FU-induced apoptosis, transfection 
efficiency was only approximately 30% (data not shown). I thus sought an assay 
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that specifically looked at GRK5-transfected cells. While it is possible to transfect 
cells with a GFP-tagged GRK5 construct and measure percentage cell death in the 
population of GRK5-transfected cells by FACS, using a tagged construct is not 
ideal. Adding a tag, such as GFP on to a construct can distort its usual 
conformation, which may affect its cellular localisation and interaction with target 
proteins by masking protein binding sites. Nevertheless I did attempt to sort for 
GFP-GRK5 transfected cells but due to technical difficulties with the FACS 
machine it was not possible to obtain data. I therefore wanted to use a wildtype 
GRK5 construct to ascertain whether GRK5 has an effect on apoptosis. I decided 
to try an immunofluorescence based experiment, which is not only technically 
easier but would also enable the analysis of apoptosis specifically in GRK5-
transfected cells.  
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Figure 5.8 GRK5 enhances 5-FU induced apoptosis  
HT-29 cells were transfected as indicated and treated or not with 5-fluorouracil (5-FU, 200 µM) 
24 hours post transfection. A. Increasing amounts of GRK5 were transfected into HT-29 cells 
and apoptotic cells were sorted 48 hours later by flow cytometry using the 7-AAD viability dye. 
The percentage of cells positively stained with 7-AAD is shown relative to total cell number. B. 
Representative confocal images from three separate experiments following transfection with 2.5 
µg GRK5 and treatment with 200 µM 5-FU. Cells were stained with an anti-active caspase 3 
antibody (red), an anti GRK4-6 antibody (green) and Hoechst stain (blue). C. Quantification of 
cleaved caspase 3 staining by immunofluorescence. The number of cleaved caspase 3 cells 
were counted relative to the number of GRK5-transfected cells and expressed as a percentage 
of cell death. In mock-transfected conditions, nuclei were counted at random and then assessed 
for cleaved caspase 3 staining. Error bars represent standard error of the mean from three 
separate experiments; *P = 0.01. 
 
HT-29 cells were grown on coverslips and transfected or not with GRK5, using the 
pcDNA3 vector as a mock, and treated with DMSO or 200 µM 5-FU 24 hours later. 
Cells were then stained using an anti-GRK4-6 antibody (green) to detect 
transfected cells and an active caspase 3 antibody (red) as an indicator of 
apoptosis (Figure 5.8B). Caspase 3, an effector caspase, is one of the later 
caspases that is cleaved and subsequently activated during the apoptosis caspase 
cascade, as explained in section 1.3.3.2. Caspase 3 is present as an inactive 
zymogen whose cleavage, which occurs following the induction of apoptosis, 
results in its activation. Caspase 3 is cleaved by caspase 8, 9 or 10 and goes on to 
activate caspase 6 and caspase 7. Detection of cleaved caspase 3, like cleaved 
PARP-1, thereby serves as an indicator of apoptosis. The number of GRK5-
positive cells that were also positive for active caspase 3 were recorded as a 
measure of apoptosis. Under mock-transfected conditions, nuclei were counted at 
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random following DNA staining with the bisBenzimide Hoechst stain and 
subsequently assessed for cleaved caspase 3 staining to determine percentage 
cell death. Treatment with 5-FU does not significantly increase apoptosis in mock-
transfected cells, as shown in the immunofluorescence images of Figure 5.8B, as 
well as in data quantified in Figure 5.8C; 0.77% ± 0.1 death occurred in DMSO-
treated, mock-transfected cells, which increased to 0.93% ± 0.2 following 5-FU 
treatment. The overexpression of GRK5, however, greatly increased apoptosis, as 
can be seen from the positive caspase 3 staining in Figure 5.8B, as well as from 
data in Figure 5.8C. DMSO treatment caused 9.0% ± 0.5 of GRK5-overexpressing 
cells to undergo apoptosis, which increased to 22.4% ± 3.6 (P = 0.01) following 5-
FU treatment. HT-29 therefore appear to be resistant to 5-FU treatment and GRK5 
increases HT-29 cell death independently of 5-FU, as well as by enhancing 
treatment effects. Additionally, this assay also enabled monitoring of the cellular 
morphological changes in response to apoptosis. Cells positive for active caspase 
3, following combined GRK5 overexpression and 5-FU treatment, appear more 
spherical in shape compared to untreated cells, which is indicative of apoptosis 
induction (Figure 5.8B).  
 
In order to ascertain whether the nuclear localisation of GRK5 is necessary for 
GRK5-mediated apoptosis, I overexpressed the GRK5!NLS mutant, which is 
excluded from the nucleus, in HT-29 cells. Following 5-FU treatment the 
percentage of apoptotic cells overexpressing wildtype GRK5 was compared to cells 
overexpressing the GRK5!NLS mutant. Figure 5.9 shows that while GRK5 
expression sensitises cells to 5-FU treatment, expression of the GRK5!NLS has a 
less pronounced effect. The percentage of caspase 3 positive cells increases from 
2.1% ± 0.2 in mock-transfected cells to 20.0% ± 0.7 in GRK5-expressing cells. In 
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contrast, only 6.5% ± 0.9 of GRK5!NLS-expressing cells are caspase 3 positive 
after treatment with 200 µM 5-FU for 24 hours. The nuclear localisation of GRK5 is 
therefore important for its role in regulating apoptosis in HT-29 cells.  
 
 
 
Figure 5.9 GRK5 enhances apoptosis in a class I HDAC and Sin3A dependent manner 
HT-29 cells were transfected as indicated, with either a mock, GRK5 wildtype (GRK5), 
GRK5!NLS mutant (NLS), or wildtype GRK5 co-transfected with a Myc-tagged Sin3A mutant 
(N205, N479, N680 or N1015). At the time of transfection cells were treated with MS-275 (10 
µM) as indicated. 24 hours post transfection, cells were treated with 5-FU (200 µM) and left for 
a further 24 hours. Cells were stained with an anti-GRK5 antibody (Mock, GRK5, NLS) or an 
anti-Myc antibody (GRK5 + N205, GRK5 + N479, GRK5 + N680, GRK5 + N1015), as well as an 
anti-cleaved caspase 3 antibody, as a measure of apoptosis. The percentage of transfected 
cells stained with cleaved caspase 3 were counted relative to total cell number, giving an 
indication of cell death. The bar graph shows mean data from at least 3 experiments. Error bars 
represent standard error of the mean. *P<0.001 relative to GRK5 5-FU treated cells. 
 
To further probe the mechanism by which GRK5 is controlling apoptosis, cells were 
treated with 10 µM of the class I HDAC inhibitor, MS-275, 24 hours prior to 5-FU 
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treatment. Treatment with MS-275 does not affect apoptosis in mock transfect cells, 
as the percentage of caspase 3 positive cells is 2.1% ± 0.2 and 2.4% ± 0.5 in 5-FU 
treated and combined 5-FU and MS-275 treated cells respectively. MS-275 
treatment does however reduce apoptosis in GRK5-transfected cells, as the 
percentage caspase 3 positive cells falls from 20.0% ± 0.7 following 5-FU treatment 
to 10.6% ± 0.8 following combined 5-FU and MS-275 treatment. GRK5 mediated 
apoptosis regulation is therefore class I HDAC dependent.  
 
In order to determine whether Sin3A is equally important in GRK5-mediated 
apoptosis regulation, the Myc-tagged Sin3A C-terminal deletion mutants, as 
described in section 5.3, were co-transfected with GRK5. Cells were stained with 
an anti-Myc antibody and cleaved caspase 3 staining recorded in cells staining 
positive for Sin3A deletion mutants and GRK5. Co-expression of the longest Sin3A 
mutant, N1015, with GRK5 reduces apoptosis by 12.8% ± 0.4, compared to 20.0% 
± 0.8 when GRK5 is expressed alone. Specific to the Sin3A N1015 mutant is the 
inclusion of PAH4 and the HCR in the construct, compared to the N205, N479 and 
N680 mutants, which only encompass PAH1, PAH1 and PAH2, and PAH1–3 and 
the HID, respectively (Figure 5.5A). In addition to inhibiting GRK5-mediated 
apoptosis, the N1015 mutant is also the most effective inhibitor of GRK5-mediated 
transcriptional repression of luciferase genes, as shown in Figure 5.5B. Data in 
Figure 3.6 suggests that GRK5 binds directly to a GST-Sin3A-545-1157 mutant 
that encompasses the HID, PAH4 and the HCR. The N1015 mutant, whose 
residues overlap with those included in the GST-Sin3A-5454-1157 mutant, is 
therefore likely to act as a Sin3A inhibitor, binding to GRK5 and preventing its 
interaction with the endogenous Sin3A repressor complex and thereby reducing 
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GRK5-mediated apoptosis. The N-terminal fragments, N205 and N479 do not bind 
to GRK5 and thus would not be predicted to inhibit the GRK5/Sin3A interaction. 
These mutants neither affect GRK5-mediated transcriptional repression nor 
apoptosis (Figure 5.5B and 5.9). The N680 mutant encompasses the HID, to which 
GRK5 may interact, and this mutant slightly reduces GRK5-mediated 
transcriptional repression (Figure 5.5) but does not affect GRK5-mediated 
apoptosis, as 19.6% ± 1.8 cells stain positive for caspase 3 compared to 20.0% ± 
0.7 when GRK5 is transfected alone (Figure 5.9), suggesting the longest Sin3A 
construct binds most tightly to GRK5. These data imply that GRK5 increases 
apoptosis sensitivity in HT-29 cells following 5-FU treatment, in both a class I 
HDAC and possibly a Sin3A-dependent manner. 
5.5 Inhibiting the micro RNA, miR-135, upregulates GRK5 and 
increases apoptosis sensitivity 
Micro RNAs (miRNAs) are short non-coding RNA sequences of 21–23 nucleotides 
that bind target mRNAs, cause their degradation and thus repress gene expression 
at the level of translation. MiRNAs bind Argonaute proteins in the RNA-induced 
silencing complex, thereby directing the complex to specific complementary mRNA 
targets to mediate their degradation by the activation of RNAase in a process 
known as RNA interference [182]. The human genome encodes over 1000 miRNAs 
[miRBase 19, August 201], which are thought to regulate approximately one third of 
all human genes [183]. Considering the direct involvement of miRNAs in regulating 
gene translation, it isn’t surprising that they have been implicated in tumourigenesis 
and cancer metastasis. MiRNA signatures are being investigated as diagnostic 
markers, as levels differ between benign and malignant tissues and even correlate 
Chapter 5: Results !
! 174 
with differentiation states of cancers [184]. The upregulation of miRNA-135a and 
miRNA-135b are likely to be one of the earliest events in the progression of normal 
colorectal epithelium to early adenomas and represent a novel mechanism of APC 
and thus WNT signalling regulation; their upregulation correlates with reduced APC 
levels and both miRNAs reduce APC translation in vitro [185]. The inactivation of 
APC is a major initiating event in colorectal cancer development, occurring in over 
60% of cases [186]. Manipulating endogenous miRNA levels as a therapeutic 
approach is currently being researched and tested through the use of specific 
miRNA mimics and oligonucleotides to stimulate upregulation, and anti-sense 
oligonucleotides and synthetic analogues to reduce levels. The use of a miRNA-
122 inhibitor is now in a human phase II hepatitis C virus clinical trial. The virus 
hijacks miRNA-122, which is thereby required for viral replication, such that a 
miRNA-122 inhibitor should halt viral replication and thus the progression of liver 
disease [182]. Furthermore, miRNA-122 is upregulated in high-grade prostate 
tumours, thus suggesting that the development of such a miRNA inhibitor could be 
used as a cancer therapeutic [187]. 
 
Both mature miRNA-135a and miRNA-135b are predicted to target GRK5 mRNA 
and levels of miRNA-135 and GRK5 mRNA are upregulated and downregulated in 
GBMs respectively [188]. The upregulation of miRNA-135a and b in CRC and in 
HT-29 cells [185] may therefore account for the low levels of GRK5, such that 
manipulating miRNA expression could provide a novel approach to regulating 
levels of the kinase. In comparison to HT-29 cells, HeLa cells have negligible levels 
of miRNA-135a and b [185], such that I used this cell line as a control, to study 
whether transfection of either a mature human miRNA-135a mimic or an anti-sense 
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oligonucleotide could affect GRK5 protein levels and furthermore, apoptosis 
sensitivity. I transfected either the human miRNA-135a mimic or anti-sense 
oligonucleotide into each cell line, along with dsRed fluorescent protein, as a 
measure of transfection efficiency, and 48 hours later GRK5 protein expression 
levels were measured by Western blot. Cells were also assayed for apoptosis by 
immunofluorescence staining with a cleaved caspase 3 antibody. As shown in 
Figure 5.10Ai and ii, overexpression of the miRNA-135a mimic reduces GRK5 
protein expression levels in both HeLa and HT-29 cells, which corresponds with a 
reduction in cleaved caspase 3 staining compared to mock transfected cells (Figure 
5.10B). The percentage of HeLa cells staining positive for cleaved caspase 3 
decreases from 11.6% ± 0.8 in mock transfected cells to 5.8 ± 0.8 following 
overexpression of the miRNA-135a mimic, and from 8.7 ± 0.6 to 6.0 ± 0.7 in HT-29 
cells  (Figure 5.10B). Overexpression of the antisense oligonucleotide, which 
inhibits endogenous miRNA-135a, causes the reverse effect in HT-29 cells, 
upregulating GRK5 protein expression levels, as well as cleaved caspase 3 
staining to 14.8% ± 1.3. By comparison, GRK5 expression levels in HeLa cells are 
not affected by overexpressing the antisense oligonucleotide, and cleaved caspase 
3 levels are not significantly affected either, as was hypothesised (Figure 5.10A 
and B). These data suggest that a miR-135a mimic and inhibitor can manipulate 
endogenous GRK5 proteins levels in cells and also affect apoptosis. These data 
imply that use of a miR-135a inhibitor may be a potentially novel and effective 
therapeutic strategy in the treatment of colon cancer by not only upregulating levels 
of APC but also, potentially, GRK5. 
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Figure 5.10 A miRNA-135a mimic reduces GRK5 protein expression levels and apoptosis 
HeLa and HT-29 cells were transfected with either a mock or 100 nM miRNA-135a mimic (m) or 
inhibitor (i) along with 10 nM dsRed for 48 hours. A. i. GRK5 protein expression levels were 
assessed by Western blot using an anti-GRK4-6 antibody. Total ERK levels were detected as a 
housekeeping gene using an anti-ERK antibody. ii. Quantification of A. The amount of GRK5 is 
calculated relative to the amount of ERK. B. Additionally, transfected cells were stained with an 
anti-cleaved caspase 3 antibody, as a measure of apoptosis. dsRed staining was used as a 
measure of transfection and the percentage of transfected cells stained with cleaved caspase 3 
counted, giving an indication of cell death. The bar graph shows mean data from 3 experiments 
with error bars representing standard error of the mean. *P<0.05, **P<0.01 relative to mock 
transfected cells for each cell line. m = mimic; i = inhibitor 
5.6 Summary 
GRK5 binds to class I HDACs and Sin3A directly. The aim of this chapter was to 
investigate whether GRK5 could play a role in colon cancer pathogenesis by 
regulating transcription, in conjunction with HDACs and Sin3A. To summarise my 
findings: 
• Grade II and metastatic colon cancer cells, HT-29 and SW620, respectively, 
have the lowest GRK5 levels in comparison to cervical, ovarian and 
prostate cancer cell lines. 
• GRK5 overexpression reduces expression of the anti-apoptotic protein, Bcl-
2, in HT-29 cells. 
• The GRK5-mediated Bcl-2 repression is class I HDAC-dependent. 
• GRK5 represses Gal4-mediated transcription in a Sin3A-dependent manner. 
• GRK5 knockdown increases Bcl-2 mRNA levels, thus suggesting the 
negative regulation of Bcl-2 by GRK5 is at the transcriptional level. 
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• Compared to HT-29 cells, which have 10-fold less GRK5 protein, OVCAR3 
undergo more apoptosis following DOXO treatment. 
• GRK5 overexpression increases apoptosis in HT-29 cells following 5-FU 
treatment, as measured by FACS and immunofluorescence. 
• GRK5 increases 5-FU induced apoptosis in HT-29 cells in a nuclear and 
class I HDAC dependent manner. Furthermore, overexpressing Sin3A 
mutant, N1015, which is likely to bind GRK5, significantly inhibits apoptosis, 
thus suggesting that GRK5-mediated apoptosis is also Sin3A dependent. 
• Overexpression of a miR-135a mimic reduces GRK5 protein expression and 
apoptosis levels in HT-29 and HeLa cells. 
• GRK5 protein expression levels and apoptosis are enhanced in HT-29 cells 
but not HeLa cells, following the overexpression of a miR-135a inhibitor.  
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Chapter 6. Discussion 
This thesis describes the identification of novel GRK5 binding partners: class I 
HDACs, HDAC1, 3 and 8, and the repressor protein, Sin3A, and outlines a 
potential functional role for these interactions in inhibiting Bcl-2 transcription and 
increasing the sensitivity of the colon cancer cell line, HT-29, to 
chemotherapeutically induced apoptosis. Furthermore, GRK5 levels, which are 
downregulated in the diseased state, can be artificially upregulated by 
overexpressing a miR-135a inhibitor and this in turn increases apoptosis levels in 
HT-29 cells, thus highlighting a potential novel therapeutic strategy for the 
treatment of colon cancer. 
 
GRK5 plays a causative role in pathological cardiac hypertrophy by acting as an 
HDAC5 kinase, thereby promoting the transcription of MEF2-regulated pro-
hypertrophic genes indirectly, by relieving inhibition by HDAC5.  [81]. The NLS and 
NTPB domains of GRK5, however, contain functional DNA binding sites, 
suggesting that GRK5 may additionally play a more direct role in controlling gene 
expression [11]. Class I HDACs function in a pro-hypertrophic manner in contrast to 
class II HDACs, which are anti-hypertrophic. Considering GRK5 and class I HDACs 
both play a causative role in pathological cardiac hypertrophy and that GRK5 can 
interact with DNA, the aim of my thesis was to investigate whether, in addition to its 
role as an HDAC5 kinase, GRK5 regulates HDAC activity and gene transcription 
directly, via a class I HDAC-dependent mechanism.  
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6.1 GRK5 as a transcriptional repressor 
6.1.1 GRK5 binds class I HDACs and Sin3A 
Chapter 3 identified class I HDACs and Sin3A as novel GRK5 interacting proteins. 
Relative to class II HDACs and HDAC2 binding, GRK5 binds strongly to the class I 
HDACs, HDAC1, HDAC3 and HDAC8 and these interactions are direct. The 
relative strength of the GRK5 interactions with class I HDACs compared to class II 
HDACs, as assessed by co-immunoprecipitation and pull-down assays, suggests 
that GRK5 may act as more than just a class I HDAC kinase. HDAC5 is a class II 
HDAC and a known GRK5 substrate. The relatively weak binding detected 
between these proteins may reflect the transient nature of the substrate/kinase 
relationship, which can be difficult to detect by co-immunoprecipitation [166]. In 
certain cases, binding of substrates and their corresponding kinases can only be 
detected using a kinase-dead mutant in co-immunoprecipitation experiments. 
Indeed, an interaction between the Ena/VASP like protein splice variant, EVL-1, 
and PKD was only detected in HEK293T cells following the overexpression of a 
kinase-dead PKD1 mutant [189]. Similar studies have been reported for the binding 
of thiamine pyrophosphokinase 1 to PKA substrates; binding to substrates was only 
observed with an inactive thiamine pyrophosphokinase 1 mutant, as opposed to the 
wildtype kinase [190].  
 
Interestingly, the Koch group, when studying the substrate/kinase relationship of 
HDAC5 and GRK5, did manage to show by co-immunoprecipitation that GRK5 
interacts with HDAC5 in whole cell lysates and nuclear extracts of NRVM [81]. The 
co-immunoprecipitation experiments performed investigated only a potential 
interaction between HDAC5 and GRK5, which was not compared to GRK5 binding 
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other HDACs or other known interactors. Figure 3.1B shows that GRK5 does 
interact with HDAC5 in HeLa cells, but that this interaction is less easily detected 
than the interactions with the class I HDACs, HDAC1, HDAC3 and HDAC8. My 
results do not contradict work by the Koch group, but rather emphasise the strength 
of the interactions between class I HDACs and GRK5, which may suggest an 
alternative role for GRK5 in regulating these HDACs in addition to, or instead of, its 
role as a kinase. GRK5 could, for example, be directly modulating the activity of 
class I HDACs or altering their cellular localisation. Work by the Qin group, who 
identified GRK5 as a negative regulator of Bcl-2 transcription in SHSY5Y cells, also 
found that knocking down GRK5 in this cell line significantly reduced HDAC activity 
by up to 70% [80]. I have shown GRK5 to negatively regulate Bcl-2 transcription in 
HT-29 cells and results from an in vitro Gal4 luciferase assay suggests that GRK5-
mediated transcriptional repression is Sin3A dependent. Furthermore, I have 
shown that GRK5-mediated negative regulation of Bcl-2 protein expression levels 
is class I HDAC dependent. I would therefore predict that in HT-29 cells, like in 
SHSY5Y cells, GRK5 might be enhancing HDAC activity. While the Qin group did 
not show which class of HDAC GRK5 regulates, I hypothesise that GRK5 may be 
specifically upregulating class I HDAC activity. It would be interesting to test 
whether the catalytic activity of GRK5 is necessary for mediating not only the 
binding to class I HDACs and Sin3A, but also whether it is required for GRK5-
mediated Bcl-2 transcriptional regulation and potentially class I HDAC activity, 
which is often upregulated by phosphorylation.  
 
That GRK5 interacts relatively poorly with HDAC2 as compared to HDAC1, as 
shown by co-immunoprecipitation in HeLa cell lysates, by immunofluorescence in 
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HEp2 cells and by in vitro direct binding experiments, is somewhat surprising 
considering the high degree of sequence homology between HDAC1 and HDAC2. 
As discussed briefly in section 3.2, while HDAC1 and HDAC2 have some 
redundant and compensatory roles, several functions specific to each HDAC have 
also been identified. The global and targeted deletion of HDAC1 in mice results in 
early embryonic lethal death and a down-regulation of cellular HDAC activity is 
reported in HDAC1-null embryonic stem cells, despite the compensatory 
upregulation of HDAC2 [168]. HDAC1 and HDAC2 share 91% sequence identity at 
the amino acid level in the combined N-terminal and catalytic domains but are only 
34% identical in their C-termini, thus suggesting a GRK5 binding site may be 
located in the C-terminus of HDAC1 [170]. The HDAC1 C-terminus is essential for 
its function, responsible for controlling its association with co-factors including 
Sin3A and its core component, RBBP4, as well the enzyme’s catalytic activity. A C-
terminal HDAC1 truncated mutant displays perturbations in both of these cellular 
phenotypes, as does the mutation of residues Ser421 and Ser423 to alanine, which 
are critical C-terminal HDAC1 phosphorylation sites [191]. It is therefore possible 
that phosphorylation of these residues by GRK5 or another kinase, such as casein 
kinase II, which phosphorylates these residues in T-Ag Jurkat cells [191], might be 
a prerequisite for GRK5 binding to HDAC1. HDAC2, by contrast, is phosphorylated 
at different C-terminal sites compared to HDAC1 [192], which may induce a 
conformational change to the protein that does not enable GRK5 binding. 
Performing co-immunoprecipitation experiments with wildtype GRK5 and a 
S421/423A HDAC1 mutant would confirm whether indeed C-terminal 
phosphorylation of HDAC1 is required for GRK5 binding and using a kinase dead 
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GRK5 mutant would ascertain whether the catalytic activity of GRK5 is necessary 
for mediating the binding event.  
 
A serendipitous discovery from a mass spectrometry screen by the Ma group 
identified the mammalian transcriptional repressor protein, Sin3A, as a potential 
interactor of GRK5 [171]. Proteins in complex with GRK5 in MDA-MB-231 cells 
were analysed by mass spectrometry, following their separation on SDS-PAGE 
gels. Major GRK5-interacting proteins identified include DDB1, a subunit of the 
CUL4-ROC1 E3 ubiquitin ligase complex. DDB1 was further characterised by the 
group to be involved in regulating GRK5 levels; DDB1 binds and thus recruits 
GRK5 to the ubiquitin ligase complex, leading to its ubiquitination and degradation 
[171]. An additional hit from the screen that was not followed up by the group was 
the mammalian transcriptional repressor protein, Sin3A.  
 
By co-immunoprecipitation experiments I have shown GRK5 interacts with Sin3A in 
HeLa cells. This interaction is direct and is mediated by the Sin3A C-terminal 
fragment, the region of the protein where components of the core complex 
assemble. The identification of Sin3A as a bona fide binding partner of GRK5 
suggests a potential method whereby GRK5 could regulate HDAC function. HDACs 
are known to act in concert with accessory proteins, functioning as the enzymatic 
members of repressor complexes, which rely on recruiting transcription factors to 
target their activity to specific genes. Indeed, HDAC1 is a core component of the 
Sin3A complex and along with HDAC2 is responsible for the deacetylase activity of 
the repressor complex, which is required for full transcriptional repression by Sin3A 
[133]. The direct interaction of GRK5 with both HDAC1 and Sin3A is highly 
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suggestive of a functional role for the kinase in repressing transcription of Sin3A-
regulated genes. In vitro direct binding assays detailed in chapter 3, show GRK5 
binds directly to Sin3A between residues 545–1157. This region encompasses the 
HID, PAH4 and the HCR. The core Sin3A components, which include HDAC1, 
HDAC2, RBBP4, RBBP7, SAP18, SAP30 and SDS3, assemble on Sin3A in a 
region encompassing the PAH3–HID (Figure 6.1). The HID spans amino acids 
545–678 and is the best characterised domain in the C-terminus of Sin3A. PAH4 
and the HCR have few identified binding partners, namely O-GlcNAc transferase 
and the nuclear co-repressor, Alien, respectively [178, 193]. HDAC2 binds to the 
HID of Sin3A and this domain is necessary and sufficient to mediate transcriptional 
repression in vitro, implying that HDAC1 also binds this domain [161]. Neither 
HDAC1 nor HDAC2 have been shown to bind directly to Sin3A but instead the 
SDS3 protein, which also binds to the HID, bridges the gap between 
HDAC1/HDAC2 and Sin3A and augments HDAC activity [139, 148].  
 
Considering GRK5 binds to HDAC1 and Sin3A directly it may also be involved in 
HDAC recruitment to Sin3A, possibly functioning as a ‘core’ Sin3A component. 
Including Sin3A there are eight core mammalian Sin3A complex proteins, which 
are highly conserved from yeast to man and were identified by affinity purification 
experiments. The mammalian Sin3A complex elutes over a broad range from size 
exclusion columns, suggesting many Sin3A complexes may exist within one cell. 
Results from multiple laboratories identified HDAC1, HDAC2, RBBP4, RBBP7, 
SDS3, SAP30 and SAP18 to associate with Sin3A with high stoichiometry and 
were thus labelled as ‘core’ Sin3A complex proteins (Figure 6.1). In the years 
following the identification of the core complex, a number of other Sin3A-associated 
proteins have been identified, including additional SAP proteins, SAP130, SAP25 
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and SAP180, which are known as accessory proteins and whose functions are 
largely unknown [139, 194]. The terminology ‘core’ or ‘accessory’ protein is 
somewhat ambiguous, possibly depending on the time at which the binding partner 
was identified, its conservation in yeast and whether a discernable function for its 
interaction with Sin3 has been found. 
 
Purification of the Sin3A repressor complex in a gel filtration experiment and 
Western blotting, probing with anti-GRK5 antibodies, would confirm whether indeed 
GRK5 is a component of the repressor complex. Simultaneously probing for other 
Sin3A components would also ascertain whether GRK5 binding to Sin3A is in 
conjunction with the core complex, or whether the Sin3A/GRK5 interaction 
represents a distinct function of this master scaffold protein. GRK5 may specifically 
recruit HDAC1 to Sin3A or to SDS3 and through these interactions indirectly bind to 
HDAC2. It would be interesting to perform co-immunoprecipitation experiments to 
test whether indeed GRK5 can interact with SDS3 and whether GRK5 is important 
for HDAC binding to the repressor complex. Knocking down GRK5 in HeLa cells 
and then performing co-immunoprecipitation experiments to identify interactions 
between HDACs and Sin3A would identify whether GRK5 is important for these 
binding events. If GRK5 was found to be a crucial Sin3A binding partner required 
for complex formation and/or function, it may still be classed as an accessory, 
rather than a core complex protein. This would most likely be due to the delayed 
identification of GRK5 as a Sin3A binding partner, given that the core complex 
proteins were identified and labelled as such in the 1990s. 
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Figure 6.1 Full-length Sin3A and deletion mutants used in Chapter 5 
A schematic representation of full length Sin3A is shown, with the core complex proteins in blue, 
assembling between PAH3–HID. A. A schematic representation of the Myc-tagged Sin3A 
mutants used in the Gal4 luciferase assay and the apoptosis assay. B. A schematic 
representation of the GST-tagged Sin3A mutants used in the direct binding assays are 
illustrated, with the longest mutant, which binds GRK5 directly, shaded in grey.  
 
Additional binding partners of the Sin3A complex have also been identified, 
including the transcription factor, p53, and Rb, which are thought to bring specificity 
to Sin3A function by targeting the complex to specific genes. These binding 
partners were identified by co-immunoprecipitation experiments from cell lysates, 
much like the ones I performed to identify GRK5 as a Sin3A interacting protein. 
Following the identification of the protein-protein interactions, a potential functional 
role for the interaction was investigated. P53 binds to Sin3A between PAH2 and 
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PAH3 and this interaction is critical for p53-mediated gene repression, as Sin3A 
binding prevents p53 degradation [195, 196]. Rb recruits the Sin3 complex via Rb-
binding protein 1 that binds directly to SAP30 and this interaction may account for 
the Rb-dependent transcriptional repression of E2F1-dependent promoters in 
quiescent cells [197]. Instead of acting as a core or accessory protein to the Sin3A 
complex, there is potential for GRK5 to act like a transcription factor and direct the 
Sin3A complex to the promoter of the Bcl-2 gene, rather than regulating the 
repressor complex assembly and function as a whole. That being said, most 
additional Sin3A binding partners interact with the repressor at PAH2 and data from 
the in vitro direct binding assay in chapter 3 identified a direct interaction of GRK5 
with Sin3A in the C-terminus, between the HID, PAH4 and the HCR. I therefore 
propose GRK5 to play a role in regulating the Sin3A complex in a mechanism that 
may not only be limited to repression of the Bcl-2 gene.  
6.1.2 GRK5 as a transcriptional repressor 
Experiments in chapter 5 illustrated the potential capabilities of GRK5 to act as a 
transcriptional repressor. Using a Gal4 luciferase assay, which has been used 
previously to identify bona fide Sin3-interacting proteins that have a functional role 
in transcriptional repression, I was able to show that GRK5, when fused to the 
Gal4-DBD, represses transcription of Gal4 target genes in vitro. Furthermore, using 
Sin3A deletion mutants I showed that Gal4-mediated gene repression by GRK5 
might be Sin3A dependent. GRK5 binds Sin3A between residues 545–1157, 
identified by in vitro direct binding assays using GST-Sin3A mutants, which are 
illustrated in Figure 6.1B, with the longest mutant that binds GRK5 directly, shaded 
in grey. Figure 6.1 compares the GST-Sin3A mutants used in the direct binding 
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assays shown in chapter 3, to the Myc-Sin3A mutants used in the Gal4 luciferase 
assay and in the apoptosis assays in chapter 5. The overexpression of GRK5 with 
Myc-tagged Sin3A mutants encompassing residues 1–680 (N680) or 1–1015 
(N1015) (Figure 6.1A) modestly but significantly relieves GRK5-mediated luciferase 
gene repression, I predict, by competing with the endogenous Sin3A complex for 
GRK5 binding and thus preventing the GRK5/Sin3A complex localisation at the 
Gal4 promoter. In support of my hypothesis, the Myc-Sin3A deletion mutants that 
don’t encompass residues 545–1157, N205 and N479, as illustrated in Figure 6.1, 
do not relieve GRK5-mediated transcriptional repression. Unlike GRK5, whose 
transfection efficiency was approximately 30%, the Sin3A deletion mutants were 
less well expressed in HT-29 cells. It is therefore likely that not all cells expressing 
the Gal4-DBD-GRK5 construct were also expressing the Sin3A mutant. The Gal4 
luciferase assay does not discriminate between transfected and untransfected cells 
and the relatively low number of HT-29 cells co-expressing Gal4-DBD-GRK5 and 
Sin3A deletion mutants may therefore account for only a modest relief of GRK5-
mediated transcriptional repression by N680 and N1015. Results from the Gal4 
luciferase assay suggest that Sin3A residues 545–680, which encompass the HID, 
may be most critical for GRK5 binding. However, although not statistically different, 
the GRK5-mediated luciferase gene repression is relieved slightly more by co-
expressing Gal4-DBD-GRK5 with N1015 compared to N680, which implies that the 
C-terminal Sin3A domains, PAH4 and the HCR, may provide additional stability to 
the GRK5/Sin3A interaction. 
 
Considering GRK5 is capable of regulating transcription in an in vitro system, I then 
wanted to investigate whether the kinase could regulate transcription of the anti-
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apoptotic protein, Bcl-2, in the colon cancer cell line, HT-29. GRK5 expression 
levels are predicted to be downregulated in high-risk patients and colon cancer cell 
lines and I observed that HT-29 and SW620 cells, both of which are derived from 
colorectal adenocarcinomas, have relatively low GRK5 levels in comparison to 
other tumour derived cell lines (Figure 5.1). Since Bcl-2 levels are upregulated in 
colon cancer and GRK5 negatively regulates Bcl-2 transcription in an unrelated cell 
line, SHSY5Y [80, 116], I investigated whether the low GRK5 expression levels 
were playing a causative role in colon cancer pathogenesis. Extending the original 
study by the Qin group, who observed a modest but significant increase in Bcl-2 
mRNA levels of approximately 10% following GRK5 knockdown in SHSY5Y cells, I 
performed a knockdown of GRK5 in HeLa cells, which increased Bcl-2 mRNA 
levels by 22% ± 0.1. Like the Qin group, I also showed GRK5 to negatively regulate 
Bcl-2 protein expression, both by knocking down GRK5, as well as by 
overexpressing the kinase. I further showed the repression of GRK5-mediated Bcl-
2 protein expression is dependent on class I HDACs, as treatment with the class I 
specific inhibitor, MS-275, abolished the reductions in Bcl-2 protein levels observed 
following overexpression of the kinase. While the Qin group did not use HDAC 
inhibitors, the concomitant upregulation of HDAC activity in SHSY5Y cells following 
GRK5 knockdown, supports their hypothesis that GRK5 negatively regulates Bcl-2 
transcription in SHSY5Y cells by upregulating HDAC activity. They propose this 
mechanism may play a role in PD pathogenesis by regulating apoptosis, although 
they do not investigate this hypothesis [80]. My data supports and extends their 
work, confirming that indeed, GRK5 expression levels enhance the apoptotic 
sensitivity of HT-29 cells to the chemotherapeutic agent, 5-FU, but also 
independently of drug treatment. Moreover, I show that GRK5-dependent apoptosis 
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is Sin3A-dependent, thus providing a mechanistic explanation for the Qin group’s 
findings, implicating the Sin3A complex and potentially HDAC activity in GRK5-
mediated Bcl-2 gene repression. 
 
The Qin group performed a chromatin immunoprecipitation (ChIP) experiment in 
SHSY5Y cells and showed GRK5 to interact with the Bcl-2 promoter. Using anti-
GRK5 antibodies to immunoprecipitate GRK5 from cell lysates, the corresponding 
DNA bound to GRK5 was purified and detected by RT-PCR using primers specific 
for the Bcl-2 promoter. In control SHSY5Y cells, GRK5 bound to the Bcl-2 promoter 
but this interaction was significantly reduced in SHSY5Y cells overexpressing the 
GRK5 shRNA [80]. Given more time, I would have liked to perform a ChIP 
experiment in HT-29 cells to investigate GRK5 binding at the Bcl-2 promoter. 
Assuming that the results in SHSY5Y cells hold true in HT-29 cells, which is 
possible considering that GRK5 negatively regulates Bcl-2 transcription in both cell 
lines, it would also be interesting to test whether HDAC and Sin3A interactions are 
necessary to mediate the potential interactions of GRK5 with the Bcl-2 promoter. 
Given my data showing the importance of class I HDACs and the interaction with 
Sin3A in mediating Bcl-2 repression, I would predict GRK5 to bind to the Bcl-2 
promoter in conjunction with the Sin3A complex. Sin3A binds to many promoters in 
differentiated myotubes to maintain muscle cell differentiation [198], and the 
complex also binds the promoter region of the transcription factor gene, E2F1 and 
the prostate suppressor antigen gene and enhances gene repression by Ebp1 
[199]. In some cases, however, the complex does not function as an independent 
transcriptional regulator and instead relies on the association of other proteins in 
order to repress transcription. In keratinocytes, for example, Sin3A binds to the 
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telomerase promoter, hTERT, in complex with the repressor protein, NFX1-91. 
Degradation of NFX1-91 dissociates the Sin3A complex from the promoter and 
initiates hTERT transcription [200]. Perhaps GRK5 is recruiting Sin3A to the Bcl-2 
promoter. If indeed Sin3A binds to the Bcl-2 gene, it would be interesting to note 
whether this interaction is dependent on GRK5. 
 
Both the Qin group and myself have highlighted the Bcl-2 gene as a cellular target 
of GRK5 transcriptional repression. Extending their work, my data in HT-29 cells 
thereby implicates GRK5 as a causative factor in colon cancer, as I have shown 
GRK5 protein levels are downregulated in colon cancer cells, HT-29 and SW620, 
and Bcl-2 upregulation is associated with the early development of CRCs [116]. 
While the Qin group showed GRK5 to negatively regulate Bcl-2 protein and mRNA 
levels in SHSY5Y cells, by Western blot and by RT-PCR respectively, following the 
overexpression of GRK5 siRNAs [80], my data gives mechanistic insight into this 
regulation, highlighting a possible role for GRK5 within a well-established repressor 
complex. An obvious question to pose is how GRK5 is acting, potentially in concert 
with Sin3A and HDAC1, to mediate gene repression. One possibility, as mentioned 
briefly in section 6.1.1 is by directing the complex to gene targets. Sin3A itself does 
not posses DNA binding capabilities, but depends on binding to transcription 
factors to target the HDAC activity of the complex to specific promoters. The 
majority of transcription factors that bind Sin3A do so via the N-terminal PAH1 and 
PAH2 domains and in fact no such interactions have been reported to occur at 
PAH3, PAH4 or the HCR. The nuclear co-repressor, Alien, however, binds Sin3A at 
the HID and HCR [139, 148]. Mammalian Sin3A was originally identified as a 
binding partner of the Mad family of repressor proteins and the formation of a 
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ternary complex of Sin3A with the Mad-Max heterodimer results in transcriptional 
repression of c-Myc. Mad1 binds to the PAH2 domain of Sin3A via a sequence of 
13 amino acids in a conserved region of Mad1 that is known as a Sin3A interaction 
domain [201]. A PAH2-interacting consensus sequence has since been identified 
and is common to not only the Mad family but other transcription factors including 
transforming growth factor ! inducible early response gene 2 (TIEG2) [202]. 
Transcription factors target Sin3A to specific genes and GRK5 may also play a role 
in this process. Perhaps GRK5, by virtue of its ability to bind Sin3A at sites distinct 
from other transcription factors, modifies the promoter-binding characteristics of 
specific transcription factor/Sin3A complexes.  
 
The NTPB and NLS domains of GRK5 contain DNA binding sites. Based on the 
GRK6 homodimer crystal structure, the NLS and NTPB are oriented at opposite 
ends, such that a homodimer may wrap itself around DNA with the NLS and NTPB 
domains forming direct contacts with the nucleotides [11, 19]. As discussed in 
section 1.1.1, GRK6 was crystallised by the Tesmer group as a dimer, via a surface 
of its RH domain that is shared between the GRK4 and GRK1 subfamily members. 
The Tesmer group showed that dimerisation is not required for receptor 
phosphorylation, as GRK6 mutants with residues at the dimer interface mutated to 
alanine, phosphorylated rhodopsin to the same degree as wildtype GRK6 in COS-1 
cells [19]. Lan Ma’s group have shown that GRK5 can dimerise in HEK293 cells 
and they propose that dimerisation works to crosslink F-actin into bundles at the 
plasma membrane, a process which is responsible for neurite outgrowth and the 
formation of dendritic spines [25]. These data suggest that perhaps the 
conformation of the GRK5 dimer is important for binding macromolecules, such as 
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actin polymers and DNA. To investigate this hypothesis it would be interesting to 
test whether a C-terminal GRK5 mutant that fails to bind actin also fails to interact 
with DNA. 
 
GRK5 may also be regulating Sin3A-mediated repression of gene transcription via 
its kinase activity. Phosphorylation is a known regulatory mechanism for abolishing 
interactions of Sin3A with transcription factors. Indeed, phosphorylation of TIEG2 at 
four sites near the Sin3A interaction domain disrupts binding to mouse Sin3A, 
resulting in loss of repression. Signalling via epidermal growth factor inhibits TIEG2 
repression via a Ras/MEK1/ERK2 signalling pathway [202]. I have demonstrated 
that GRK5 overexpression in HT-29 cells increases Bcl-2 repression and that 
GRK5 knockdown causes the reverse effect. If GRK5 is playing a kinase-
dependent role in regulating Sin3A it would be to enhance such interactions. 
Additionally, the enzymatic activity of HDAC1 is enhanced by phosphorylation [191]. 
In SHSY5Y cells, where GRK5 has been shown to negatively regulate Bcl-2 
transcription, knockdown of GRK5 also reduced HDAC activity by up to 70% [80]. 
GRK5 may therefore be working to activate HDAC1 in the Sin3A complex to 
promote the repression of Bcl-2 gene transcription. Initial fluorometric HDAC 
activity assays were carried out to investigate whether GRK5 regulates HDAC 
activity in HT-29 cells, but due to technical difficulties clear results were not 
obtained. It would be worthwhile testing whether the GRK5!K215R kinase dead 
GRK5 mutant is capable of repressing Bcl-2 transcription, as well as interactions of 
GRK5 with class I HDACs and Sin3A, to shed further light on the mechanistic role 
played by GRK5 in the Sin3A repressor complex. 
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Many proteins involved in transcriptional repression bind to multiple repressor 
complexes, such as HDACs 1 and 2, which bind not only to Sin3A but also to 
NuRD, N-CoR, SMRT and CoREST. SAP30 is a core component specific to the 
Sin3A complex and while it is not responsible for the intrinsic repressor activity of 
the complex, it is involved in Sin3A-mediated N-CoR repression, by acting as a 
bridging factor between the two repressors [203]. GRK5 might play a similar role, 
recruiting accessory proteins to Sin3A, including other transcriptional repressors. 
N-CoR binds HDAC3 as part of its core complex. Data in Figure 3.2 shows GRK5 
binds directly to HDAC3, albeit to a lesser extent than HDAC1 and HDAC8. There 
is, therefore, the potential for GRK5 to be involved in N-CoR-mediated repression, 
possibly by bridging the gap between N-CoR and Sin3A via its interaction with 
Sin3A and HDAC3. GRK5 could also potentially be recruited to N-CoR solely via 
HDAC3 binding. Whether GRK5 is involved in other mammalian repressor 
complexes, such as N-CoR, remains to be determined but could be tested by co-
immunoprecipitation experiments using cell lysates. Considering Sin3A also binds 
to N-CoR, it would be interesting to investigate whether Sin3A would be necessary 
to mediate the interactions of GRK5 with not only N-CoR, but also other 
mammalian repressor complexes. 
6.2 GRK5 is pro-apoptotic in cancer cells 
Cancer, like many disease states, is associated with altered gene expression. 
Given that GRK5 binds to class I HDACs as well as the repressor protein, Sin3A, I 
wanted to investigate whether the kinase could play a role in colon cancer 
pathogenesis, potentially through modulating gene expression at the transcriptional 
level. Evidence in the literature suggests that levels of GRK5 are altered in colon 
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cancer, with high-risk patients showing reduced expression of the kinase and I 
have shown GRK5 protein levels are lowest in colon cancer cells in comparison to 
other tumour-derived cell lines. An obvious physiological consequence of 
repressing Bcl-2 levels is enhanced apoptosis. I compared apoptosis in OVCAR3 
and HT-29 cells. OVCAR3 cells express approximately 10 times more GRK5/unit 
actin than HT-29 cells. At the highest level of GRK5 expression tested, 2.5-times as 
many OVCAR3 cells underwent apoptosis as compared to HT-29 cells, in response 
to the same dose of the chemotherapeutic agent, DOXO. The mechanism of 
DOXO-induced apoptosis has not been well classified but is reported to act by 
inhibiting topoisomerase II and generating hydrogen peroxide, which causes 
oxidative DNA damage [204]. Apoptosis was assessed by Western blotting, 
probing for cleaved PARP-1 using a specific antibody. PARP-1 is a caspase 3 
substrate, such that levels of cleaved PARP-1 rise following the initiation of the 
apoptosis caspase cascade. I subsequently sought to investigate whether 
modulating GRK5 levels alters the sensitivity of cells to chemotherapeutic agents in 
the same cell line. GRK5 was overexpressed in HT-29 cells and two different 
assays were performed following treatment with the colon cancer drug, 5-FU: 
measuring cell viability by FACS and staining for apoptotic cells with an anti active 
caspase 3 antibody by immunofluorescence. In both experimental cases, GRK5 
overexpression increases the percentage of apoptotic cells and this effect is 
exaggerated following treatment with the chemotherapeutic agent, 5-FU. 
Examining cell morphology following GRK5 overexpression and 5-FU treatment 
shows cells to adopt a more spherical shape (Figure 5.8), concomitant with 
apoptosis induction. Thus, apoptosis in HT-29 cells can be increased by GRK5 
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overexpression, suggesting that indeed GRK5 increases sensitivity to 
chemotherapeutic agents, potentially via the repression of Bcl-2. 
 
Treatment with the class I HDAC inhibitor, MS-275, reduces 5-FU-mediated, 
GRK5-dependent apoptosis by approximately 50%, demonstrating that class I 
HDACs are important for the GRK5-mediated enhancement of apoptosis. Co-
expression of GRK5 with the Sin3A mutant, N1015, reduces apoptosis by 
approximately 65%. This is the longest Sin3A deletion fragment, which 
encompasses the C-terminus, including the HID, PAH4 and the HCR and includes 
the GRK5 binding domain. I therefore hypothesise, as previously discussed, that 
this Sin3A fragment acts as a competitive inhibitor with endogenous Sin3A for 
GRK5, preventing GRK5 binding to the functional Sin3A complex and thereby 
inhibiting Sin3A-mediated effects of GRK5. This notion is supported by the 
observation that the GRK5-mediated transcriptional repression of Gal4 luciferase 
gene targets is slightly but significantly inhibited by the N1015 fragment and to a 
lesser extent the N680 fragment. The N1015 mutant also inhibits GRK5-mediated 
apoptosis but the N680 Sin3A mutant does not. As mentioned previously, although 
the HID is the most critical Sin3A domain for GRK5 binding, perhaps the remaining 
Sin3A C-terminal domains are necessary for maintaining the interaction with the 
kinase, potentially by recruiting other proteins to the complex to help stabilise the 
interaction. The apoptosis phenotype lies downstream of Bcl-2 regulation, such that 
the disruption of GRK5/Sin3A binding by N680 may not have been strong enough 
to affect GRK5-mediated, Sin3A-dependent apoptosis. 
Chapter 6: Discussion !
! 197 
6.2.1 GRK5-dependent apoptosis occurs via p53 dependent and 
independent mechanisms 
In osteosarcoma cells, GRK5 phosphorylates the tumour suppressor protein, p53, 
to inhibit p53 induced apoptosis [49], yet here we show GRK5 promotes apoptosis 
in HT-29 cells. P53 is a key player in the cellular response to stress and it has a 
well-established role in promoting apoptosis by transcriptionally regulating 
components of both the extrinsic and intrinsic apoptotic pathways [73]. These 
pathways of p53-dependent apoptosis, however, are not operative in all cancer cell 
lines; p53 is mutated in over 50% of cancers and over 75% of these mutations 
render the protein inactive in a manner that is dominant over any remaining 
wildtype protein [205]. Alternative, p53-independent apoptotic signalling pathways 
can be induced in such cases. Indeed, the cyclin-dependent kinase inhibitor, p21, 
is tightly regulated by p53, yet in HT-29 cells, which are p53 deficient, induction of 
p21 can occur in a p53-independent manner [206]. In HT-29 cells, the p53 gene 
carries a point missense mutation (Arg273His) in the DNA binding domain to 
render the protein inactive [207, 208]. I can, therefore, reconcile the opposite roles 
played by GRK5 in apoptosis regulation in osteosarcoma cells and in HT-29 cells, 
based on differences in p53 status. I propose that in HT-29 cells where p53 is non-
functional, GRK5 enhances apoptosis sensitivity in a Sin3A dependent manner, via 
a novel mechanism that is distinct from and has opposing cellular consequences to 
that regulated by p53.  
 
P53 is a molecular target of 5-FU and although its mutation accounts for apoptosis 
resistance, 5-FU can induce apoptosis in p53 deficient cell lines, albeit to a lesser 
extent. Indeed, as illustrated in Figure 5.8, GRK5-mediated apoptosis is increased 
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in HT-29 cells following 5-FU treatment. The mechanism of p53-independent 
apoptosis is not currently known but interferon-" has been shown to induce 
expression and activation of double stranded RNA (dsRNA)-dependent protein 
kinase (PKR), which is an innate immune and antiviral protein that plays a role in 
cell differentiation, growth and apoptosis. Stable knockdown of PKR reduces 5-FU 
induced apoptosis in the colon cancer cell line, HCT116, compared to control cells. 
Furthermore, this reduction in apoptosis is similar in HCT116 p53+/+ and HCT116 
p53-/- cells, thus suggesting that 5-FU is capable of inducing a p53-independent 
apoptosis mechanism via PKR [209]. Apoptosis was inferred from levels of Annexin 
V staining, which is a calcium-dependent phospholipid-binding protein that binds to 
phosphatidylserine to identify apoptotic cells. Apoptosis induction causes the 
relocalisation of phosphatidylserine from the cytosolic side of the plasma 
membrane to the extracellular matrix, where it is available for detection by 
fluorescently labeled Annexin V. Similar to GRK5, PKR is a serine/threonine kinase 
whose autophosphorylation is required for kinase activation. PKR phosphorylates 
translation initiation factor, eIF2", inhibiting its activity as well as protein synthesis 
[210].  
 
In a mouse xenograft model, colon cancer cells with reduced PKR expression 
established solid tumours faster than control cells, which were also resistant to 
DOXO treatment [211], implying that lower expression levels of PKR correlate with 
increased severity of colon tumours. Additionally, 5-FU treatment increases PKR 
protein expression levels in HCT116 cells following 24 hours treatment with 10 µM 
5-FU [209]. In HT-29 cells, levels of GRK5 are low and overexpression of GRK5 
renders HT-29 cells sensitive to 5-FU treatment, as shown in Figure 5.8 and Figure 
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5.10. It is therefore unlikely that 5-FU treatment increases GRK5 protein expression 
or activation, as overexpression of the kinase is necessary to induce sensitivity to 
5-FU. Western blotting to detect GRK5 protein expression levels in 5-FU treated 
and untreated cells would, however, ascertain whether this is the case. Either way, 
GRK5 functions similarly to PKR to induce a p53-independent mechanism of 
apoptosis in response to 5-FU treatment in HT-29 cells.  
6.2.2 GRK5 mediates apoptosis regulation 
Data from my thesis points to a p53-independent mechanism of apoptosis induction 
by GRK5, potentially involving the Sin3A-mediated repression of Bcl-2 transcription. 
Apoptosis is a highly regulated cellular event and GRK5 is implicated in multiple 
signalling pathways that converge on apoptosis, suggesting that direct regulation of 
Bcl-2 levels may not be the only mechanism whereby GRK5 promotes apoptosis. 
 
Bcl-2 is transcriptionally activated by NF#B, which itself is regulated by GRK5, as 
explained in detail in section 1.3.3.1 [65, 66, 69, 70, 212, 213]. DNase I footprinting 
analysis with purified NF#B isoform, p50, identified a putative binding site for the 
transcription factor within the Bcl-2 P2 promoter site. The ability of this promoter 
region to interact with nuclear components in prostate cancer cell line, LNCaP, was 
tested by gel retardation and supershift analysis and the NF#B heterodimer p50/65 
was detected following probing with specific antibodies. The heterodimer activates 
Bcl-2 transcription, with overexpression of p50/65 in HeLa cells increasing 
transcription of a luciferase construct fused to the P2 promoter region of Bcl-2. Bcl-
2 protein expression levels and transcription were increased following TNF"-
stimulation and abrogated by preventing the phosphorylation of I#B", either through 
Chapter 6: Discussion !
! 200 
the use of inhibitors or a dominant negative I#B" construct [212]. Bcl-2 is 
upregulated in the early stages of colon cancer and NF#B is constitutively activated 
in a range of cancers, including colorectal [210]. Indeed, one such study found 
NF#B to be constitutively activated in 40% of tumours and 67% of cell lines, 
including HT-29 cells, albeit at relatively low levels compared to other colorectal 
carcinoma cell lines such as DLD-1 and LOVO. Knockdown of NF#B in colorectal 
cancer cell lines expressing high levels of NF#B, increased 5-FU induced apoptosis 
and reduced tumour expansion in mice by 44% compared to wildtype mice [210]. 
The concomitant down-regulation of GRK5 and upregulation of NF#B activity in 
colon cancer may therefore function to coordinately upregulate Bcl-2 expression. 
Furthermore, GRK5 is able to regulate NF#B, providing another avenue for Bcl-2 
regulation. The functional consequence of GRK5-mediated NF#B regulation 
however, may depend on the stimulus, cell line and I#B member involved. 
 
Following TNF"-stimulation in macrophages, GRK5 binds and phosphorylates the 
NF#B inhibitor, I#B", leading to its degradation and subsequent NF#B activation. 
Nuclear translocation of NF#B ensues and its target genes are subsequently 
upregulated [70]. The same group, however, showed that GRK5 negatively 
regulates TLR4 induced ERK activation in macrophages by inhibiting the 
phosphorylation of NF#B subunit, p105 [66]. A similar, TLR4 induced, negative 
regulation of NF#B by GRK5 was reported in endothelial cells, this time via the 
stabilisation of the NF#B/I#B" complex [65]. The mechanism of GRK5-mediated 
NF#B activation is likely to be evolutionarily conserved in Drosophila, zebrafish and 
mice, resulting in upregulated cytokine expression [69, 71]. While NF#B is activated 
in colon cancer, based on the literature and from screening GRK5 protein 
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expression levels in a range of cancer cell lines (Figure 5.1), I hypothesise that 
GRK5 is downregulated in the diseased state. Based on these data, reduced 
expression of GRK5 may therefore relieve the NF#B inhibition and may account for 
the upregulated Bcl-2 expression. 
 
The resultant phenotype of GRK5 overexpression in HT-29 cells is an increase in 
5-FU induced apoptosis. NF#B has a well-known role in the immune response, 
particularly inflammation, but it also has pro- and anti-apoptotic functions 
depending on the inducing stimulus. TNF-", ionizing radiation and the 
chemotherapeutic drug, daunorubicine, initiate an anti-apoptotic NF#B pathway. 
NF#B also inhibits p53-independent apoptosis induced by oncogenic Ras [214, 
215]. The viability of Rat-1 cell lines stably co-expressing oncogenic Ras and I#B" 
was reduced by over 50% compared to control Rat-1 cells overexpressing 
oncogenic Ras alone. The same phenotype was observed in p53 null MEFs with 
combined overexpression of oncogenic Ras and I#B", suggesting that inhibition of 
NF#B is having a pro-apoptotic effect [215]. These findings are in keeping with my 
hypothesis that in HT-29 cells, where p53 is mutated, NF#B is likely to function in 
an anti-apoptotic manner, in keeping with its role as an activator of Bcl-2 
transcription. Overexpression of GRK5 may therefore serve to upregulate a 5-FU 
induced, p53-independent mechanism of apoptosis by promoting Sin3A-mediated 
and maybe NF#B-mediated inhibition of Bcl-2 transcription. 
 
In addition to upregulating apoptosis regulatory pathways, another means of 
increasing susceptibility of cells to programmed cell death is by reducing 
proliferation. Stimulation of Wnt signalling converges upon $-catenin, which is re-
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localised to the nucleus and activates the transcription of genes including c-Myc 
and cyclin D1, which promote proliferation. APC is part of a multiprotein complex 
that phosphorylates $-catenin, triggering its degradation by the proteasome. The 
down-regulation of APC is one of the earliest events in the progression of a 
colorectal adenoma to a carcinoma, which results in upregulated transcription of 
Wnt target genes due to $-catenin stabilisation and excessive cell proliferation, 
which is a hallmark of cancer cells [40]. GRK5, as well as GRK6, phosphorylate the 
Wnt signalling receptor, LRP6, and thereby activate $-catenin nuclear localisation 
[41].  The down-regulation of GRK5 and APC in colon cancer reduces and 
activates Wnt signalling respectively, thereby causing opposing Wnt signalling 
phenotypes. The upregulation of Wnt signalling is concomitant with cancer 
pathogenesis, such that I would therefore predict that the down-regulation of APC 
plays a dominant role in the Wnt pathway over the regulation by GRK5. The role of 
GRK5 is therefore likely to be concerned with activating apoptosis rather than 
inhibiting proliferation. 
 
The GRK5-mediated inhibition of Bcl-2 transcription is consistent with the ability of 
the kinase to activate 5-FU-induced apoptosis, but I am yet to show that the two 
cellular events are connected. The simultaneous forced overexpression of Bcl-2 
and GRK5 in HT-29 cells may show whether 5-FU induced apoptosis is dependent 
on the reduced Bcl-2 levels. The results, however, may not be as anticipated, as 
apoptosis is controlled by a complex regulatory network, such that compensatory 
mechanisms may be initiated. 
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6.2.3 GRK5 may potentially promote cell death via autophagy  
In addition to apoptosis, another means of regulating cell death is by autophagy, 
otherwise known as type II programmed cell death. Autophagy is a cellular auto-
digestion process by which proteins and old organelles are transported to 
lysosomes for degradation. The role of autophagy in colon cancer is paradoxical, 
having pro-survival and pro-death functions depending on whether cells are 
stressed or unstressed, respectively [216]. Autophagy can compensate for 
apoptosis to initiate death of colon cancer cells but it has also been shown to limit 
5-FU induced apoptosis [217, 218]. HCT116 cells with mutated Bak or PUMA, and 
thus defective apoptosis, displayed similar sensitivities to 5-FU compared to 
wildtype HCT116 cells. While apoptosis was impaired, autophagy was increased in 
HCT116 Bak-/- and HCT116 PUMA-/- cells and cell death was reduced when 
autophagy was inhibited by treatment with the inhibitor, 3-Methyladenine [217]. 
These data therefore suggest that autophagy can act as an alternative to apoptosis 
to initiate cell death. Conversely, autophagy can also limit chemotherapeutically 
induced apoptosis, as 3-Methyladenine treatment significantly increases 5-FU 
induced apoptosis in HT-29 cells. The upregulated apoptosis observed following 
combined 3-Methyladenine and 5-FU treatment is concomitant with reduced 
expression of the anti-apoptotic protein, Bcl-xl, compared to 5-FU treatment alone 
[218]. It is possible that GRK5 may also be down-regulating Bcl-xl, as well as Bcl-2 
expression, in HT-29 cells. I focussed exclusively on investigating whether the 
GRK5-mediated Bcl-2 repression in HT-29 cells affected apoptosis, but it is 
possible that Bcl-2 repression may also affect autophagy. Bcl-2 inhibits Beclin 1-
dependent autophagy in HT-29 cells by blocking the formation of the Beclin 
1/vacuolar sorting protein 34 autophagic complex by binding to Beclin 1. Vacuolar 
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sorting protein 34 is a phosphoinositide 3-kinase that plays a role in vesicle 
nucleation to induce autophagy [219]. It may therefore be possible that GRK5 is not 
only promoting apoptosis but also autophagy, potentially via Bcl-2 and/or Bcl-xl 
down-regulation, to mediate 5-FU induced HT-29 cell death. Expression of a GFP-
tagged microtubule associated protein light chain 3 construct has been used as an 
indicator of autophagy. Prior to 5-FU treatment, transfection of the construct into 
HT-29 cells, with or without GRK5, will facilitate the investigation of whether indeed 
GRK5 promotes cell death via an autophagic mechanism.  
6.3 GRK5 in disease 
I have outlined a novel GRK5-dependent mechanism operative in colon cancer 
cells that increases chemotherapeutically induced apoptosis in a class I HDAC- 
and Sin3A-dependent manner and, as such, I hypothesise that GRK5 may play a 
nuclear role as an HDAC regulator in colon cancer. A microarray study of gene 
expression profiles of patients with colorectal liver metastases identified GRK5 as 
being significantly under expressed in higher-risk patients [Chung, J., 2013, 
personal communication]. Furthermore, a patent application published by Dr 
Stephen Gruber of the University of Michigan stated that a whole genome 
association study identified a SNP in the intron of GRK5 to be associated with a 
35% increased risk of developing CRC [Patent publication number: 
WO2009046422 A2]. It is possible that this SNP affects GRK5 expression levels, 
possibly down-regulating GRK5 expression in keeping with the microarray data. 
Data from my thesis extends previous work that showed GRK5 to negatively 
regulate Bcl-2 transcription in SHSY5Y cells and extends this regulation to HT-29 
cells. It is therefore feasible that GRK5 may be playing a causative role in colon 
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cancer progression to a metastatic state; down-regulation of the kinase may relieve 
Bcl-2 transcriptional inhibition and render cells resistant to pro-apoptotic stimuli, 
thus accelerating cancer cell growth.  
 
A major limitation of my work is that all my experiments have been performed in 
cell lines or in vitro, which limits the inferences I can make as to whether this 
mechanism is operative in human colon cancer patients. The natural progression of 
this work is to move in vivo and study whether GRK5 can affect colon tumour 
shrinkage in nude mice infected with colon cancer cells, in response to 
chemotherapy. Through the use of HDAC inhibitors, overexpression and 
knockdown of the key proteins, one could also ascertain whether HDACs and 
Sin3A may be playing a role in disease pathogenesis. There are well-established 
and characterised mouse models of colon cancer, with mutated APC genes and 
mutated $-catenin signalling pathways. Whether the overexpression of GRK5 in 
these mice models can compensate for these mutations is worth investigating.  
 
One disease where GRK5 is known to contribute to disease progression and which 
has been studied in depth in vivo, is pathological cardiac hypertrophy. GRKs 2, 3, 5 
and 6 are found in the heart, with expression of GRK2 and GRK5 being the highest. 
As discussed in section 1.4.1, while both GRK2 and GRK5 are implicated in heart 
failure, the kinases have distinct cardiovascular functions, with upregulated GRK2 
common to hypertension and upregulated GRK5 common to left ventricular 
overload disease. The role played by GRK5 in the heart has only been appreciated 
in recent years, while GRK2, well known for its role in $-adrenergic receptor 
phosphorylation, has long been known to play a causative role in heart failure [85, 
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86]. It was only in 2008 that work published by the Koch group explained the 
significance of upregulated GRK5 levels in CVD pathology. In comparison to 
littermate control mice and transgenic mice with cardiac specific overexpression of 
GRK2, GRK5 transgenic mice developed exaggerated pathological cardiac 
hypertrophy, premature heart failure and death following stress by TAC [81]. This 
pathological phenotype was not observed in transgenic mice overexpressing a 
GRK5!NLS mutant, thus giving a mechanistic insight into GRK5-mediated 
pathological cardiac hypertrophy. The Koch group investigated this mechanism in 
NRVM and found GRK5 to act as an HDAC5 kinase. HDAC5 phosphorylation 
induces its nuclear export, relieving the inhibition of MEF2 and thus resulting in the 
upregulation of pro-hypertrophic foetal cardiac genes [81]. Unlike HDAC5 and the 
remaining class II HDACs, which are anti-hypertrophic, class I HDACs are pro-
hypertrophic, with class I HDAC inhibitors having cardioprotective effects in mice 
[129]. Data from my thesis suggests that GRK5 may be regulating class I HDACs, 
such that targeting GRK5 may also be a valuable therapeutic option. This is 
discussed further in section 6.3.1.  
6.3.1 Targeting GRK5 as a therapeutic option  
CRC is the second largest cause of cancer mortality in the United Kingdom. 40, 
695 cases were diagnosed in 2010 alone, with 15,708 CRC related deaths reported 
in the same year [Cancer Research UK]. A major contributing factor to CRC 
mortality rates is the stage at which the disease is detected. Patients diagnosed 
with stage I cancers, which are confined to the colon, have up to approximately 
87% more chance of survival five years post diagnosis compared to those 
diagnosed with metastatic CRCs, yet only 39% of patients present with stage I 
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tumours [112] [American Cancer Society, Cancer Facts and Figures 2012]. While 
stage I cancers are often cured by surgery, 5-FU treatment is the main 
chemotherapeutic used to treat stage II or III CRCs post surgery. Treatment of 
stage IV metastatic CRCs represents a more serious clinical problem, however, as 
these cancers are often resistant to chemotherapeutic agents.  
6.3.1.1 Chemotherapy 
Adjuvant chemotherapy is given post surgery to stage III colon cancers, but its use 
in stage II tumours remains controversial, as survival rates following surgery alone 
are 75–80% [115]. HT-29 cells are derived from a colorectal adenocarcinoma and 
form well differentiated grade I or II tumours. Such tumours are most often operable 
but the risk of recurrence is high in some stage II tumour patients, particularly in 
advanced stages where the tumour has invaded neighbouring organs. In such 
cases, patients would most likely benefit from chemotherapy to reduce their long-
term risk. HT-29 cells are widely used to investigate colon cancer therapeutic 
options and numerous studies of 5-FU resistance and toxicity have been carried 
out in these cells. Here, I have shown that GRK5 overexpression increases 
sensitivity of HT-29 to 5-FU in a class I HDAC and Sin3A dependent manner and 
that treatment alone does not promote apoptosis. These findings may therefore 
prove beneficial in advancing colon cancer treatment options. While increasing 
GRK5 expression levels in colon cancer cells of patients in order to boost 
chemotherapy efficacy is not practical, the use of miRNA strategies may provide a 
safe and efficacious method to achieve such results, while circumventing the need 
for chemotherapy. This is discussed in more detail in section 6.3.1.4. 
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6.3.1.2 HDAC inhibitors 
Many studies have investigated the use of HDAC inhibitors to treat pathological 
cardiac hypertrophy, whose action is cardioprotective. Treatment of mice with pan-
HDAC inhibitors such as TSA and NaB prevent cardiac remodelling, activation of 
the foetal cardiac gene program and improve cardiac function [125, 220]. These 
results seem paradoxical with research published by the Koch group suggesting 
that class II HDACs are anti-hypertrophic. The overexpression of class I HDACs 1, 
2 and 3 are directly involved in cardiac myocyte proliferation and hypertrophy, thus 
implying that the two classes of classical HDACs have opposing functions in the 
context of this CVD [164, 221, 222]. Treatment with class I specific HDAC inhibitors 
has cardioprotective effects; following hypertrophic induction, disease development 
was significantly reduced in mice treated with the class I specific HDAC inhibitor, 
SK-7041 [129]. Whether the regulation of class I HDACs involves GRK5 is yet to be 
confirmed, but considering both proteins have pro-hypertrophic functions, they may 
well be involved in the same pro-hypertrophic pathway. If the GRK5/HDAC1/Sin3A 
complex is operative in pathological cardiac hypertrophy, I would expect the 
repressor complex to be involved in switching off adult cardiac genes. If the kinase 
activity of GRK5 is necessary to mediate this repression, potentially by activating 
HDAC1, small molecule inhibitors that disrupt the complex may be an effective 
treatment option.  
 
HDAC inhibitors including NaB and MS-275 promote growth arrest, differentiation 
and apoptosis in colon cancer cell lines and in vivo [223]. Expression levels of class 
I HDACs are often upregulated in colon cancers, with upregulation of HDACs 1, 2 
and 8 demonstrated at both protein and mRNA levels [223]. APC represses 
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HDAC2 in HT-29 cells, most likely at the transcriptional level, and knockdown of 
HDAC2 reduces cell growth [224]. HDAC gene expression is induced following loss 
of APC, leading to overexpression of the HDAC in the diseased state. In contrast to 
these data, the stable overexpression of HDAC2 in the colon cancer cell line, RKO, 
reduces proliferation, suggesting potentially cell-line dependent roles of the HDAC 
[225].  Class I HDAC upregulation in colon cancer is mechanistically linked to the 
repression of p21, which induces growth arrest [226]. HDAC inhibitors also promote 
apoptosis in colon cancer cell lines, with NaB increasing the expression of the pro-
apoptotic protein, Bak. Furthermore, overexpression of Bcl-2 only conferred 
protection against apoptosis when Bak levels were not elevated. This suggests that 
the HDAC inhibitors exert their effects predominantly through elevating Bak levels 
as opposed to repressing Bcl-2 [227]. This is in keeping with my findings that NaB 
and MS-275 treatment do not affect Bcl-2 protein levels in HT-29 cells (Figure 5.3). 
Furthermore, treatment of HT-29 cells with MS-275 does not affect 5-FU induced 
apoptosis but the simultaneous overexpression of GRK5 and treatment with MS-
275 reduced apoptosis, as observed by reduced cleaved caspase 3 staining 
(Figure 5.9). Overexpression of GRK5 represses Bcl-2 and thereby increases 
apoptosis in response to 5-FU in a class I HDAC-dependent manner. The 
overexpression of GRK5 and the induction of HDAC/Sin3A-mediated repression of 
Bcl-2 is likely to dominate over the possible upregulation of Bak induced by MS-275. 
So while HDAC inhibitors have protective effects in colon cancer, I propose that 
targeting the GRK5 mechanism of Bcl-2 repression may be more beneficial. As 
previously mentioned, the emerging use of miRNAs as therapeutics could prove to 
be a viable and efficacious method of boosting GRK5 expression levels and thus 
promoting GRK5-mediated apoptosis via Bcl-2 repression.    
Chapter 6: Discussion !
! 210 
6.3.1.3 GRK5-NT 
Constitutive activation of NF#B, which is common to many cancers including those 
in the colon, contributes to chemo-resistance [228, 229]. Regulating NF#B 
signalling may therefore provide an alternative means of increasing sensitivity to 
apoptosis and the Iaccarino group have investigated the role of GRK5 in this 
potential novel therapeutic avenue. Following the mapping of the NF#B binding site 
to the RH domain in the N-terminus of GRK5, use of a GRK5 N-terminal fragment 
(GRK5-NT) reduces NF#B activation and functions in a protective manner in cancer 
and hypertrophy [65, 93, 230] as described below.  
 
An AdGRK5-NT construct reduced NF#B transcriptional activity in cardiomyoblasts 
following phenylephrine treatment, as a means of inducing hypertrophy. Moreover, 
in vivo studies showed that intracardiac injection of the construct inhibits 
hypertrophy development in spontaneously hypertensive rats and Wistar Kyoto 
control rats treated with chronic injection of phenylephrine [93]. In the human 
thyroid tumour cell line, KAT-4, overexpression of AdGRK5-NT blocked NF#B 
transcriptional activity and increased apoptosis. In BALB/c mice with KAT-4 
induced neoplasias, intra-tumour delivery of AdGRK5-NT reduced tumour growth in 
a dose-dependent manner. Moving towards a more pharmacological method of 
GRK5-mediated inhibition of NF#B, the GRK5 N-terminal RH domain was fused to 
a synthetic TAT protein (TAT-RH) for active transport into cells, and tested for its 
anti-cancer properties. In KAT-4 cells and in BALB/c mice, TAT-RH reduced cell 
survival and tumour growth respectively. I#B" and cleaved caspase 3 levels were 
also increased in cells and mice [230]. TAT-tagged proteins can be effectively 
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transduced into human cells in tissue culture, although their expression is short 
lived [231].  
6.3.1.4 miRNAs 
170 different miRNAs have been reported to be upregulated in human CRC, 
including miR-135a and miR-135b [232]. Upregulation of these miRNAs correlate 
with reduced APC mRNA expression levels, which occurs early in the development 
of colon cancer [185]. Mutated APC and upregulated Wnt signalling promotes 
tumourigenesis by stabilising $-catenin [40]. miR-135a and b are predicted to target 
GRK5 in GBMs [188]. I have shown in Figure 5.10 that overexpression of an 
antisense miR-135a oligonucleotide upregulates GRK5 levels in HT-29 cells, which 
corresponds with increased apoptosis, as assessed by immunofluorescence. 
Overexpression of an antisense miR-135a or miR-135b oligonucleotide will 
undoubtedly increase APC expression levels, which will result in degradation of $-
catenin. In addition to upregulating genes that control proliferation, $-catenin also 
upregulates Bcl-2 mRNA in HEK293 cells and in rats treated with heterocyclic 
amine 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine to induce colon cancer. 
Bcl-2 mRNA levels are upregulated in colon tumours containing mutations in the 
CTNNB1 gene that encodes $-catenin [233]. The increased apoptosis observed 
following the inhibition of miR-135a may, therefore, be due not only to the 
upregulation of GRK5 and the concomitant Sin3A and HDAC1-dependent Bcl-2 
repression, but also to upregulated APC expression. Increasing APC expression 
results in $-catenin degradation, which thereby reduces $-catenin-mediated Bcl-2 
transcription. 
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The use of miRNA technology to treat colon cancer is already being explored. miR-
143 is downregulated in the disease and a synthetic miR-143 mimic has significant 
tumour suppressive effects in mouse CRC models [234]. Much research is still 
needed to ensure the safe delivery of miRNA mimics and inhibitors and confirm 
their protective effects in patients. Research, however, is progressing, as the use of 
a miR-122 inhibitor is already being tested in a human phase II, hepatitis C virus 
clinical trial [182]. miR-122 is also upregulated in high-grade prostate tumours, 
such that that the development of an miR-122 inhibitor may be a useful cancer 
therapeutic [187]. A miR-135b inhibitor is already being investigated to treat 
lymphoma and nanoparticle delivery of the inhibitor reduced tumour growth in in 
vivo mouse models [235]. This method of delivering the miR-135b inhibitor has not 
been tested in colon cancer mouse models, but is definitely worth investigating. 
6.4 Future work 
 
6.4.1 Mapping the binding sites of HDAC1 and Sin3A on GRK5 
Sin3A regulates transcription of a multitude of genes. Previous work has shown 
that mutating binding partners, such as the Sap30L protein, is an effective strategy 
to investigate their function, particularly if they are involved in a multiprotein 
repressor complex like Sin3A. Following the identification of Sap30 and Sap30L as 
Sin3A interactors, the binding site on Sap30L was mapped to the C-terminus. 
Transfection of a C-terminal truncated Sap30L mutant prevented Sin3A nuclear 
localisation that occurs following transfection with Sap30L wildtype protein [236]. 
Sin3A itself does not contain an NLS and these studies therefore highlight the role 
of Sap30L in localising Sin3A to the nucleus. With similar principles in mind, I 
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attempted to map the binding sites of HDAC1 and Sin3A on GRK5, in order to 
elucidate the function of these interactions.  
 
Using GRK5 peptide arrays comprising 25mer immobilised peptides, I attempted to 
identify specific GRK5 peptides that mediate binding to HDAC1 and Sin3A. The 
arrays were incubated with the respective fusion proteins and developed as per a 
Western blot. Following the analysis of arrays developed from multiple experiments, 
specific peptides were selected based on repeated binding patterns to the target 
proteins; peptides 69 and 112 were selected as HDAC1 binding peptides, peptides 
76 and 106 as Sin3A binding peptides and peptides 82 and 96 were detected in 
both HDAC1 and Sin3A experiments. To further investigate the potential binding 
sites, these peptides were incorporated into an alanine scanning substitution array. 
Analysis of the alanine scanning arrays highlighted three regions of GRK5 to 
mutate to potentially create GRK5!HDAC1, GRK5!Sin3A and GRK5!HDAC1 
!SIn3A binding deficient mutants. The following GRK5 mutants, M1–M5, were 
made: E355A/V356A, D485A, D486A, D487A and D485/486/487A (Table 4.2). The 
ability of these mutants to bind HDAC1 and Sin3A were examined in direct binding 
assays with immobilised GST-HDAC1 and GST-Sin3A-545-1157 and in vitro 
translated radiolabelled wildtype and mutant GRK5 constructs. None of the 
mutations made disrupted binding to the fusion proteins as compared to wildtype 
GRK5. Mutant M4, D487A, displayed enhanced binding capabilities to both HDAC1 
and Sin3A, suggesting the final aspartate residue in this sequence is a negative 
determinant for binding to both target proteins. This result apparently contradicts 
what was observed in the alanine scanning array, whereby mutation of this final 
aspartate behaved like the ones previous and appeared to abolish binding to 
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HDAC1 and Sin3A. It could be argued that when in the tertiary complex, the 
mutation of this aspartate residue may alter protein folding and form a GRK5 
mutant that is more receptive to interacting with HDAC1 and Sin3A. 
 
A potential Sin3A binding site on GRK5 was identified between Arg388 and Lys389. 
A pre-existing GRK5!NLS mutant in which residues Arg388, Lys389, Lys391, 
Lys393 and Arg394 are mutated to alanine has already been tested and 
characterised, such that I decided to test this construct as a potential binding 
mutant. Indeed, binding of the GRK5!NLS to both HDAC1 and Sin3A was 
inhibited; in vitro translation of GRK5!NLS and incubation with both GST-HDAC1 
and GST-Sin3A-545-1157 resulted in weaker binding to the fusion proteins in 
comparison to wildtype GRK5. The caveat of using this pre-existing GRK5!NLS 
mutant, however, is that any differences in binding cannot be attributed to residues 
Arg388 and Lys389 alone, as additional residues are mutated to exclude GRK5 
from the nucleus. So despite GRK5!NLS functioning as a GRK5!HDAC1 and 
GRK5!Sin3A binding deficient mutant, I cannot use it to further investigate the 
physiological implications of the GRK5/HDAC1 and GRK5/Sin3A interactions in a 
cellular setting; any notable alteration in phenotype cannot be attributed solely to 
perturbed binding to HDAC1 and Sin3A but instead may be due to the exclusion of 
the kinase from the nucleus.  
 
Many of the spots chosen from the peptide arrays for alanine scanning mutation 
were single peptides that appeared repeatedly on the arrays in multiple 
experiments, such that I presumed these peptides were important for mediating 
binding. These include peptides 69, 76, 96 and 82. In hindsight, selecting peptides 
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that were part of a run of positive interactors may have been more prudent. A string 
of dark spots can been seen on the array in Figure 4.3 probed with GST-Sin3A-
545-1157, running inclusively from peptides 106–112. Considering the peptides 
overlap by five amino acids, it is most likely that more than one peptide will mediate 
a binding event. Choosing a peptide included in a run of positively interacting spots 
rather than individual, isolated spots may have been wiser. That being said, the 
Baillie group successfully mapped the binding site of PDE4D5 on RACK1 by 
selecting one isolated peptide from RACK1 peptide arrays incubated with full-
length PDE4D5 [237].  
 
In light of these array results I investigated a functional role for nuclear GRK5 in 
coordination with HDAC1 and the Sin3A complex and studied the importance of 
this interaction through the use of HDAC and Sin3A inhibitors. While this worked 
effectively to illustrate the Sin3A and class I HDAC dependence of GRK5-mediated 
Bcl-2 repression and apoptosis, It is worth revisiting the arrays in the future, to 
repeat the alanine scanning arrays with different GRK5 peptides and potentially 
create GRK5!HDAC1 and GRK5!Sin3A binding deficient mutants. 
6.4.2 GRK5 is a potentiator of apoptosis  
Data from my thesis suggests GRK5 is a potentiator of apoptosis, which could have 
considerable therapeutic implications. In order to pursue this hypothesis it is 
imperative to test whether my findings hold true in vivo. Microinjection of human 
colon cancer cell lines, SW620, HCT116 and DLD-1, into the colonic mucosa of 
nude mice cause colon tumours to development in up to 88% of infected mice [238]. 
By comparison, injecting colon cancer cells overexpressing GRK5 into nude mice 
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may halt or delay tumour growth and is a study worth performing. Before 
commencing with in vivo studies, however, it may be interesting to repeat the 
apoptosis experiments in SW620 cells, or another metastatic colon cancer cell line. 
HT-29 cells are models of early stage colon cancer, of grade I or II tumours. Many 
patients present with later stage colon cancers, which are more akin to the SW620 
cell model. While the results I have obtained in HT-29 cells are useful in 
understanding the regulation of apoptosis in colon cancer, it would be 
advantageous to know whether similar mechanisms are still functional later in 
disease pathology. 
 
If GRK5 is indeed downregulated in colon cancer, as hypothesised, this would 
highlight the potential use of GRK5 as a disease biomarker. While I have shown 
GRK5 expression levels to be lowest in HT-29 and SW620 cells in comparison to 
other tumour derived cell lines, this does not confirm whether indeed GRK5 is 
downregulated in the disease. In order to pursue this investigation it would be 
advantageous to test GRK5 expression levels in human subjects with the GRK5 
SNP that increases the risk of CRC development by up to 35% (Patent publication 
number: WO2009046422 A2). Following an endoscopic biopsy to collect a sample 
of colon cells, GRK5 mRNA levels could be tested by RT-PCR experiments and 
compared to cells from control subjects without the GRK5 SNP. Comparing GRK5 
expression levels between CRC and control patients would ascertain whether 
indeed GRK5 levels are reduced in the disease. Furthermore, if a difference in 
GRK5 levels is observed between subjects with and without the GRK5 SNP, this 
may suggest that down-regulation of GRK5 is an early event in CRC development, 
possibly predisposing subjects to the disease. It is estimated that 60% of CRC 
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related deaths could be prevented if screening methods were more widely utilised 
[113]. If reductions in GRK5 expression levels occur in the early stages of disease 
pathology then screening for kinase levels may represent a novel diagnostic 
approach. 
 
An initial experiment suggests that induction of apoptosis by GRK5 may not be 
limited to colon cancer. OVCAR3 cells, which have 10-fold higher expression levels 
of GRK5, were more sensitive to DOXO treatment compared to HT-29 cells (Figure 
5.7). It will be interesting to note whether GRK5 levels correlate with apoptosis 
sensitivity in a range of cancer cells and whether GRK5 can halt the growth of 
different tumours in vivo. Like HT-29 cells, OVCAR3 have mutated p53. Comparing 
apoptosis in cancer cells with wildtype and mutated p53 will ascertain how 
important functional p53 is in mediating apoptosis and whether the mechanism of 
GRK5-induced apoptosis, via transcriptional repression of Bcl-2, also functions in 
cells with functional p53. 
 
It will also be interesting to note whether the mechanism of GRK5-mediated 
transcriptional regulation, shown here in HT-29 cells, is also functional in 
pathological hypertrophic hearts. GRK5 is upregulated in patients with left 
ventricular overload disease, which is associated with hypertrophy and nuclear 
localisation of the kinase is important for regulation of HDAC5 [81, 87]. GRK5 may, 
therefore, also be functioning to repress Bcl-2 in hypertrophic cardiac myocytes, as 
a pathological hallmark of the disease is increased myocyte apoptosis [239]. 
Indeed, chronic pressure overload in rat hearts causes significant apoptosis, which 
correlates with reduced expression of Bcl-2 [240]. 
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6.4.3 Other GRK4 subfamily members 
Like GRK5, GRK4 and GRK6 also have functional NLSs and adopt a nuclear 
localisation in HEp2 cells [11], suggesting that these GRKs also have the potential 
to be involved in regulating transcription. The NLS of GRK4, unlike GRK5 and 
GRK6, is unable to interact with DNA [10], such the mechanism shown here for the 
role of nuclear GRK5 as a transcriptional regulator and inducer of apoptosis, may 
be applicable to GRK6 but perhaps not GRK4. Investigating whether GRK4 can 
affect the sensitivity of HT-29 cells to apoptosis via Sin3A and HDAC1 may shed 
further light on the GRK5-mediated mechanism of gene repression, possibly 
indicating whether DNA binding is important. Performing co-immunoprecipitation 
experiments in HeLa cells co-expressing Sin3A or HDAC1, as well as either GRK4 
or GRK6, would test whether these kinases, like GRK5, bind HDAC1 and Sin3A in 
cell lysates. Testing the ability of GRK4 and GRK6 to bind to all the HDACs would 
identify whether the specificity of GRK5 interacting with class I over class II HDACs 
is GRK specific. While the mechanism of GRK5-mediated regulation of 
HDAC/Sin3A-controlled transcription may be operative in cardiac myocytes to 
repress adult cardiac genes, it is unlikely that GRK4 or GRK6 will function in a 
similar manner, as GRK5 and GRK2 are the predominant GRKs expressed in the 
heart. This, however, does not rule out the possibility that a potential mechanism of 
GRK4 or GRK6-mediated gene repression may be operative in other cell types, 
including colon cancer, although no known nuclear substrates or binding partners 
of either kinase have currently been reported. While GRK5 binds to Sin3A, perhaps 
GRK4 and GRK6 bind to other repressor complexes. Additionally, extending these 
investigations to include the GRK2 subfamily would also be of interest. 
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6.5 Concluding remarks 
In conclusion, I present data in this thesis highlighting a role for GRK5 as a 
transcriptional repressor, repressing Bcl-2 gene expression and increasing 
chemotherapeutically induced apoptosis in HT-29 cells. Since the discovery of the 
GRK4 subfamily NLS and NES sequences in 2004, numerous nuclear substrates 
and binding partners of GRK5 have been identified, expanding the repertoire of 
GRK5 functions far beyond GPCR regulation. GRK5 is implicated in a variety of 
diseases, including pathological cardiac hypertrophy and cancer. GRK5-mediated 
pathological cardiac hypertrophy depends on the nuclear localisation of the kinase 
and the data presented in this thesis suggests the same is true for GRK5-mediated 
colon cancer pathogenesis.  
 
Here, I have shown for the first time, a potential mechanism of GRK5-mediated 
gene repression by acting as a component of the Sin3A transcriptional repressor 
complex. Through directly binding Sin3A and HDAC1, I infer that GRK5 is able to 
repress Bcl-2 transcription and thereby increases apoptosis induced by DNA-
damaging agents. In the colon cancer cell line, HT-29, where levels of GRK5 are 
low in relation to cells derived from other tumours, GRK5 overexpression by the 
method of cDNA transfection, increases apoptosis in response to 5-FU treatment. 
Moreover, overexpression of a miR-135a inhibitor enhances endogenous GRK5 
protein expression as well as apoptosis in untreated HT-29 cells, thus representing 
a potentially valuable therapeutic strategy in the treatment of colon cancer. 
Provisional experiments suggest that apoptosis regulation by GRK5 may not be 
limited to colon cancer, but may represent a universal function of the kinase; 
OVCAR3 cells, which have higher endogenous GRK5 expression levels, are more 
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sensitive to DOXO treatment. While these findings need to be confirmed in vivo, my 
work highlights the potential for a GRK5-targetted therapy as a means of treating 
colon cancer patients, for which the use of a miR-135a inhibitor may be effective. 
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